WO2022232949A1 - Processes for the preparation of the enantiomers of 3,4-methylenedioxymethamphetamine (mdma) and n-methyl-1,3-benzodioxolylbutanamine (mbdb) - Google Patents
Processes for the preparation of the enantiomers of 3,4-methylenedioxymethamphetamine (mdma) and n-methyl-1,3-benzodioxolylbutanamine (mbdb) Download PDFInfo
- Publication number
- WO2022232949A1 WO2022232949A1 PCT/CA2022/050720 CA2022050720W WO2022232949A1 WO 2022232949 A1 WO2022232949 A1 WO 2022232949A1 CA 2022050720 W CA2022050720 W CA 2022050720W WO 2022232949 A1 WO2022232949 A1 WO 2022232949A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- formula
- reacting
- acid
- butyis
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 132
- SHXWCVYOXRDMCX-UHFFFAOYSA-N 3,4-methylenedioxymethamphetamine Chemical compound CNC(C)CC1=CC=C2OCOC2=C1 SHXWCVYOXRDMCX-UHFFFAOYSA-N 0.000 title abstract description 31
- 238000002360 preparation method Methods 0.000 title abstract description 11
- USWVWJSAJAEEHQ-UHFFFAOYSA-N 1,3-benzodioxolyl-n-methylbutanamine Chemical compound CCC(NC)CC1=CC=C2OCOC2=C1 USWVWJSAJAEEHQ-UHFFFAOYSA-N 0.000 title description 14
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 title description 5
- 150000001875 compounds Chemical class 0.000 claims abstract description 577
- USWVWJSAJAEEHQ-SNVBAGLBSA-N (2r)-1-(1,3-benzodioxol-5-yl)-n-methylbutan-2-amine Chemical compound CC[C@@H](NC)CC1=CC=C2OCOC2=C1 USWVWJSAJAEEHQ-SNVBAGLBSA-N 0.000 claims abstract description 42
- SHXWCVYOXRDMCX-MRVPVSSYSA-N (2r)-1-(1,3-benzodioxol-5-yl)-n-methylpropan-2-amine Chemical compound CN[C@H](C)CC1=CC=C2OCOC2=C1 SHXWCVYOXRDMCX-MRVPVSSYSA-N 0.000 claims abstract description 39
- SHXWCVYOXRDMCX-QMMMGPOBSA-N (2s)-1-(1,3-benzodioxol-5-yl)-n-methylpropan-2-amine Chemical compound CN[C@@H](C)CC1=CC=C2OCOC2=C1 SHXWCVYOXRDMCX-QMMMGPOBSA-N 0.000 claims abstract description 38
- 238000004519 manufacturing process Methods 0.000 claims abstract description 36
- USWVWJSAJAEEHQ-JTQLQIEISA-N (2s)-1-(1,3-benzodioxol-5-yl)-n-methylbutan-2-amine Chemical compound CC[C@H](NC)CC1=CC=C2OCOC2=C1 USWVWJSAJAEEHQ-JTQLQIEISA-N 0.000 claims abstract description 34
- BDSGOXYXFMSOQV-VIFPVBQESA-N CCC[C@@H](C1OC(C=CC=C2)=C2O1)NC Chemical compound CCC[C@@H](C1OC(C=CC=C2)=C2O1)NC BDSGOXYXFMSOQV-VIFPVBQESA-N 0.000 claims abstract description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 123
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 121
- 239000002253 acid Substances 0.000 claims description 117
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 117
- 150000003839 salts Chemical class 0.000 claims description 98
- SATCULPHIDQDRE-UHFFFAOYSA-N piperonal Chemical compound O=CC1=CC=C2OCOC2=C1 SATCULPHIDQDRE-UHFFFAOYSA-N 0.000 claims description 54
- 239000003054 catalyst Substances 0.000 claims description 45
- 230000001035 methylating effect Effects 0.000 claims description 32
- 239000012442 inert solvent Substances 0.000 claims description 28
- 239000010936 titanium Substances 0.000 claims description 28
- 229940081310 piperonal Drugs 0.000 claims description 27
- 238000006268 reductive amination reaction Methods 0.000 claims description 26
- 239000003153 chemical reaction reagent Substances 0.000 claims description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 claims description 21
- 229910052719 titanium Inorganic materials 0.000 claims description 21
- 239000002585 base Substances 0.000 claims description 18
- -1 methyl halide Chemical class 0.000 claims description 17
- ZDYVRSLAEXCVBX-UHFFFAOYSA-N pyridinium p-toluenesulfonate Chemical compound C1=CC=[NH+]C=C1.CC1=CC=C(S([O-])(=O)=O)C=C1 ZDYVRSLAEXCVBX-UHFFFAOYSA-N 0.000 claims description 16
- 230000001590 oxidative effect Effects 0.000 claims description 15
- 239000003638 chemical reducing agent Substances 0.000 claims description 12
- DYROHZMICXBUMX-UHFFFAOYSA-N methoxymethylidene(triphenyl)-$l^{5}-phosphane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=COC)C1=CC=CC=C1 DYROHZMICXBUMX-UHFFFAOYSA-N 0.000 claims description 12
- 238000007239 Wittig reaction Methods 0.000 claims description 10
- MUJIDPITZJWBSW-UHFFFAOYSA-N palladium(2+) Chemical compound [Pd+2] MUJIDPITZJWBSW-UHFFFAOYSA-N 0.000 claims description 10
- JMXKSZRRTHPKDL-UHFFFAOYSA-N titanium ethoxide Chemical compound [Ti+4].CC[O-].CC[O-].CC[O-].CC[O-] JMXKSZRRTHPKDL-UHFFFAOYSA-N 0.000 claims description 10
- BDSGOXYXFMSOQV-SECBINFHSA-N CCC[C@H](C1OC(C=CC=C2)=C2O1)NC Chemical compound CCC[C@H](C1OC(C=CC=C2)=C2O1)NC BDSGOXYXFMSOQV-SECBINFHSA-N 0.000 claims description 9
- 239000007818 Grignard reagent Substances 0.000 claims description 8
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 8
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 claims description 7
- 239000012458 free base Substances 0.000 claims description 7
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 7
- 150000004795 grignard reagents Chemical group 0.000 claims description 6
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical group Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 claims description 6
- VXUYXOFXAQZZMF-UHFFFAOYSA-N titanium(IV) isopropoxide Chemical group CC(C)O[Ti](OC(C)C)(OC(C)C)OC(C)C VXUYXOFXAQZZMF-UHFFFAOYSA-N 0.000 claims description 6
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical group Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 claims description 4
- 239000012279 sodium borohydride Substances 0.000 claims description 4
- 229910000033 sodium borohydride Inorganic materials 0.000 claims description 4
- BLHLJVCOVBYQQS-UHFFFAOYSA-N ethyllithium Chemical compound [Li]CC BLHLJVCOVBYQQS-UHFFFAOYSA-N 0.000 claims description 3
- DVSDBMFJEQPWNO-UHFFFAOYSA-N methyllithium Chemical compound C[Li] DVSDBMFJEQPWNO-UHFFFAOYSA-N 0.000 claims description 3
- PBDBXAQKXCXZCJ-UHFFFAOYSA-L palladium(2+);2,2,2-trifluoroacetate Chemical compound [Pd+2].[O-]C(=O)C(F)(F)F.[O-]C(=O)C(F)(F)F PBDBXAQKXCXZCJ-UHFFFAOYSA-L 0.000 claims description 3
- 229910021578 Iron(III) chloride Inorganic materials 0.000 claims description 2
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 claims description 2
- CESUXLKAADQNTB-SSDOTTSWSA-N 2-methylpropane-2-sulfinamide Chemical compound CC(C)(C)[S@](N)=O CESUXLKAADQNTB-SSDOTTSWSA-N 0.000 abstract description 8
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 51
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 50
- 239000000243 solution Substances 0.000 description 43
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical group CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 37
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical group ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 36
- 238000006243 chemical reaction Methods 0.000 description 36
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical group C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 34
- 239000002904 solvent Substances 0.000 description 33
- 239000000203 mixture Substances 0.000 description 32
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 31
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 25
- 239000003921 oil Substances 0.000 description 22
- 235000019439 ethyl acetate Nutrition 0.000 description 20
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 18
- 239000000047 product Substances 0.000 description 18
- 239000012453 solvate Substances 0.000 description 18
- 239000000126 substance Substances 0.000 description 18
- 239000000725 suspension Substances 0.000 description 16
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- 239000011541 reaction mixture Substances 0.000 description 14
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 230000035484 reaction time Effects 0.000 description 12
- QYKIQEUNHZKYBP-UHFFFAOYSA-N Vinyl ether Chemical compound C=COC=C QYKIQEUNHZKYBP-UHFFFAOYSA-N 0.000 description 11
- 239000000706 filtrate Substances 0.000 description 11
- RRMZTAWQQFJQHL-UHFFFAOYSA-N 2-(1,3-benzodioxol-5-yl)acetaldehyde Chemical compound O=CCC1=CC=C2OCOC2=C1 RRMZTAWQQFJQHL-UHFFFAOYSA-N 0.000 description 10
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 10
- 229940002612 prodrug Drugs 0.000 description 10
- 239000000651 prodrug Substances 0.000 description 10
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
- 238000004440 column chromatography Methods 0.000 description 9
- 235000019253 formic acid Nutrition 0.000 description 9
- 238000000746 purification Methods 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical group CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 8
- ZMQAAUBTXCXRIC-UHFFFAOYSA-N safrole Chemical compound C=CCC1=CC=C2OCOC2=C1 ZMQAAUBTXCXRIC-UHFFFAOYSA-N 0.000 description 8
- 229910000104 sodium hydride Inorganic materials 0.000 description 8
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 8
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 7
- 125000006239 protecting group Chemical group 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 6
- CESUXLKAADQNTB-ZETCQYMHSA-N 2-methylpropane-2-sulfinamide Chemical compound CC(C)(C)[S@@](N)=O CESUXLKAADQNTB-ZETCQYMHSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical group CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical group [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 239000002480 mineral oil Substances 0.000 description 6
- 235000010446 mineral oil Nutrition 0.000 description 6
- 239000012074 organic phase Substances 0.000 description 6
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical group [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 6
- 229910052938 sodium sulfate Inorganic materials 0.000 description 6
- 235000011152 sodium sulphate Nutrition 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 238000005160 1H NMR spectroscopy Methods 0.000 description 5
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 5
- 238000005481 NMR spectroscopy Methods 0.000 description 5
- 239000012267 brine Substances 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- FRIJBUGBVQZNTB-UHFFFAOYSA-M magnesium;ethane;bromide Chemical compound [Mg+2].[Br-].[CH2-]C FRIJBUGBVQZNTB-UHFFFAOYSA-M 0.000 description 5
- 239000007800 oxidant agent Substances 0.000 description 5
- 239000003444 phase transfer catalyst Substances 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- VHVOLFRBFDOUSH-NSCUHMNNSA-N Isosafrole Chemical compound C\C=C\C1=CC=C2OCOC2=C1 VHVOLFRBFDOUSH-NSCUHMNNSA-N 0.000 description 4
- VHVOLFRBFDOUSH-UHFFFAOYSA-N Isosafrole Natural products CC=CC1=CC=C2OCOC2=C1 VHVOLFRBFDOUSH-UHFFFAOYSA-N 0.000 description 4
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 4
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- 239000006184 cosolvent Substances 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- 238000006722 reduction reaction Methods 0.000 description 4
- 239000011369 resultant mixture Substances 0.000 description 4
- 239000012312 sodium hydride Substances 0.000 description 4
- CESUXLKAADQNTB-UHFFFAOYSA-N tert-butanesulfinamide Chemical compound CC(C)(C)S(N)=O CESUXLKAADQNTB-UHFFFAOYSA-N 0.000 description 4
- CYLPXUHJWJWYJJ-UHFFFAOYSA-N 5-(2-methoxyethenyl)-1,3-benzodioxole Chemical compound COC=CC1=CC=C2OCOC2=C1 CYLPXUHJWJWYJJ-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- VYOHAAPQYKJYQU-FKIZINRSSA-N CC[C@@H](CC(C=C1)=CC2=C1OCO2)N[S@@](C(C)(C)C)=O Chemical compound CC[C@@H](CC(C=C1)=CC2=C1OCO2)N[S@@](C(C)(C)C)=O VYOHAAPQYKJYQU-FKIZINRSSA-N 0.000 description 3
- JXOOMXGMOITJGB-ASSNKEHSSA-N CC[C@H](CC(C=C1)=CC2=C1OCO2)N(C)[S@](C(C)(C)C)=O Chemical compound CC[C@H](CC(C=C1)=CC2=C1OCO2)N(C)[S@](C(C)(C)C)=O JXOOMXGMOITJGB-ASSNKEHSSA-N 0.000 description 3
- VYOHAAPQYKJYQU-ODXCJYRJSA-N CC[C@H](CC(C=C1)=CC2=C1OCO2)N[S@](C(C)(C)C)=O Chemical compound CC[C@H](CC(C=C1)=CC2=C1OCO2)N[S@](C(C)(C)C)=O VYOHAAPQYKJYQU-ODXCJYRJSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 239000012024 dehydrating agents Substances 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 235000019341 magnesium sulphate Nutrition 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- SJFNDMHZXCUXSA-UHFFFAOYSA-M methoxymethyl(triphenyl)phosphanium;chloride Chemical compound [Cl-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(COC)C1=CC=CC=C1 SJFNDMHZXCUXSA-UHFFFAOYSA-M 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 208000028173 post-traumatic stress disease Diseases 0.000 description 3
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical group O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 2
- SWKXHWCUDGJLNA-UHFFFAOYSA-N 1-(1,3-benzodioxol-5-yl)butan-2-one Chemical compound CCC(=O)CC1=CC=C2OCOC2=C1 SWKXHWCUDGJLNA-UHFFFAOYSA-N 0.000 description 2
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- JNQFACAMPWCNEO-SFHVURJKSA-N CC(C)(C)[S@@](N=CCC(C=C1)=CC2=C1OCO2)=O Chemical compound CC(C)(C)[S@@](N=CCC(C=C1)=CC2=C1OCO2)=O JNQFACAMPWCNEO-SFHVURJKSA-N 0.000 description 2
- JNQFACAMPWCNEO-GOSISDBHSA-N CC(C)(C)[S@](N=CCC(C=C1)=CC2=C1OCO2)=O Chemical compound CC(C)(C)[S@](N=CCC(C=C1)=CC2=C1OCO2)=O JNQFACAMPWCNEO-GOSISDBHSA-N 0.000 description 2
- JXOOMXGMOITJGB-YEJXKQKISA-N CC[C@@H](CC(C=C1)=CC2=C1OCO2)N(C)[S@@](C(C)(C)C)=O Chemical compound CC[C@@H](CC(C=C1)=CC2=C1OCO2)N(C)[S@@](C(C)(C)C)=O JXOOMXGMOITJGB-YEJXKQKISA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 150000004703 alkoxides Chemical class 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 150000007514 bases Chemical class 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 125000005605 benzo group Chemical group 0.000 description 2
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 239000010779 crude oil Substances 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 125000000219 ethylidene group Chemical group [H]C(=[*])C([H])([H])[H] 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- 150000003949 imides Chemical class 0.000 description 2
- 239000002608 ionic liquid Substances 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
- 238000003760 magnetic stirring Methods 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 238000001671 psychotherapy Methods 0.000 description 2
- 238000002390 rotary evaporation Methods 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- UYCAUPASBSROMS-AWQJXPNKSA-M sodium;2,2,2-trifluoroacetate Chemical compound [Na+].[O-][13C](=O)[13C](F)(F)F UYCAUPASBSROMS-AWQJXPNKSA-M 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Substances C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 238000001665 trituration Methods 0.000 description 2
- 238000005292 vacuum distillation Methods 0.000 description 2
- 238000003828 vacuum filtration Methods 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- LFXXIXAVEJVYGY-UHFFFAOYSA-N 1-(1,3-benzodioxol-5-yl)-n-methylbutan-2-amine;hydrochloride Chemical compound Cl.CCC(NC)CC1=CC=C2OCOC2=C1 LFXXIXAVEJVYGY-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- OIFBSDVPJOWBCH-UHFFFAOYSA-N Diethyl carbonate Chemical compound CCOC(=O)OCC OIFBSDVPJOWBCH-UHFFFAOYSA-N 0.000 description 1
- 241000110847 Kochia Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229920004482 WACKER® Polymers 0.000 description 1
- 238000005923 Wacker-Tsuji oxidation reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000005042 acyloxymethyl group Chemical group 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 238000005576 amination reaction Methods 0.000 description 1
- 239000012296 anti-solvent Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 230000005595 deprotonation Effects 0.000 description 1
- 238000010537 deprotonation reaction Methods 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N hydroxymaleic acid group Chemical group O/C(/C(=O)O)=C/C(=O)O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- FBAFATDZDUQKNH-UHFFFAOYSA-M iron chloride Chemical group [Cl-].[Fe] FBAFATDZDUQKNH-UHFFFAOYSA-M 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- RQXUDOCAWHFOMD-QMMMGPOBSA-N n,2-dimethylpropane-2-sulfinamide Chemical compound CN[S@@](=O)C(C)(C)C RQXUDOCAWHFOMD-QMMMGPOBSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000005580 one pot reaction Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 229960005235 piperonyl butoxide Drugs 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- CHKVPAROMQMJNQ-UHFFFAOYSA-M potassium bisulfate Chemical compound [K+].OS([O-])(=O)=O CHKVPAROMQMJNQ-UHFFFAOYSA-M 0.000 description 1
- 229910000343 potassium bisulfate Inorganic materials 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 229940001470 psychoactive drug Drugs 0.000 description 1
- 239000004089 psychotropic agent Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- CWXOAQXKPAENDI-UHFFFAOYSA-N sodium methylsulfinylmethylide Chemical compound [Na+].CS([CH2-])=O CWXOAQXKPAENDI-UHFFFAOYSA-N 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 150000003628 tricarboxylic acids Chemical class 0.000 description 1
- FIQMHBFVRAXMOP-UHFFFAOYSA-N triphenylphosphane oxide Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=O)C1=CC=CC=C1 FIQMHBFVRAXMOP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
- C07D317/58—Radicals substituted by nitrogen atoms
Definitions
- TITLE PROCESSES FOR THE PREPARATION OF THE ENANTIOMERS OF 3,4- METHYLENEDIOXYMETHAMPHETAMINE (MDMA) AND N-METHYL-1,3- BENZODIOXOLYLBUTANAMINE (MBDB)
- the present application is related to processes for preparing (R)- or (S)-
- MDMA 3,4-Methylenedioxymethamphetamine
- E ecstasy
- molly is a psychoactive drug first developed in 1912 by Merck.
- MDMA is often used recreationally today.
- an initial use of MDMA was as an adjunct to psychotherapy.
- MDMA has been studied in various clinical trials, for example, investigating MDMA-assisted psychotherapy for posttraumatic stress disorder (PTSD), anxiety related to advanced-stage illness, and social anxiety in autistic adults.
- MDMA has now been grated Breakthrough Therapy Designation to MDMA for the treatment of PTSD by the United States Food and Drug Administration (FDA).
- FDA United States Food and Drug Administration
- R (-)-MDMA may provide an improved therapeutic index maintaining the therapeutic effects of ( ⁇ )-MDMA with a reduced side effect profile (Pitts et al. Psychopharmacology 235, 377-392, 2018).
- MBDB N-methyl-1 ,3-benzodioxolylbutanamine
- Eden or Methyl-J is an analogue of MDMA which has an ethyl group instead of a methyl group attached to the alpha carbon next to the amine.
- MBDB is also classified as an entactogen.
- the present application includes processes for preparing the (R)- or (S)- enantiomers of 3,4-methylenedioxymethamphetamine (MDMA) and (N-methyl-1 ,3- benzodioxolylbutanamine (MBDB) using (R)-tert-butanesulfinamide or (S)-tert- butanesulfinamide as a chiral auxiliary.
- the application includes a process for preparing the enantiomers of MDMA and MBDB through the reduction of an imide intermediate derived from using tert-butanesulfinamide.
- the present application includes a process for preparing an acid salt of a compound of Formula (R)-l or (S)-l: wherein R 1 is selected from CH 3 and CH 2 CH 3 ; the process comprising: reacting a compound of Formula B: wherein R 1 is selected from CH 3 and CH 2 CH 3 ; with (R)-t-butylS(0)NH 2 or (S)- )-t-butylS(0)NH 2 under reductive amination conditions to provide a compound of Formula (R),(R)-C or (S),(S)-C, respectively: wherein R 1 is selected from CH 3 and CH 2 CH 3 ; or homologating piperonal, ⁇ °t ° , to provide a compound of Formula B': reacting the compound of Formula B' with (S)-t-butylS(0)NH 2 or (R)-t- butylS(0)NH 2 to provide a compound of Formula (S)-C im or(R)-C im respectively: reacting the compound of
- the present application also includes a compound of Formula (S)-C': wherein R 1 is CH 30r CH 2 CH 3 .
- the present application also includes a compound of Formula (R),(R)-C: wherein R 1 is selected from CH 3 and CH 2 CH 3 .
- the present application also includes a compound of Formula (S),(S)-C: wherein R 1 is selected from CH 3 and CH 2 CH 3
- the present application includes a compound of Formula (S)-C im : [0014] The present application also includes a compound of Formula (R)-C im :
- the present application includes a compound of Formula (R),(S)-C": wherein R 1 is Chl3or CH2CH3.
- the present application also includes a compound of Formula (S),(R)-C": wherein R 1 is selected from CH3 and CH 2 CH3.
- the present application also includes a compound of Formula (R),(R)-D: wherein R 1 is CH 3 or CH 2 CH 3 .
- the present application also includes a compound of Formula (S),(S)-D: wherein R 1 is CH 3 or CH 2 CH 3 .
- the present application also includes a compound of Formula (R),(S)-D': wherein R 1 is CH 3 or CH 2 CH 3 .
- the present application also includes a compound of Formula (S),(R)-D': wherein R 1 is CH 3 or CFhCFh.
- process of the application refers to a process of preparing (R)- or (S)-MDMA or (R)- or (S)-MBDB, or an acid salts thereof, as described herein.
- the term “and/or” as used herein means that the listed items are present, or used, individually or in combination. In effect, this term means that “at least one of or “one or more” of the listed items is used or present.
- the term “and/or” with respect to pharmaceutically acceptable salts and/or solvates thereof means that the compounds of the application exist as individual salts and hydrates, as well as a combination of, for example, a solvate of a salt of a compound of the application.
- suitable means that the selection of the particular compound or conditions would depend on the specific synthetic manipulation to be performed, the identity of the molecule(s) to be transformed and/or the specific use for the compound, but the selection would be well within the skill of a person trained in the art. All process/method steps described herein are to be conducted under conditions to provide the product shown. A person skilled in the art would understand that, unless otherwise indicated, all reaction conditions, including, for example, reaction solvent, reaction time, reaction temperature, reaction pressure, reactant ratio and whether or not the reaction should be performed under an anhydrous or inert atmosphere, can be varied to optimize the yield of the desired product and it is within their skill to do so.
- alkyl as used herein, whether it is used alone or as part of another group, means straight or branched chain, saturated alkyl groups.
- the number of carbon atoms that are possible in the referenced alkyl group are indicated by the prefix “Cni-n2”.
- Ci_ 6 alkyl means an alkyl group having 1 , 2, 3, 4, 5 or 6 carbon atoms.
- available refers to atoms that would be known to a person skilled in the art to be capable of replacement by a substituent.
- MDMA refers to a compound having the chemical name: 1-(1 ,3-benzodioxol-5-yl)-N-methylpropan-2-amine or 3,4- methylenedioxymethamphetamine, and having the chemical formula:
- (R)-MDMA refers to a compound having the chemical name: (2R)-1-(1,3-benzodioxol-5-yl)-N-methylpropan-2-amine or (R)-3,4- methylenedioxymethamphetamine, and having the chemical formula: [0037]
- (S)-MDMA refers to a compound having the chemical name: (2S)-1-(1,3-benzodioxol-5-yl)-N-methylpropan-2-amine, or (S)-3,4- methylenedioxymethamphetamine, and having the chemical formula:
- MBDB refers to a compound having the chemical name: 1-(1,3-benzodioxol-5-yl)-N-methylbutan-2-amine or N-methyl-1 ,3- benzodioxolylbutanamine, and having the chemical formula: [0039]
- the term “(R)-MBDB” as used herein refers to a compound having the chemical name: (2R)-1-(1 ,3-benzodioxol-5-yl)-N-methylbutan-2-amine or (R)-N-methyl- 1 ,3-benzodioxolylbutanamine, and having the chemical formula: [0040]
- (S)-MBDB” as used herein refers to a compound having the chemical name: (2S)-1-(1 ,3-benzodioxol-5-yl)-N-methylbutan-2-amine or (S)-N-methyl- 1 ,3-benzodi
- reducing agent means any compound or combination of compounds that reduces a desired functional group.
- a reducing agent results in the overall addition of electrons, or in the case of organic chemistry, hydrogen atoms to the functional group.
- inert solvent means a solvent that does not interfere with or otherwise inhibit a reaction. Accordingly, the identity of the inert solvent will vary depending on the reaction being performed. The selection of inert solvent is within the skill of a person in the art.
- solvent includes both a single solvent and a mixture comprising two or more solvents.
- protecting group or “PG” and the like as used herein refers to a chemical moiety which protects or masks a reactive portion of a molecule to prevent side reactions in those reactive portions of the molecule, while manipulating or reacting a different portion of the molecule.
- the protecting group is removed under conditions that do not degrade or decompose the remaining portions of the molecule.
- the selection of a suitable protecting group can be made by a person skilled in the art.
- Many conventional protecting groups are known in the art, for example as described in “Protective Groups in Organic Chemistry” McOmie, J.F.W. Ed., Plenum Press, 1973, in Greene, T.W. and Wuts, P.G.M., “Protective Groups in Organic Synthesis”, John Wiley & Sons, 3 rd Edition, 1999 and in Kocienski, P. Protecting Groups, 3rd Edition, 2003, Georg Thieme Verlag (The Americas).
- major isomer refers to a stereochemical isomer, including a regional isomer, that is the most abundant isomer in a mixture of isomers of the same compound.
- minor isomer refers to a stereochemical isomer, including a regional isomer, that is not the most abundant isomer in a mixture of isomers of the same compound.
- enantiomeric excess or “ee” is the absolute difference between the mole fraction of each enantiomer for a racemic compound.
- the products of the processes of the application may be isolated according to known methods, for example, the compounds may be isolated by evaporation of the solvent, by filtration, centrifugation, chromatography or other suitable method.
- the present application includes a process for preparing (R)- or (S)-3,4- methylenedioxymethamphetamine (R-MDMA or S-MDMA) or (R)- or (S)-N-methyM ,3- benzodioxolylbutanamine (R-MBDB or S-MBDB) using (R)-tert-butanesulfinamide or (S)- tert-butanesulfinamide as a chiral auxiliary.
- the application includes a process for preparing (R)- or (S)-3, 4-methylenedioxymethamphetamine (R-MDMA or S- MDMA) or (R)- or (S)-N-methyM ,3-benzodioxolylbutanamine (R-MBDB or S-MBDB) through the reduction of an imide intermediate derived from using tert-butanesulfinamide.
- the present application includes a process for preparing an acid salt of a compound of Formula (R)-l or (S)-l: wherein R 1 is selected from CH 3 and CH 2 CH 3 ; the process comprising: reacting a compound of Formula B: B wherein R 1 is selected from CH 3 and CH 2 CH 3 ; with (R)-t-butylS(0)NH 2 or (S)- )-t-butylS(0)NH 2 under reductive amination conditions to provide a compound of Formula (R),(R)-C or (S),(S)-C, respectively: wherein R 1 is selected from CH 3 and CH 2 CH 3 ; or homologating piperonal, , to provide a compound of Formula B': reacting the compound of Formula B' with (S)-t-butylS(0)NH 2 or (R)-t- butylS(0)NH 2 to provide a compound of Formula (S)-C im or(R)-C im respectively: reacting the compound of Formula (S)-
- the present application also includes a process for preparing an acid salt of a compound of Formula (R)-l wherein R 1 is selected from CH 3 and CH2CH3; the process comprising: reacting a compound of Formula B B wherein R 1 is selected from CH 3 and CH 2 CH 3 ; with (R)-t-butylS(0)NH 2 under reductive amination conditions to provide a compound of (R),(R)-Formula C wherein R 1 is selected from CH 3 and CH 2 CH 3 ; or homologating piperonal, , to provide a compound of Formula B' reacting the compound of Formula B' with (S)-t-butylS(0)NH 2 to provide a compound of Formula (S)-C im ; reacting the compound of Formula (S)-C im with a methyl or ethyl organometallic reagent to provide the compound of Formula (R),(S)-C" wherein R 1 is CH 3 or CH 2 CH 3 ; methylating the compound of Formula (R),
- the present application also includes a process for preparing an acid salt of a compound of Formula (S)-l wherein R 1 is selected from CH 3 and CH2CH3; the process comprising: reacting a compound of Formula B B wherein R 1 is selected from CH 3 and CH 2 CH 3 ; with (S)-t-butylS(0)NH 2 under reductive amination conditions to provide a compound of Formula (S),(S)-C wherein R 1 is selected from CH 3 and CH 2 CH 3 ; or homologating piperonal, , to provide a compound of Formula B' reacting the compound of Formula B' with (R)-t-butylS(0)NH 2 to provide a compound of Formula (R)-C im ; reacting the compound of Formula (R)-C im with a methyl or ethyl organometallic reagent to provide the compound of Formula (S),(R)-C" wherein R 1 is CH 3 or CH 2 CH 3 ; methylating the compound of Formula (S),(S)
- the present application includes a process for preparing an acid salt of a compound of Formula (R)-l or (S)-l: wherein R 1 is selected from CH 3 and CH 2 CH 3 ; the process comprising: reacting a compound of Formula B: B wherein R 1 is selected from CH 3 and CH 2 CH 3 ; with (R)-t-butyiS(0)NH 2 or (S)-t-butyiS(0)NH 2 under reductive amination conditions to provide a compound of Formula (R),(R)-C or (S),(S)-C, respectively: wherein R 1 is selected from CH 3 and CH 2 CH 3 ; methylating the compound of Formula (R),(R)-C or (S),(S)-C to provide a compound of Formula (R),(R)-D or (S),(S)-D, respectively: wherein R 1 is CH 3 or CH 2 CH 3 ; and reacting the compound of Formula (R),(R)-D or (S),(S)-D
- the compound of Formula B is either commercially available or may be prepared using methods known in the art.
- R 1 is CH 3 and the compound of Formula B is .
- the compound of Formula B wherein R 1 is CH 3 is prepared by a process comprising oxidizing a compound of Formula A or a compound of Formula A': wherein indicates that the bond is in a cis and/or trans orientation to provide a compound of Formula B: wherein R 1 is CH 3 .
- the compound of Formula (R)-l wherein R 1 is CH 3 is (R)-3,4- methylenedioxymethamphetamine ((R)-MDMA).
- the compound of Formula (S)-l wherein R 1 is CH 3 is (S)-3, 4-methylenedioxymethamphetamine ((S)-MDMA).
- the present application also includes a process for preparing an acid salt of (R)- 3, 4-methylenedioxymethamphetamine ((R)-MDMA) or an acid salt of (S)-3,4- methylenedioxymethamphetamine ((S)-MDMA): the process comprising: oxidizing a compound of Formula A or a compound of Formula A': wherein - « indicates that the bond is in a cis and/or trans orientation to provide a compound of Formula B: wherein R 1 is CH 3 ; reacting the compound of Formula B with (R)-t-butylS(0)NH 2 or (S) (R)-t- butyiS(0)NH 2 under reductive amination conditions to provide a compound of Formula (R),(R)-C or (S),(S)-C, respectively: wherein R 1 is CH 3 ; methylating the compound of Formula (R),(R)-C or (S),(S)-C to provide a compound of Formula
- the compound of Formula (R)-l when R 1 is CH2CH3 is (R)-N-methyl-1 ,3- benzodioxolylbutanamine ((R)-MBDB).
- the compound of Formula (S)-l when R 1 is CH2CH3 is (S)-N-methyM ,3-benzodioxolylbutanamine ((S)-MBDB).
- the present application includes a process for preparing an acid salt of (R)-N- methyl-1 ,3-benzodioxolylbutanamine ((R)-MBDB) or (S)-N-methyl-l ,3- benzodioxolylbutanamine ((S)-MBDB): the process comprising: reacting a compound of Formula B: B wherein R 1 is CH 2 CH 3 ; with (R)-t-butyiS(0)NH 2 or (S) (R)-t-butyiS(0)NH 2 under reductive amination conditions to provide a compound of Formula (R),(R)-C or (S),(S)-C.
- R 1 is CH 2 CH 3 ; methylating the compound of Formula (R),(R)-C or (S),(S)-C to provide a compound of Formula (R),(R)-D or (S),(S)-D, respectively: wherein R 1 is CH 2 CH 3 ; and reacting the compound of Formula (R),(R)-D or (S),(S)-D with an acid to provide the acid salt of (R)-MBDB or the acid salt of (S)-MBDB, respectively.
- the present application also includes a process for preparing an acid salt of a compound of Formula (R)-l or (S)-l: wherein R 1 is selected from CFh and CFhCFh; the process comprising: reacting the compound of Formula B' with (S)-t-butyiS(0)NH 2 or (R)-t- butyiS(0)NH 2 to provide a compound of Formula (S)-C im or (R)-C im , respectively: reacting the compound of Formula (S)-C im or (R)-C im with a methyl or ethyl organometallic reagent to provide the compound of Formula (R),(S)-C" or (S)(R)-C", respectively: wherein R 1 is selected from CH 3 and CH 2 CH 3 ; methylating the compound of Formula (R),(S)-C" or (S)(R)-C" to provide a compound of Formula (R),(S)-D' or (S),(R)-D', respectively: wherein
- the present application includes a process for preparing an acid salt of (R)-3,4- methylenedioxymethamphetamine ((R)-MDMA) the process comprising: homologating piperonal, , to provide a compound of Formula (B') reacting the compound of Formula B' with (S)-t-butylS(0)NH 2 to provide a compound of Formula S-C im : reacting the compound of Formula (S)-C im with a methyl organometallic reagent to provide the compound of (R),(S)-C": wherein R 1 is CH 3 ; methylating the compound of Formula (R),(S)-C" to provide a compound of
- Formula (R),(S)-D' wherein R 1 is CH 3 ; and reacting the compound of Formula (R),(S)-D', with an acid to provide the acid salt of (R)-MDMA.
- R 1 is CH 2 CH 3 and the compound of Formula I is
- the compound of Formula A is known as safrole.
- the compound of Formula A is either commercially available or may be prepared using methods known in the art.
- the compound of Formula A (safrole) is available from Sigma Aldrich (St. Louis, Missouri, USA).
- the compound of Formula A is oxidized to provide a compound of Formula B using any suitable conditions for oxidizing the compound of Formula A to provide the compound of Formula B known in the art, for example, using the synthetic procedures found in Advanced Synthesis & Catalysis 361(11) p2582-2593, 2019 or Forensic Science International, 248, 140-147; 2015.
- the compound of Formula A is oxidized to provide a compound of Formula B using Wacker oxidation or Wacker-Tsuji oxidation conditions.
- the compound of Formula A is oxidized to provide a compound of Formula B in the presence of a palladium (II) catalyst and water or an iron (III) catalyst and water, or a combination thereof at temperatures and at times to provide the compound of Formula B.
- the palladium (II) catalyst is selected from palladium chloride (PdCI 2 ) or palladium (II) trifluoroacetate ((CF 3 C0 2 ) 2 Pd).
- the iron (III) catalyst is iron (III) chloride (FeCI 3 ).
- the suitable conditions further comprise a co-oxidant.
- the co-oxidant is benzoquinone.
- the oxidation conditions further comprise a co solvent.
- the co-solvent is selected from dimethylformamide, acetonitrile and methanol, and combinations thereof.
- the temperature for oxidizing the compound of Formula A to provide the compound of Formula B is about 10 °C, about 20 °C, about 30 °C, about 40 °C, about 50 °C, about 60 °C or about 70 °C.
- the compound of Formula A is oxidized to provide a compound of Formula B in the presence of an excess amount (for example about 2% to 5% molar equivalents, or a 2.5% molar equivalent) of a palladium (II) catalyst, an excess amount (for example about 1 to 3 molar equivalent, or 1.5 molar equivalent) of an iron (III) catalyst and water at temperatures and at times to provide the compound of Formula B.
- the palladium (II) catalyst is palladium (II) trifluoroacetate ((CF 3 C0 2 ) 2 Pd) and the iron (III) catalyst is iron chloride (FeCI 3 ).
- the suitable conditions further comprise using acetonitrile as the co solvent.
- the temperature for oxidizing the compound of Formula A in the presence of a palladium (II) catalyst, and an iron (III) catalyst to provide the compound of Formula B is about 40 °C, about 50 °C, or about 60 °C and representative, non-limiting example of reaction time, is about 4 hour to about 24 hours, about 8 hours to about 18 hours, about 12 hours to about 18 hours, about 14 hours to about 18 hours or about 16 hours.
- the compound of Formula A is oxidized to provide a compound of Formula B in the presence of a catalytic amount (for example about 1 to about 15 mole percent) of a palladium (II) catalyst, an excess amount (for example, about 1.1 to about 5 molar equivalents) of a co-oxidant and water at temperatures and at times to provide the compound of Formula B.
- a catalytic amount for example about 1 to about 15 mole percent
- a palladium (II) catalyst is palladium (II) chloride (PdCI 2 ) and the co-oxidant is benzoquinone.
- the suitable conditions further comprise using methanol as the co-solvent.
- the temperature for oxidizing the compound of Formula A in the presence of a palladium (II) catalyst and a co-oxidant to provide the compound of Formula B is about 10 °C, about 10 °C, about 20 °C, or about 30 °C, and representative, non-limiting example of reaction time, is about 1 hour to about 5 hours, about 1 hours to about 4 hours, about 2 hours to about 4 hours, or about 3 hours.
- the compound of Formula A' is known as isosafrole.
- the compound of Formula A' is either commercially available or may be prepared using methods known in the art.
- the compound of Formula A' (isosafrole) is available from Sigma Aldrich (St. Louis, Missouri, USA).
- the compound of Formula A' is a mixture of cis and trans isomers.
- the compound of Formula A' is prepared by isomerizing the compound of Formula A. Therefore, alternatively, in some embodiments, the process comprises isomerizing the compound of Formula A: to provide a compound of Formula A': wherein indicates that the bond is in a cis and/or trans orientation; and oxidizing the compound of Formula A' to provide a compound of Formula B: wherein R 1 is CH 3 .
- the compound of Formula A is isomerized to provide a compound of Formula A' using any suitable conditions for isomerizing the compound of Formula A to provide the compound of Formula A' known in the art, for example, using the synthetic procedures found in Forensic Science International 155 (2005) 141-157.
- the step of isomerizing a compound of Formula A to provide a compound of Formula A' comprises reacting the compound of Formula A in the presence of a base and an inert solvent at a temperature and for a time to provide the compound of Formula A'.
- the base is potassium tert-butoxide, sodium hydroxide or potassium hydroxide.
- the base is potassium hydroxide.
- the inert solvent is DMSO.
- the step of isomerizing a Formula A to provide a compound of Formula A' is in the presence of potassium tert-butoxide in DMSO at a temperature and for a time to provide the compound of Formula A'.
- the temperature is maintained at boiling point of the solvent (reflux) for about 1 hour to about 6 hours, about 2 hours to about 5 hours, about 3 hours to about 5 hours, or about 4 hours to provide the compound of Formula B.
- the step of isomerizing a compound of Formula A to provide a compound of Formula A' comprises reacting the compound of Formula A in the presence of a base and a phase transfer catalyst at a temperature and for a time to provide the compound of Formula A'.
- the phase transfer catalyst is an ionic liquid.
- the phase transfer catalyst is aliquot 336 (Stark’s catalyst).
- the step of isomerizing a Formula A to provide a compound of Formula A' comprises reacting the compound of Formula A in the presence of a potassium hydroxide and aliquot 336 at a temperature and for a time to provide the compound of Formula A'.
- the compound of Formula A, the base and the phase transfer catalyst are combined at room temperature and are agitated for about 15 minutes to about 30 minutes, or about 20 minutes, followed by heating to a temperature of about 50°C to about 90°C, about 60°C to about 90°C, or about 80°C for about 30 minutes to about 2 hours, about 45 minutes to about 90 minutes, about 60 minutes to about 90 minutes or about 75 minutes to provide the compound of Formula A'.
- the compound of Formula A' is oxidized to provide a compound of Formula B using any suitable conditions for oxidizing the compound of Formula A' to provide the compound of Formula B known in the art, for example, using the synthetic procedures found in Forensic Science International 155 (2005) 141-157.
- the compound of Formula A' is oxidized to provide a compound of Formula B in the presence of hydrogen peroxide and formic acid in water at a time and a temperature to provide the compound of Formula B.
- the step of oxidizing a compound of Formula A' to provide a compound of Formula B further comprises an inert solvent.
- the inert solvent is acetone.
- the hydrogen peroxide and formic acid in water is added, for example, dropwise to a solution of the compound of Formula B in an inert solvent to provide a reaction mixture which is maintained with cooling at a temperature of from about 18 °C to about 45 °C, about 25°C to about 40 °C, or about 30 °C to about 40 °C.
- the reaction mixture is maintained at room temperature (e.g., about 18 °C to about 25 °C) for about 14 to about 20hours, or about 16 hours.
- the reaction mixture is concentrated and then dissolved in a solvent and treated with an acid for a time and at a temperature to provide the compound of Formula B.
- the solvent is methanol or ethanol.
- the solvent is methanol.
- the acid is sulfuric acid.
- the reaction is heated to about 30 °C to about 80°C, about 30 °C to about 60 °C, or about 40 °C to about 60 °C for about 1 hour to about 6 hours, about 2 hours to about 4 hours or about 3 hours.
- the (R)-t-butylS(0)NH 2 has an enantiomeric purity of about 97% or greater or of about 98% or greater. In some embodiments, the (R)-t- butyiS(0)NH 2 has an enantiomeric purity of about 97% to about 99.9%, about 97% to about 99.8%, about 97% to about 99.5%, about 97% to about 99%, about 97% to about 98%, about 98% to about 99.8%, about 98% to about 99.5%, or about 98% to about 99%.
- the (R)-t-butyiS(0)NH 2 having an enantiomeric purity of about 97% or greater or of about 98% or greater is either commercially available or may be prepared using methods known in the art.
- (R)-t-butyiS(0)NH 2 with a purity of about 98% or greater is available from Sigma Aldrich (St. Louis, Missouri, USA) or Fischer Scientific (Waltham, Massachusetts, USA).
- the (S)-t-butyiS(0)NH 2 has an enantiomeric purity of about 97% or greater. In some embodiments, the (S) -t-butyiS(0)NH 2 has an enantiomeric purity of about 97% to about 99.9%, about 97% to about 99.8%, about 97% to about 99.5%, about 97% to about 99%, about 97% to about 98%, or about 98% to about 99%. In some embodiments, the (S)-t-butyiS(0)NH 2 having an enantiomeric purity of about 97% or greater is either commercially available or may be prepared using methods known in the art.
- (S)-t-butyiS(0)NH 2 with a purity of about 97% or greater is available from Sigma Aldrich (St. Louis, Missouri, USA).
- the compound of Formula B is reacted with (R)-t- butyiS(0)NH 2 or (S)-t-butylS(0)NH 2 under any suitable reductive amination conditions to provide a compound of Formula (R),(R)-C or (S),(S)-C, respectively, for example, using the synthetic procedures found in Llabres et al (2014), European Journal of Medicinal Chemistry 81 (2014) 35-46.
- the suitable reductive amination conditions comprise a first step of reacting a compound of Formula B with (R)-t-butylS(0)NH 2 or (S)- t-butyiS(0)NH 2 in the presence of a titanium catalyst followed by a second step of adding a suitable reducing agent to provide the compound of Formula (R),(R)-C or (S),(S)-C.
- the suitable reductive amination conditions comprise a first step of reacting a compound of Formula B with (R)-t-butylS(0)NH 2 or (S)-t-butylS(0)NH 2 in the presence of a titanium catalyst to provide a compound of Formula C: wherein R 1 is selected from CH 3 and CH 2 CH 3 ; followed by a second step of adding a suitable reducing agent to provide the compound of Formula (R),(R)-C or (S),(S)-C.
- the suitable reductive amination conditions comprise a first step of reacting a compound of Formula B with an excess amount (for example, about 1.1 to about 2 molar equivalents) of (R)-t-butylS(0)NH 2 or (S)-t- butyiS(0)NH 2 in the presence of an excess amount (for example, about 1.1 to about 10 equivalents) of a titanium catalyst in a solvent at a temperature and a time to react the compound of Formula B with (R)-t-butylS(0)NH 2 or (S)-t-butylS(0)NH 2 to provide a compound of Formula C, followed by a second step of adding a suitable reducing agent to the compound of Formula C to provide the compound of Formula (R),(R)-C or (S),(S)- C.
- an excess amount for example, about 1.1 to about 2 molar equivalents
- an excess amount for example, about 1.1 to about 10 equivalents
- the compound of Formula C is not isolated.
- the reaction of the compound of Formula B with the titanium catalyst is maintained at boiling point of the solvent (reflux) for about 1 hour to about 8 hours, about 2 hours to about 6 hours, about 3 hours to about 6 hours, or about 5 hours to provide the compound of Formula C, and then cooled to about -25 °C to about 15 °C, or about -20°C before the second step of adding a suitable reducing agent to provide the compounds of Formula (R),(R)-C or (S),(S)-C.
- the reduction reaction to provide the compound of Formula (R),(R)-C or (S),(S)-C is maintained at about -25 °C to about -15 °C, or about -20°C for about 1 hour to about 4 hours or about 2 to about 3 hours or about 3 hours and then at room temperature (e.g., about 18 °C to 25 °C) for about 8 to about 12 hours.
- the first and second step of the reduction amination of the compound of Formula B to provide the compound of Formula (R),(R)-C or (S),(S)- C occur sequentially in one reaction vessel (one pot).
- the compound of Formula C is isolated before proceeding with the second step.
- the suitable reductive amination conditions comprise reacting the compound of Formula B with (R)-t-butylS(0)NH 2 or (S)- t-butylS(0)NH 2 to provide a compound of Formula C, and wherein R 1 is selected from CH 3 and CH 2 CH 3 ; reducing the compound of Formula C with a reducing agent to provide a compound of Formula (R),(R)-C or (S),(S)-C.
- the titanium catalyst is selected from titanium (IV) isopropoxide (Ti(OiPr)4) and titanium (IV) ethoxide (Ti(OEt)4).
- the titanium catalyst is titanium (IV) ethoxide (Ti(OEt)
- the inert solvent is tetrahydrofuran, toluene or xylene. In some embodiments, the inert solvent is tetrahydrofuran.
- the suitable reducing agent to provide the compound of Formula (R),(R)-C or (S),(S)-C is any suitable reducing agent that reduces the fe/f-butanesulfinyl imine compound of Formula C to provide a compound of Formula (R),(R)-C or (S),(S)-C.
- the suitable reducing agent is sodium borohydride.
- piperonal is either commercially available or may be prepared using methods known in the art.
- piperonal is available from Sigma Aldrich (St. Louis, Missouri, USA).
- piperonal is homologated to provide a compound of Formula B' using any suitable conditions for homologating piperonal to provide a compound of Formula B' known in the art, for example, using the synthetic procedures found in Tetrahedron: Asymmetry, 27(6), 274-284; 2016.
- the step of homologating piperonal to provide a compound of Formula (B') is with the Wittig reagent methoxymethylenetriphenylphosphine under Wittig reaction conditions. Accordingly, in some embodiments, the process comprises homologating piperonal with methoxymethylenetriphenylphosphine under Wittig reaction conditions to provide a compound of Formula (B').
- the methoxymethylenetriphenylphosphine is generated in situ, for example, by the deprotonation of, for example, methoxymethyl(triphenyl)phosphonium chloride with a suitable base.
- the Wittig reaction conditions comprise combining methoxymethyl(triphenyl)phosphonium chloride with an excess amount (for example, about 1.1 to about 2 molar equivalents) of suitable base in an inert solvent at a temperature of about 0 °C to about 15°C, about 0 °C to about 10 °C, or about 0 °C to about 5 °C or about 0 °C and then stirring at about room temperature (e.g., about 18 °C to 25 °C) for about 15 minutes to about 1 hour, about 30 minutes to about 1 hour, about 30 minutes to about 45 minutes, or about 30 minutes, to provide the methoxymethylenetriphenylphosphine.
- an excess amount for example, about 1.1 to about 2 molar equivalents
- room temperature e.g., about 18 °C to 25 °C
- the suitable base is selected from alkyllithiums; alkoxides such as sodium methoxide or potassium tert- butoxide; dimsyl sodium; hydrides such as sodium hydride, amides; and amines such as triethylamine.
- the suitable base is an alkoxide such as sodium methoxide or potassium tert-butoxide.
- the suitable base potassium tert-butoxide.
- the suitable inert solvent is THF or toluene.
- the Wittig reaction conditions further comprise reacting piperonal with the methoxymethylenetriphenylphosphine for a time and at temperature to provide a vinyl ether intermediate, reacting the vinyl ether intermediate with a suitable acid for a time and at a temperature to provide the compound of Formula B'.
- the piperonal is reacted with the methoxymethylenetriphenylphosphine at about room temperature (e.g., about 18 °C to 25 °C) for about 8 to about 20 hours, about 10 to about 16 hours, about 10 to about 14 hours or about 12 hours (e.g. overnight).
- the vinyl ether intermediate is reacted with a suitable acid at room temperature (e.g., about 18 °C to 25 °C) for about 24 hours about 72 hours, about 36 to about 60 hours, about 40 hours to about 50 hours, about 36 hours to about 72 hours, about 48 hours to about 72 hours, or about 72 hours.
- the suitable acid is selected from hydrochloric acid and formic acid. In some embodiments, the suitable acid is formic acid.
- the compound of Formula B' is reacted with (S)-t- butyiS(0)NH 2 or (R)-t-butylS(0)NH 2 under any suitable conditions to provide a compound of Formula (S)-C im or (R)-Ci m , respectively, for example, using the synthetic procedures found in Angewandte Chemie, International Edition, 53(48), 13215-13219; 2014 and Wakefield, Bryan Hall (2008) Synthetic studies on (E)-alkene peptide isosteres and thiophene-containing furanosteroids [Ph.D Thesis, University of Pittsburgh]
- the compound of Formula B' is reacted with (S)-t- butyiS(0)NH 2 or (R)-t-butyiS(0)NH 2 in the presence of a catalyst such as pyridinium p- toluenesulfonate (PPTS) or a titanium catalyst to provide the compound of Formula (S)- C im or (R)-C im .
- a catalyst such as pyridinium p- toluenesulfonate (PPTS) or a titanium catalyst to provide the compound of Formula (S)- C im or (R)-C im .
- the compound of Formula B' is reacted with (S)-t- butyiS(0)NH 2 or (R)-t-butyiS(0)NH 2 in the presence of a catalyst such as pyridinium p- toluenesulfonate or a titanium catalyst in an inert solvent at a temperature and a time to provide the compound of Formula (S)-C im or (R)-C im .
- a catalyst such as pyridinium p- toluenesulfonate or a titanium catalyst in an inert solvent at a temperature and a time to provide the compound of Formula (S)-C im or (R)-C im .
- the compound of Formula B' is reacted with (S)-t-butyiS(0)NH 2 or (R)-t-butyiS(0)NH 2 in the presence of pyridinium p-toluenesulfonate in an inert solvent at a temperature and a time to provide the compound of Formula (S)-C im or (R)-C im .
- the compound of Formula B' is reacted with (S)-t-butyiS(0)NH 2 or (R)-t-butyiS(0)NH 2 in the presence of pyridinium p-toluenesulfonate and a dehydrating agent in an inert solvent at a temperature and a time to provide the compound of Formula (S)-C im or (R)-C im .
- the compound of Formula B' is reacted with a slight excess (for example, about 1.1 to about 1.5 molar equivalents) of (S)-t-butyiS(0)NH 2 or (R)-t-butyiS(0)NH 2 in the presence of catalytic amounts (for example, 0.1 to 1 , or about 0.25 to about 0.75 molar equivalents) of pyridinium p-toluenesulfonate in the present of an excess amount (for example, about 7 to about 12 molar equivalents, or about 9 to about 11 molar equivalents) of a dehydrating agent in an inert solvent at a temperature and a time to provide the compound of Formula (S)-C im or (R)-C im .
- catalytic amounts for example, 0.1 to 1 , or about 0.25 to about 0.75 molar equivalents
- pyridinium p-toluenesulfonate in the present of an excess amount (for example, about 7 to about 12 molar equivalent
- the dehydrating reagent is magnesium sulfate.
- the inert solvent is methylene chloride.
- the compound of Formula B' is reacted with excess amount (for example, about 1.1 to about 2 molar equivalents) of (S)-t-butylS(0)NH 2 or (R)-t-butylS(0)NH 2 in the of an excess amount (for example, about 1.1 to about 10 molar equivalents) of a titanium catalyst in a solvent at a temperature and a time to react the compound of Formula B with (R)-t-butylS(0)NH 2 (R)-t-butylS(0)NH 2 to provide a compound of Formula (S)-C im or (R)-C im .
- excess amount for example, about 1.1 to about 2 molar equivalents
- excess amount for example, about 1.1 to about 10 molar equivalents
- the reaction of the compound of Formula B' with the titanium catalyst is maintained at boiling point of the solvent (reflux) for about 1 hour to about 8 hours, about 2 hours to about 6 hours, about 3 hours to about 6 hours, or about 5 hours to provide the compound of Formula (S)-C im or (R)-C im .
- the titanium catalyst is selected from titanium (IV) isopropoxide (Ti(OiPr)4) and titanium (IV) ethoxide (Ti(OEt)4).
- the titanium catalyst is titanium (IV) ethoxide (Ti(OEt)
- the inert solvent is tetrahydrofuran, toluene or xylene. In some embodiments, the inert solvent is tetrahydrofuran.
- the conditions for providing the compound of formula (R),(S)-C" or (S),(R)-C” are any suitable conditions for reacting the compound of Formula (S)-C im or (R)-C im , respectively, with a methyl or ethyl organometallic reagent to provide a compound of Formula (R),(S)-C" or (S),(R)-C” known in the art, for example, using the synthetic procedures found Tetrahedron, 55(29), 8883-8904; 1999.
- the compound of Formula (S)-C im or (R)-C im is reacted with an excess amount (for example, about 1.1 to about 3, or about 2 molar equivalent) of the methyl or ethyl organometallic reagent in a suitable inert solvent for a time and a temperature to provide the compound of Formula (R),(S)-C" or (S),(R)-C” .
- the suitable inert solvent is selected from methylene chloride, tetrahydrofuran, and diethyl ether.
- the suitable inert solvent is methylene chloride.
- the methyl or ethyl organometallic reagents is a
- the methyl or ethyl organometallic reagents is a Grignard reagent.
- the methyl or .ethyl organometallic reagent is methyl lithium or ethyllithium, respectively.
- the methyl or ethyl organometallic reagent is a Grignard reagent.
- the methyl or ethyl Grignard reagent is Ch MgBr or CH 3 CH 2 MgBr, respectively.
- the methyl or ethyl organometallic reagent is a Grignard reagent and the compound of Formula C im is reacted with the methyl or ethyl Grignard reagent at a temperature of about -60 °C to about -20 °C, about -50 °C to about -30 °C , -50 °C to about -40 °C or about -50 °C for about 2 to about 6 hours, about 3 to about 5 hours, or about 4 hours and then at about room temperature (e.g., about 18 °C to 25 °C) for about 4 hours to about 18 hours, about 6 hours to about 16 hours, about 8 hours to about 14 hours, or about 12 hours (e.g., overnight) to provide the compound of Formula (R),(S)-C" or (S),(R)-C".
- a temperature of about -60 °C to about -20 °C, about -50 °C to about -30 °C , -50 °C to about -40
- the compound of Formula (R),(R)-C or (S),(S)-C or the compound of Formula (R),(S)-C" or (S),(R)-C” is methylated under any suitable methylation conditions to methylate the compound of Formula R),(R)-C or (S),(S)-C or the compound of Formula (R),(S)-C" or (S),(R)-C" provide the compound of Formula
- the compound of Formula (R),(R)-C or (S),(S)-C or the compound of Formula (R),(S)-C" or (S),(R)-C” is methylated with a methyl halide in the presence of a base in an inert solvent at a temperature and a time to react the compound of Formula (R),(R)-C or (S),(S)-C or the compound of Formula (R),(S)-C" or
- the compound of Formula (R),(R)-C or (S),(S)-C or the compound of Formula (R),(S)-C" or (S),(R)-C" is methylated with an excess amount (for example, about 1.1 to about 8, or about 6 molar equivalents) of a methyl halide such as methyl iodide (Mel) in the presence of an excess amount (for example, about 1.1 to about 2 equivalents) of a base such as sodium hydride in an inert solvent at a temperature and a time to react the compound of Formula (R),(R)-C or (S),(S)-C or the compound of Formula (R),(S)-C" or (S),(R)-C" with the
- the inert solvent is dimethylformamide.
- the compound of Formula (R),(R)-C or (S),(S)-C or the compound of Formula (R),(S)-C" or (S),(R)-C” is reacted with the base at about 0 °C to about 10 °C or 0 °C to about 5 °C and then at room temperature (e.g., about 18 °Cto 25 °C) for about 15 minutes to about 1 hours, about 20 minutes to about 45 minutes, or about 20 minutes to about 30 minutes to form a reaction mixture which is then cooled to at a temperature of about 0 °C to about 10 °C or 0 °C to about 5 °C and reacted with the methyl halide such as methyl iodide and then at about room temperature (e.g., about 18 °C to 25 °C) for about 4 hours to about 18 hours, about 6 hours to about 16 hours, about
- room temperature e.g., about 18 °C
- the compound of Formula (R),(R)-D or (S),(S)-D or the compound of Formula (R),(S)-D' or (S),(R)-D' is reacted with an acid under any suitable conditions to provide the acid salt of the compound of Formula (R)-l (i.e., (R)- MDMA and (R)-MBDB) or (S)-l (i.e., (S)-MDMA and (S)-MBDB), respectively, known in the art, for example, using the synthetic procedures found in European Journal of Medicinal Chemistry, 81 , 35-46; 2014.
- the compound of Formula (R),(R)-D or (S),(S)-D or the compound of Formula (R),(S)-D' or (S),(R)-D' is reacted with an excess amount (for example, about 1.1 to about 6 equivalents) of acid in a solvent at a temperature and a time to provide the acid salt of the compound of Formula (R)-l (i.e., (R)-MDMA and (R)- MBDB) or (S)-l (i.e., (S)-MDMA and (S)-MBDB)).
- the solvent is water, methanol, dioxane, and mixtures thereof.
- the solvent is methanol and dioxane. In some embodiments, the solvent is methanol.
- the compound of Formula (R),(R)-D or (S),(S)-D or the compound of Formula (R),(S)-D' or (S),(R)-D' is combined with the acid at a temperature of about 0 °C to about 10 °C or 0 °C to about 5 °C and then at then (at about room temperature (e.g., about 18 °C to 25 °C) for about for about 1 hours to about 24 hours, about 3 hours to about 16 hours, about 4 hours to about 14 hours, about 6 hours to about 12 hours, about 8 hours to about 12 hours, or about 10 hours to about 12 hours(e.g overnight).
- the acid is sulfuric acid (H 2 S0 ), trifluoroacetic acid (TFA) or hydrochloric acid (HCI).
- the acid is HCI.
- the compound of Formula (R),(R)-D or (S),(S)-D or the compound of Formula (R),(S)-D' or (S),(R)-D' is reacted with HCI to provide an HCI salt of the compound of Formula (R)-l (i.e., (R)-MDMA.HCI and (R)-MBDB.HCI) or (S)-l (i.e., (S)- MDMA.HCI and (S)-MBDB).HCI).
- the compound of Formula (R)-l i.e., (R)-MDMA.HCI and (R)-MBDB.HCI
- S)-l i.e., (S)- MDMA.HCI and (S)-MBDB).HCI.
- the compound of Formula (R)-l i.e.
- the present application includes a process for preparing an HCI salt of a compound of Formula (R)-l: wherein R 1 is selected from CH 3 and CH 2 CH 3 ; the process comprising: reacting a compound of Formula B: wherein R 1 is selected from CH 3 and CH 2 CH 3 ; with (R)-t-butyiS(0)NH 2 under reductive amination conditions in the presence of a titanium catalyst to provide a compound of Formula (R),(R)-C: wherein R 1 is selected from CH 3 and CH 2 CH 3 ; methylating the compound of Formula (R),(R)-C to provide a compound of Formula (R),(R)-D: wherein R 1 is selected from CH 3 and CH 2 CH 3 ; and reacting the compound of Formula (R),(R)-D with hydrochloric acid to provide the
- the application includes a process for preparing an HCI salt of (R)-N-methyl-1 ,3- benzodioxolylbutanamine ((R)-MBDB): the process comprising: oxidizing a compound of Formula A or a compound of Formula A': wherein /v/v/vr indicates that the bond is in a cis and/or trans orientation, to provide a compound of Formula B: wherein R 1 is CH 3 ; reacting the compound of Formula B with (R)-t-butylS(0)NH 2 under reductive amination conditions in the presence of a titanium catalyst to provide a compound of Formula (R),(R)-C: wherein R 1 is CH 3 ; methylating the compound of Formula (R),(R)-C to provide a compound of Formula (R),(R)-D: wherein R 1 is CH3; and reacting the compound of Formula (R),(R)-D with hydrochloric acid to provide
- the present application includes a process for preparing an HCI salt of (R)-N-methyl-1,3-benzodioxolylbutanamine ((R)-MBDB): the process comprising: reacting the compound of Formula B with (R)-t-butyiS(0)NH 2 under reductive amination conditions in the presence of a titanium catalyst to provide a compound of Formula (R),(R)-C: wherein R 1 is CH 2 CH 3 ; methylating the compound of Formula (R),(R)-C to provide a compound of Formula (R),(R)-D: wherein R 1 is CH 2 CH 3 ; and reacting the compound of Formula (R),(R)-D with hydrochloric acid to provide the (R)- MBDB.HCI.
- the present application also includes a process for preparing an HCI salt of a compound of Formula (R)-l: wherein R 1 is selected from CH 3 and CH 2 CH 3 ; the process comprising: homologating piperonal, , with methoxymethylenetriphenylphosphine under Wittig reaction conditions to provide a compound of Formula B': reacting the compound of Formula B' with (S)-t-butylS(0)NH 2 to provide a compound of Formula (S)-C im : reacting the compound of Formula (S)-C im with a methyl or ethyl organometallic reagent to provide the compound of Formula (R),(S)-C": wherein R 1 is selected from CH 3 and CH 2 CH 3 ; methylating the compound of Formula (R),(S)-C" to provide a compound of Formula (R),(S)-D': wherein R 1 is selected from CH 3 and CH 2 CH 3 ; and reacting the
- the Wittig reaction conditions further comprise reacting piperonal with the methoxymethylenetriphenylphosphine to provide a vinyl ether intermediate, reacting the vinyl ether intermediate with a suitable acid the compound of Formula B'.
- the compound of Formula B' is reacted with (S)-t- butylS(0)NH 2 or (R)-t-butylS(0)NH 2 in the presence of a catalyst such as pyridinium p- toluenesulfonate to provide the compound of Formula (S)-C im or (R)-C im , respectively.
- a catalyst such as pyridinium p- toluenesulfonate
- the compound of Formula (R),(S)-D' or (S),(R)-D' is reacted hydrochloric acid to provide the hydrochloric acid salt of the compound of Formula (R)-l or (S)-l, respectively.
- the present application includes a process for preparing an HCI salt of (R)- 3,4- methylenedioxymethamphetamine ((R)-MDMA): the process comprising: homologating piperonal, , with methoxymethylenetriphenylphosphine under Wittig reaction condition to provide a compound of Formula B': reacting the compound of Formula B' with (S)-t-butyiS(0)NH 2 to provide a compound of Formula (S)-C im : reacting the compound of Formula (S)-C im with a methyl organometallic reagent to provide the compound of (R),(S)-C": wherein R 1 is CH 3 ; methylating the compound of Formula (R),(S)-C" to provide a compound of Formula (R),(S)-D': wherein R 1 is CH 3 ; and reacting the compound of Formula (R),(S)-D', with hydrochloric acid to provide the
- the compound of Formula B' is reacted with (S)-t- butyiS(0)NH 2 in the presence of a catalyst such as pyridinium p-toluenesulfonate to provide the compound of Formula (S)-C im .
- a catalyst such as pyridinium p-toluenesulfonate
- the present application includes a process for preparing an HCI salt of (R)-N- methyl-1 ,3-benzodioxolylbutanamine ((R)-MBDB): the process comprising: homologating piperonal, with methoxymethylenetriphenylphosphine under Wittig reaction conditions to provide a compound of Formula B': reacting the compound of Formula B' with (S)-t-butyiS(0)NH 2 to provide a compound of Formula (S)-C im : reacting the compound of Formula (S)-C im with an ethyl organometallic reagent to provide the compound of (R),(S)-C": wherein R 1 is CH 2 CH 3 ; methylating the compound of Formula (R),(S)-C" to provide a compound of Formula (R),(S)-D': wherein R 1 is CH 2 CH 3 ; and reacting the compound of Formula (R),(S)-D', with hydrochloric acid to
- the present application includes a process for preparing an acid salt of a compound of Formula (S)-l: wherein R 1 is selected from CH 3 and CH 2 CH 3 ; the process comprising: reacting a compound of Formula B: B wherein R 1 is selected from CH 3 and CH 2 CH 3 ; with (S)-t-butyiS(0)NH 2 under reductive amination conditions to provide a compound of Formula (S),(S)-C: wherein R 1 is selected from CH 3 and CH 2 CH 3 ; methylating the compound of Formula (S),(S)-C to provide a compound of Formula (S),(S)-D: wherein R 1 is CH 3 or CH 2 CH 3 ; and reacting the compound of Formula (S),(S)-D with an acid to provide an acid salt of the compound of Formula (S)-l.
- the present application also includes an exemplary process for preparing (S)-3, 4-methylenedioxymethamphetamine (S-MDMA): the process comprising: oxidizing a compound of Formula A or a compound of Formula A': wherein indicates that the bond is in a cis and/or trans orientation to provide a compound of Formula B: wherein R 1 is CH 3 ; reacting the compound of Formula B with (S)-t-butyiS(0)NH 2 under reductive amination conditions to provide a compound of Formula (S),(S)-C: wherein R 1 is CH 3 ; methylating the compound of Formula (S),(S)-C to provide a compound of Formula (S),(S)-D: wherein R 1 is CH 3 ; and reacting the compound of Formula (S),(S)-D with an acid to provide an acid salt of (S)-MDMA.
- S-MDMA 4-methylenedioxymethamphetamine
- the present application also includes an exemplary process for preparing an acid salt of (S)-N-methyl-1 ,3-benzodioxolylbutanamine (S- MBDB): the process comprising: reacting a compound of Formula B: wherein R 1 is CH 2 CH 3 ; with (S)-t-butylS(0)NH 2 under reductive amination conditions to provide a compound of Formula (S),(S)-C: wherein R 1 is CH 2 CH 3 ; methylating the compound of Formula (S),(S)-C to provide a compound of
- Formula (S),(S)-D wherein R 1 is CH 2 CH 3 ; and reacting the compound of Formula (S),(S)-D with an acid to provide an acid salt of (S)-MBDB.
- the present application also includes an exemplary process for preparing an acid salt of a compound of Formula (S)-l: wherein R 1 is selected from CH 3 and CH 2 CH 3 ; the process comprising: reacting the compound of Formula B' with (R)-t-butyiS(0)NH 2 to provide a compound of Formula (R)-C im : reacting the compound of Formula (R)-C im with a methyl or ethyl organometallic reagent to provide the compound of Formula (S),(R)-C": wherein R 1 is selected from CH 3 and CH 2 CH 3 ; methylating the compound of Formula (S),(R)-C" to provide a compound of Formula (S),(R)-D': wherein R 1 is selected from CH 3 and CH 2 CH 3 ; and reacting the compound of Formula (S),(R)-D', with an acid to provide an acid salt of the compound of Formula (S)-l.
- the process further comprises converting the acid salt of S-MDMA to S-MDMA.
- the acid salt of the compound of Formula (R)-l or (S)-l prepared by a process of the application is further converted to a solvate and/or prodrug thereof, for example, a pharmaceutically acceptable salt, solvate and/or prodrug thereof.
- the acid salt of (R)-MDMA or (S)-MDMA prepared by a process of the application is further converted to a solvate and/or prodrug thereof, for example, a pharmaceutically acceptable salt, solvate and/or prodrug thereof.
- the acid salt of (R)-MBDB or (S)-MBDB prepared by a process of the application is further converted to a solvate and/or prodrug thereof, for example, a pharmaceutically acceptable salt, solvate and/or prodrug thereof.
- the process of the application further comprises converting the acid salt of the compound of Formula (R)-l or (S)-l to the free base of the compound of Formula (R)-l or (S)-l, respectively. In some embodiments, the process of the application further comprises converting the acid salt of (R)- or (S)-MDMA to the free base of (R)- or (S)-MDMA. In some embodiments, the process of the application further comprises converting the acid salt of (R)- or (S)-MBDB to the free base of (R)- or (S)- MBDB.
- the acid salt of the compound of Formula (R)-l or (S)-l is converted to the free base, for example, using any suitable base under any suitable conditions known in the art, for example, using a suitable base and conditions known in the art as described below.
- the free base of the compound of Formula (R)-l or (S)-l, (i.e. (R)- or (S)-MDMA and (R)- or (S)-MBDB), prepared by a process of the application is further converted to a salt, solvate and/or prodrug thereof, for example, a pharmaceutically acceptable salt, solvate and/or prodrug thereof.
- the process provides the R or S enantiomer as the major isomer. In some embodiments, the process provides the R or S enantiomer in greater than 60% ee, 65% ee, 70% ee, 75% ee, 80% ee, 85% ee, 90% ee, 95% ee, 98% ee or 99% ee. In some embodiments, the process provides the R or S enantiomer of the MDMA ((R)-MDMA or (S)-MDMA) or the acid salt of (R)-MDMA or (S)-MDMA such as (R)-MDMAHCI or (S)-MDMA.HCI as the major isomer.
- the process provides (R)-MDMA or (S)-MDMA or acid salt of (R)-MDMA or (S)-MDMA in greater than 60% ee, 65% ee, 70% ee, 75% ee, 80% ee, 85% ee, 90% ee, 95% ee, 98% ee or 99% ee.
- the process provides the R or S enantiomer of the MBDB ((R)- MBDB or (S)-MBDB) or the acid salt of (R)-MBDB or (S)-MBDB such as (R)- MBDB.HCI or (S)-MBDB.HCI as the major isomer.
- the process provides (R)-MBDB or (S)-MBDB or acid salt of (R)-MBDB or (S)-MBDB in greater than 60% ee, 65% ee, 70% ee, 75% ee, 80% ee, 85% ee, 90% ee, 95% ee, 98% ee or 99% ee.
- the pharmaceutically acceptable salt is an acid addition salt and the selection of a suitable salt may be made by a person skilled in the art (see, for example, S. M. Berge, et al., "Pharmaceutical Salts,” J. Pharm. Sci. 1977, 66, 1-19).
- An acid addition salt that is pharmaceutically acceptable, that is suitable for, or compatible with, the treatment of subjects is any non-toxic organic or inorganic acid addition salt of any basic compound.
- Basic compounds that form an acid addition salt include, for example, compounds comprising an amine group.
- Illustrative inorganic acids which form suitable salts include hydrochloric, hydrobromic, sulfuric, nitric and phosphoric acids, as well as acidic metal salts such as sodium monohydrogen orthophosphate and potassium hydrogen sulfate.
- Illustrative organic acids which form suitable salts include mono-, di- and tricarboxylic acids.
- organic acids are, for example, acetic, trifluoroacetic, propionic, glycolic, lactic, pyruvic, malonic, succinic, glutaric, fumaric, malic, tartaric, citric, ascorbic, maleic, hydroxymaleic, benzoic, hydroxybenzoic, phenylacetic, cinnamic, mandelic, salicylic, 2-phenoxybenzoic, p- toluenesulfonic acid and other sulfonic acids such as methanesulfonic acid, ethanesulfonic acid and 2-hydroxyethanesulfonic acid.
- the mono- or di-acid salts are formed, and such salts exist in either a hydrated, solvated or substantially anhydrous form.
- acid addition salts are more soluble in water and various hydrophilic organic solvents, and generally demonstrate higher melting points in comparison to their free base forms.
- the selection criteria for the appropriate salt will be known to one skilled in the art.
- Other non-pharmaceutically acceptable salts such as but not limited to oxalates may be used, for example in the isolation of compounds of the application for laboratory use, or for subsequent conversion to a pharmaceutically acceptable acid addition salt.
- Solvates include, for example, those made with solvents that are pharmaceutically acceptable. Examples of such solvents include water (resulting solvate is called a hydrate) and ethanol and the like. Suitable solvents are physiologically tolerable at the dosage administered.
- a desired compound salt is achieved using standard techniques. For example, the neutral compound is treated with an acid in a suitable solvent and the formed salt is isolated by filtration, extraction or any other suitable method.
- solvates will vary depending on the compound and the solvate.
- solvates are formed by dissolving the compound in the appropriate solvent and isolating the solvate by cooling or using an antisolvent.
- the solvate is typically dried or azeotroped under ambient conditions. The selection of suitable conditions to form a particular solvate can be made by a person skilled in the art.
- Prodrugs may be, for example, conventional esters formed with the available amino group. Some common esters which have been utilized as prodrugs are phenyl esters, aliphatic (C1-C24) esters, acyloxymethyl esters, carbamates and amino acid esters.
- inert solvents include, but are not limited to, benzene, toluene, tetrahydrofuran, ethyl ether, ethyl acetate, dimethyl formamide (DMF), acetonitrile, Ci_ 6 alkylOH (e.g.
- methanol ethanol, n-propanol, 2-propanol, n-butanol, butan-2-ol and 2- methyl-1 -propanol
- diethylcarbonate diethylcarbonate
- hexane dimethylsulfoxide
- Further examples can include aqueous solutions, such as water and dilute acids and bases, and ionic liquids, provided that such solvents do not interfere with the reaction.
- the present application also includes compound of Formula (R)-C', (S)-C', (R),(R)-C, (S),(S)-C and (R),(R)-D and (S),(S)-D, useful forthe preparation of compounds of Formula (R)-l or (S)-l.
- the present application also includes a compound of Formula (R)-C': wherein R 1 is CH 3 or CH 2 CH 3 .
- R 1 is CH 3 or CH 2 CH 3 .
- S is CH 3 o rCH 2 CH 3 .
- R 1 in the compound of Formula (R)-C' or (S)C' is CH 3 In some embodiments, R 1 in the compound of Formula (R)-C' or (S)-C' is CH 2 CH 3 [00137]
- the present application also includes a compound of Formula (R),(R)-C: wherein R 1 is selected from CH 3 and CH 2 CH 3 .
- the present application also includes a compound of Formula (S),(S)-C: wherein R 1 is selected from CH 3 and CH 2 CH 3
- R 1 in the compound of Formula (R),(R)-C or (S),(S)-C is CH 3 In some embodiments, R 1 in the compound of Formula (R),(R)-C or (S),(S)-C is CH 2 CH 3
- the present application includes a compound of Formula (S)-C im :
- the present application also includes a compound of Formula (R)-C im : [00142]
- the present application includes a compound of Formula (R),(S)-C": wherein R 1 is CH 3 or CH 2 CH 3 .
- the present application also includes a compound of Formula (S),(R)-C": wherein R 1 is selected from CH 3 and CH 2 CH 3 .
- R 1 in the compound of Formula (R),(S)-C" or (S),(R)-C" is CH 3 In some embodiments, R 1 in the compound of Formula (R),(S)-C" or (S),(R)-C" is CH 2 CH 3
- the present application also includes a compound of Formula (R),(R)-D: wherein R 1 is CH 3 or CH 2 CH 3 .
- the present application also includes a compound of Formula (S),(S)-D: wherein R 1 is CH 3 or CH 2 CH 3 .
- R 1 in the compound of Formula (R),(R)-D or (S),(S)-D is CH 3 In some embodiments, R 1 in the compound of Formula (R),(R)-D or (S),(S)-D is CH 2 CH 3
- the present application also includes a compound of Formula (R),(S)-D': wherein R 1 is CH 3 or CH 2 CH 3 .
- the present application also includes a compound of Formula (S),(R)-D':
- R 1 is CH 3 or CH 2 CH 3 .ln some embodiments, R 1 in the compound of Formula (R),(S)-D' or (S),(R)-D' is CH 3 In some embodiments, R 1 in the compound of Formula (R),(S)-D' or (S),(R)-D' is CH 2 CH 3
- the application also includes compound of Formula (R)-l or (S)-l or an acid salt of compound of Formula (R)-l or (S)-l prepared by process of the application as described above.
- the application also includes (R)-MDMA, (S)-MDMA or an acid salt of (R)-MDMA or (S)-MDMA prepared by process of the application as described above.
- the application also includes (R)-MBDB, (S)-MBDB or an acid salt of (R)-MBDB, (S)- MBDB or an acid salt of (R)-MBDB or (S)-MBDB prepared by process of the application as described above.
- the acid salt is the HCI salt.
- Example 1 Exemplary process for preparing (R)-MDMA
- (R)-MDMA can be prepared according to the following synthetic scheme.
- reaction is stirred at 60 °C for 16 h in the absence of light and with the closed flask using crystal cap. After this time, the mixture is extracted with EtOAc (2 x 100 mL) and the organic phases are combined, dried over sodium sulfate and filtered off. The solvent is removed under reduced pressure and the resulting reaction crude is purified by column chromatography on silica gel (10% EtOAc/hexane) to give the desired compound.
- reaction is then cooled down to -20 C, NaBH 4 (75.7 mg, 2.0 mmol, 1 equiv) is added and the reaction is stirred 3 h at 20 °C and overnight at room temperature. The solution is then filtered through celite and the solvent evaporated under reduced pressure to provide the desired compound.
- Example 2 Exemplary process for preparing (S)-MDMA
- (S)-MDMA can be prepared according to the following synthetic scheme.
- reaction is stirred at 60 °C for 16 h in the absence of light and with the closed flask using crystal cap. After this time, the mixture is extracted with EtOAc (2 x 100 mL) and the organic phases are combined, dried over sodium sulfate and filtered off. The solvent is removed under reduced pressure and the resulting reaction crude is purified by column chromatography on silica gel (10% EtOAc/hexane) to give the desired compound.
- reaction is then cooled down to -20 C, NaBH 4 (75.7 mg, 2.0 mmol, 1 equiv) is added and the reaction is stirred 3 h at 20 °C and overnight at room temperature. The solution is then filtered through celite and the solvent evaporated under reduced pressure to provide the desired compound.
- Step 2 To a well stirred solution of 29 g of 35% hydrogen peroxide in 136 g of formic acid (88%) and 20.5 g of water, is added dropwise to a solution of 32.4 g isosafrole in 120 ml acetone, with cooling to keep the mixture from exceeding 40 °C. After stirring for 16 h at room temperature, the mixture is concentrated under vacuum without heating. The crude product is dissolved in 55 ml of methyl alcohol, treated with 240 g of 15% sulfuric acid and heated for 3 h. After cooling, the reaction mixture is extracted with diethyl ether. Organic layers are washed with water and then with dilute sodium hydroxide. Solvent is removed by rotary evaporation. The residue is distilled under vacuum to provide 17.4 g (50%) of the title compound as pale yellow oil.
- Example 4 Exemplary process for preparing (R)-MBDB
- (R)-MBDB.HCI can be prepared starting from 1-(benzo[d][1 ,3]dioxol-5- yl)butan-2-one following steps 2 to 5 of Example 1 .
- Example 5 Exemplary process for preparing (S)-MBDB
- (S)-MBDB.HCI can be prepared starting from 1-(benzo[d][1 ,3]dioxol-5- yl)butan-2-one following steps 2 to 5 of Example 2.
- Example 6 Exemplary process for preparing compounds of Formula (R)-l
- Homopiperonal can be prepared using the synthetic procedures found in Tetrahedron: Asymmetry, 27(6), 274-284; 2016.
- KOtBu (6.48 g, 66.6 mmol) was added portionwise to a stirred suspension of [MeOCH 2 PPh 3 ] + [Cl] (12.6 g, 36.6 mmol) in THF (50 mL) at 0°C.
- the resultant mixture was stirred for 30 min at rt and then a solution of piperonal (5.00 g, 33.3 mmol) in THF (50 mL) was added dropwise.
- the resultant mixture was stirred at rt for 12 h and then quenched by the addition of satd aq NH4CI (50 mL).
- Example 7 Exemplary process for preparing compounds of Formula (S)-l
- Homopiperonal can be prepared using the synthetic procedures found in Tetrahedron: Asymmetry, 27(6), 274-284; 2016.
- Example 8 Exemplary process for preparing (R)-MBDB
- Step 1 Preparation of 5-(2-methoxyvinyl)benzo[d][1 ,3]dioxole
- Step 2 Preparation of 2-(benzo[d][1 ,3]dioxol-5-yl)acetaldehyde
- Crude 5-(2-methoxyvinyl)benzo[d][1 ,3]dioxole was diluted with dichloromethane (100 mL) and treated with formic acid (30 mL, 660 mmol). The mixture was stirred at room temperature for 3 days, then quenched with water, extracted with dichloromethane, dried (sodium sulphate), filtered and concentrated to a brown oil.
- Step 3 Preparation of(S)-N-(2-(benzo[d][1,3]dioxol-5-yl)ethylidene)-2-methylpropane-2- sulfinamide
- Step 4 Preparation of (S)-N-((R)-1-(benzo[d][1,3]dioxol-5-yl)butan-2-yl)-2- methylpropane-2-sulfinamide
- Step 5 Preparation of (S)-N-((R)-1-(benzo[d][1,3]dioxol-5-yl)butan-2-yl)-N,2- dimethylpropane-2-sulfinamide
- N,2-dimethylpropane-2-sulfinamide 6 (0.10 g, 0.32 mmol)in methanol was treated with hydrogen chloride (2 M solution in diethyl ether, 1 mL, 2.0 mmol). The mixture was stirred at 0 °C to room temperature overnight, then concentrated with vacuo to a brown oil. The oil was triturated with methanol and diethyl ether. The off-white solid (R)-1- (benzo[d][1 ,3]dioxol-5-yl)-N-methylbutan-2-amine hydrochloride 7 (0.066 g, 85 %) was collected by vacuum filtration.
- Step 1 (R)-N-(2- ⁇ benzo[d][l,3]dioxol-5-yl)ethylidene)-2-methylpropane-2-sulfinamide
- Step 2 (R)-N-((S)-1-(benzo[d][1 ,3]dioxol-5-yl)butan-2-yl)-2-methylpropane-2- sulfinamide
- Step 3 (R)-N-((S)-1-(benzo[d][1 ,3]dioxol-5-yl)butan-2-yl)-N, 2-dimethylpropane-2- sulfinamide
- Step 4 (S)-1 -(benzo[d][1 ,3]dioxol-5-yl)-N-methylbutan-2-amine hydrochloride
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
The present application includes a process for preparing the (R)- or (S)- enantiomers of 3,4-methylenedioxymethamphetamine ((R)-MDMA or (S)-MDMA) and (R)- or (S)-N-methyl-1,3-benzodioxolylbutanamine ((R)-MBDB or (S)-MBDB) using (R)- tert-butanesulfinamide or (S)-tert-butanesulfinamideas a chiral auxiliary. (I) The present application also includes novel intermediate compounds useful in the preparation of (R/S)-MDMA and (R/S)-MBDB.
Description
TITLE: PROCESSES FOR THE PREPARATION OF THE ENANTIOMERS OF 3,4- METHYLENEDIOXYMETHAMPHETAMINE (MDMA) AND N-METHYL-1,3- BENZODIOXOLYLBUTANAMINE (MBDB)
RELATED APPLICATIONS
[0001] The present application claims the benefit of priority of co-pending United
States provisional patent application no. 63/201 ,610 filed on May 6, 2021 , co-pending United States provisional patent application no. 63/203,101 filed on July 8, 2021 and co pending United States provisional patent application no. 63/298,799 filed on January 12, 2022, the contents of each of which are incorporated herein by reference in their entirety.
FIELD
[0002] The present application is related to processes for preparing (R)- or (S)-
3, 4-methylenedioxymethamphetamine ((R)-MDMA/(S)-MDMA) and (R)- or (S)-N-methyl- 1 ,3-benzodioxolylbutanamine ((R)-MBDB/(S)-MBDB). In particular, the process uses (R)- tert-butanesulfinamide or (S)-tert-butanesulfinamide as a chiral auxiliary. The present application also relates to compounds useful in the preparation of the enantiomers of MDMA and MBDB.
BACKGROUND
[0003] 3,4-Methylenedioxymethamphetamine (MDMA), commonly known as ecstasy (E) or molly, is a psychoactive drug first developed in 1912 by Merck. MDMA is often used recreationally today. However, an initial use of MDMA was as an adjunct to psychotherapy. More recently, MDMA has been studied in various clinical trials, for example, investigating MDMA-assisted psychotherapy for posttraumatic stress disorder (PTSD), anxiety related to advanced-stage illness, and social anxiety in autistic adults. MDMA has now been grated Breakthrough Therapy Designation to MDMA for the treatment of PTSD by the United States Food and Drug Administration (FDA).
[0004] MDMA is generally available and consumed as a racemate. However, each enantiomer has been shown to provide different pharmacological and pharmacokinetic profiles. In fact, evidence suggests that R (-)-MDMA may provide an improved therapeutic index maintaining the therapeutic effects of (±)-MDMA with a reduced side effect profile (Pitts et al. Psychopharmacology 235, 377-392, 2018).
[0005] There are many methods available to synthesize MDMA including several methods to synthesize enantiopure MDMA using, for example, chiral salts, chiral synthesis, or using chiral auxiliaries [e.g. Dunlap et al (2018), ACS Chem Neurosci; 9(10):
2408-2427; Llabres et al (2014), European J. of Med. Chem. 81 (2014) 35-46; Huot et al (2011), J Neurosci. (2011) May 11 ; 31(19): 7190-7198] Llabres et al. discloses a synthesis of both enantiomers of MDMA using t-butylsulfinamide [Llabres et al (2014), European Journal of Medicinal Chemistry 81 (2014) 35-46] [0006] N-methyl-1 ,3-benzodioxolylbutanamine (MBDB) commonly known as
Eden or Methyl-J, is an analogue of MDMA which has an ethyl group instead of a methyl group attached to the alpha carbon next to the amine. Like MDMA, MBDB is also classified as an entactogen.
SUMMARY [0007] The present application includes processes for preparing the (R)- or (S)- enantiomers of 3,4-methylenedioxymethamphetamine (MDMA) and (N-methyl-1 ,3- benzodioxolylbutanamine (MBDB) using (R)-tert-butanesulfinamide or (S)-tert- butanesulfinamide as a chiral auxiliary. In some embodiments, the application includes a process for preparing the enantiomers of MDMA and MBDB through the reduction of an imide intermediate derived from using tert-butanesulfinamide.
[0008] Accordingly, the present application includes a process for preparing an acid salt of a compound of Formula (R)-l or (S)-l:
wherein R1 is selected from CH3 and CH2CH3; the process comprising: reacting a compound of Formula B:
wherein R1 is selected from CH3 and CH2CH3; with (R)-t-butylS(0)NH2 or (S)- )-t-butylS(0)NH2 under reductive amination conditions to provide a compound of Formula (R),(R)-C or (S),(S)-C, respectively:
wherein R1 is selected from CH3 and CH2CH3; or homologating piperonal, <°t ° , to provide a compound of Formula B':
reacting the compound of Formula B' with (S)-t-butylS(0)NH2 or (R)-t- butylS(0)NH2 to provide a compound of Formula (S)-Cim or(R)-Cim respectively:
reacting the compound of Formula (S)-Cim or (R)-Cim with a methyl or ethyl organometallic reagent to provide the compound of Formula (R),(S)-C" or (S),(R)-C", respectively:
wherein R1 is CH3or CH2CH3; methylating the compound of Formula (R),(R)-C or (S),(S)-C to provide a compound of Formula (R),(R)-D or a compound of Formula (S),(S)-D, respectively:
methylating the compound of Formula (R),(S)-C" or (S),(R)-C" to provide a compound of Formula (R),(S)-D' or a compound of Formula (S),(R)-D', respectively:
wherein R1 is CH3or CH2CH3; and
reacting the compound of Formula (R),(R)-D or the compound of Formula (S),(S)- D with an acid to provide the acid salt of the compound of Formula (R)-l, or reacting the compound of Formula (R),(S)-D' or the compound of Formula (S),(R)-D' with an acid to provide the acid salt of the compound of Formula (S)-l. [0009] The present application also includes a compound of Formula (R)-C:
wherein R1 is CH30rCH2CH3.
[0010] The present application also includes a compound of Formula (S)-C':
wherein R1 is CH30rCH2CH3.
[0011] The present application also includes a compound of Formula (R),(R)-C:
wherein R1 is selected from CH3 and CH2CH3.
[0012] The present application also includes a compound of Formula (S),(S)-C:
wherein R1 is selected from CH3 and CH2CH3
[0013] The present application includes a compound of Formula (S)-Cim:
[0014] The present application also includes a compound of Formula (R)-Cim:
[0015] The present application includes a compound of Formula (R),(S)-C":
wherein R1 is Chl3or CH2CH3.
[0016] The present application also includes a compound of Formula (S),(R)-C":
wherein R1 is selected from CH3 and CH2CH3.
[0017] The present application also includes a compound of Formula (R),(R)-D:
wherein R1 is CH3or CH2CH3.
[0018] The present application also includes a compound of Formula (S),(S)-D:
wherein R1 is CH3or CH2CH3. [0019] The present application also includes a compound of Formula (R),(S)-D':
wherein R1 is CH3or CH2CH3.
[0020] The present application also includes a compound of Formula (S),(R)-D':
wherein R1 is CH3or CFhCFh. [0021] Other features and advantages of the present application will become apparent from the following detailed description. It should be understood, however, that the detailed description and the specific examples, while indicating embodiments of the application, are given by way of illustration only and the scope of the claims should not be limited by these embodiments, but should be given the broadest interpretation consistent with the description as a whole.
DETAILED DESCRIPTION I. Definitions
[0022] Unless otherwise indicated, the definitions and embodiments described in this and other sections are intended to be applicable to all embodiments and aspects of the present application herein described for which they are suitable as would be understood by a person skilled in the art.
[0023] The term “process of the application” and the like as used herein refers to a process of preparing (R)- or (S)-MDMA or (R)- or (S)-MBDB, or an acid salts thereof, as described herein. [0024] The term “and/or” as used herein means that the listed items are present, or used, individually or in combination. In effect, this term means that “at least one of or “one or more” of the listed items is used or present. The term “and/or” with respect to pharmaceutically acceptable salts and/or solvates thereof means that the compounds of the application exist as individual salts and hydrates, as well as a combination of, for example, a solvate of a salt of a compound of the application.
[0025] As used in the present application, the singular forms “a”, “an” and “the” include plural references unless the content clearly dictates otherwise. For example, an embodiment including “a solvent” should be understood to present certain aspects with one solvent, or two or more additional solvents.
[0026] In embodiments comprising an “additional” or “second” component, such as an additional or second solvent, the second component as used herein is chemically different from the other components or first component. A “third” component is different from the other, first, and second components, and further enumerated or “additional” components are similarly different.
[0027] As used in this application and claim(s), the words "comprising" (and any form of comprising, such as "comprise" and "comprises"), "having" (and any form of having, such as "have" and "has"), "including" (and any form of including, such as "include" and "includes") or "containing" (and any form of containing, such as "contain" and "contains"), are inclusive or open-ended and do not exclude additional, unrecited elements or process steps.
[0028] The term “consisting” and its derivatives as used herein are intended to be closed terms that specify the presence of the stated features, elements, components, groups, integers, and/or steps, and also exclude the presence of other unstated features, elements, components, groups, integers and/or steps.
[0029] The term “consisting essentially of, as used herein, is intended to specify the presence of the stated features, elements, components, groups, integers, and/or steps as well as those that do not materially affect the basic and novel characteristic(s) of these features, elements, components, groups, integers, and/or steps.
[0030] The term “suitable” as used herein means that the selection of the particular compound or conditions would depend on the specific synthetic manipulation to be performed, the identity of the molecule(s) to be transformed and/or the specific use for the compound, but the selection would be well within the skill of a person trained in the art. All process/method steps described herein are to be conducted under conditions to provide the product shown. A person skilled in the art would understand that, unless otherwise indicated, all reaction conditions, including, for example, reaction solvent, reaction time, reaction temperature, reaction pressure, reactant ratio and whether or not the reaction should be performed under an anhydrous or inert atmosphere, can be varied to optimize the yield of the desired product and it is within their skill to do so.
[0031] The terms "about", “substantially” and “approximately” as used herein mean a reasonable amount of deviation of the modified term such that the end result is not significantly changed. These terms of degree should be construed as including a deviation of at least ±5% of the modified term if this deviation would not negate the meaning of the word.
[0032] The present description refers to a number of chemical terms and abbreviations used by those skilled in the art. Nevertheless, definitions of selected terms are provided for clarity and consistency.
[0033] The term “alkyl” as used herein, whether it is used alone or as part of another group, means straight or branched chain, saturated alkyl groups. The number of carbon atoms that are possible in the referenced alkyl group are indicated by the prefix “Cni-n2”. For example, the term Ci_6alkyl means an alkyl group having 1 , 2, 3, 4, 5 or 6 carbon atoms.
[0034] The term “available”, as in “available hydrogen atoms” or “available atoms” refers to atoms that would be known to a person skilled in the art to be capable of replacement by a substituent.
[0035] The term “MDMA” as used herein refers to a compound having the chemical name: 1-(1 ,3-benzodioxol-5-yl)-N-methylpropan-2-amine or 3,4- methylenedioxymethamphetamine, and having the chemical formula:
[0036] The term “(R)-MDMA” as used herein refers to a compound having the chemical name: (2R)-1-(1,3-benzodioxol-5-yl)-N-methylpropan-2-amine or (R)-3,4- methylenedioxymethamphetamine, and having the chemical formula:
[0037] The term “(S)-MDMA” as used herein refers to a compound having the chemical name: (2S)-1-(1,3-benzodioxol-5-yl)-N-methylpropan-2-amine, or (S)-3,4- methylenedioxymethamphetamine, and having the chemical formula:
[0038] The term “MBDB” as used herein refers to a compound having the chemical name: 1-(1,3-benzodioxol-5-yl)-N-methylbutan-2-amine or N-methyl-1 ,3- benzodioxolylbutanamine, and having the chemical formula:
[0039] The term “(R)-MBDB” as used herein refers to a compound having the chemical name: (2R)-1-(1 ,3-benzodioxol-5-yl)-N-methylbutan-2-amine or (R)-N-methyl- 1 ,3-benzodioxolylbutanamine, and having the chemical formula:
[0040] The term “(S)-MBDB” as used herein refers to a compound having the chemical name: (2S)-1-(1 ,3-benzodioxol-5-yl)-N-methylbutan-2-amine or (S)-N-methyl- 1 ,3-benzodioxolylbutanamine, and having the chemical formula:
[0041] The term “(R)-t-butyiS(0)NH2” or “(R)-tert-butanesulfinamide” as used herein to a compound having the chemical name (R)-(+)-2-methyl-2-propanesulfinamide, and having the chemical formula:
[0042] The term “(S)-t-butyiS(0)NH2” or “(S)-tert-butanesulfinamide” as used herein to a compound having the chemical name (S)-(+)-2-methyl-2-propanesulfinamide, and having the chemical formula:
[0043] The term “reducing agent” as used herein means any compound or combination of compounds that reduces a desired functional group. A reducing agent results in the overall addition of electrons, or in the case of organic chemistry, hydrogen atoms to the functional group.
[0044] The term “inert solvent” as used herein means a solvent that does not interfere with or otherwise inhibit a reaction. Accordingly, the identity of the inert solvent will vary depending on the reaction being performed. The selection of inert solvent is within the skill of a person in the art. [0045] The term “solvent” includes both a single solvent and a mixture comprising two or more solvents.
[0046] The term “protecting group” or “PG” and the like as used herein refers to a chemical moiety which protects or masks a reactive portion of a molecule to prevent side reactions in those reactive portions of the molecule, while manipulating or reacting a different portion of the molecule. After the manipulation or reaction is complete, the protecting group is removed under conditions that do not degrade or decompose the remaining portions of the molecule. The selection of a suitable protecting group can be made by a person skilled in the art. Many conventional protecting groups are known in the art, for example as described in “Protective Groups in Organic Chemistry” McOmie, J.F.W. Ed., Plenum Press, 1973, in Greene, T.W. and Wuts, P.G.M., “Protective Groups in Organic Synthesis”, John Wiley & Sons, 3rd Edition, 1999 and in Kocienski, P. Protecting Groups, 3rd Edition, 2003, Georg Thieme Verlag (The Americas).
[0047] The term “major isomer” as used herein refers to a stereochemical isomer, including a regional isomer, that is the most abundant isomer in a mixture of isomers of the same compound. Conversely, the term “minor isomer” as used herein refers to a stereochemical isomer, including a regional isomer, that is not the most abundant isomer in a mixture of isomers of the same compound.
[0048] The term “enantiomeric excess” or “ee” is the absolute difference between the mole fraction of each enantiomer for a racemic compound.
[0049] In the processes of the application, when compounds, including starting materials and products, are referred to as single isomers, e.g. R- or S-isomers, this means that the single isomer comprises less than 20%, 15%, 10%, 5%, 4%, 3%, 2% or 1% by weight of the alternate isomer based on the total amount of R- and S-isomers.
[0050] The products of the processes of the application may be isolated according to known methods, for example, the compounds may be isolated by evaporation of the solvent, by filtration, centrifugation, chromatography or other suitable method.
II. Processes of the Application
[0051] The present application includes a process for preparing (R)- or (S)-3,4- methylenedioxymethamphetamine (R-MDMA or S-MDMA) or (R)- or (S)-N-methyM ,3- benzodioxolylbutanamine (R-MBDB or S-MBDB) using (R)-tert-butanesulfinamide or (S)- tert-butanesulfinamide as a chiral auxiliary. In particular, the application includes a process for preparing (R)- or (S)-3, 4-methylenedioxymethamphetamine (R-MDMA or S- MDMA) or (R)- or (S)-N-methyM ,3-benzodioxolylbutanamine (R-MBDB or S-MBDB) through the reduction of an imide intermediate derived from using tert-butanesulfinamide.
[0052] Accordingly, the present application includes a process for preparing an acid salt of a compound of Formula (R)-l or (S)-l:
wherein R1 is selected from CH3 and CH2CH3; the process comprising: reacting a compound of Formula B:
B wherein R1 is selected from CH3 and CH2CH3; with (R)-t-butylS(0)NH2 or (S)- )-t-butylS(0)NH2 under reductive amination conditions to provide a compound of Formula (R),(R)-C or (S),(S)-C, respectively:
wherein R1 is selected from CH3 and CH2CH3; or homologating piperonal,
, to provide a compound of Formula B':
reacting the compound of Formula B' with (S)-t-butylS(0)NH2 or (R)-t- butylS(0)NH2 to provide a compound of Formula (S)-Cim or(R)-Cim respectively:
reacting the compound of Formula (S)-Cim or (R)-Cim with a methyl or ethyl organometallic reagent to provide the compound of Formula (R),(S)-C" or (S),(R)-C", respectively:
wherein R1 is CH3or CH2CH3; methylating the compound of Formula (R),(R)-C or (S),(S)-C to provide a compound of Formula (R),(R)-D or a compound of Formula (S),(S)-D, respectively:
methylating the compound of Formula (R),(S)-C" or (S),(R)-C" to provide a compound of Formula (R),(S)-D' or a compound of Formula (S),(R)-D', respectively:
wherein R1 is CH3or CH2CH3; and reacting the compound of Formula (R),(R)-D or the compound of Formula (S),(S)-
D with an acid to provide the acid salt of the compound of Formula (R)-l, or reacting the compound of Formula (R),(S)-D' or the compound of Formula (S),(R)-D' with an acid to provide the acid salt of the compound of Formula (S)-l.
[0053] Therefore the present application also includes a process for preparing an acid salt of a compound of Formula (R)-l
wherein R1 is selected from CH3 and CH2CH3; the process comprising: reacting a compound of Formula B
B
wherein R1 is selected from CH3 and CH2CH3; with (R)-t-butylS(0)NH2 under reductive amination conditions to provide a compound of (R),(R)-Formula C
wherein R1 is selected from CH3 and CH2CH3; or homologating piperonal,
, to provide a compound of Formula B'
reacting the compound of Formula B' with (S)-t-butylS(0)NH2 to provide a compound of Formula (S)-Cim;
reacting the compound of Formula (S)-Cim with a methyl or ethyl organometallic reagent to provide the compound of Formula (R),(S)-C"
wherein R1 is CH3or CH2CH3; methylating the compound of Formula (R),(R)-C or the compound of Formula
(R),(S)-C" to provide a compound of Formula (R),(R)-D or a compound of Formula (R),(S)-D, respectively
wherein R1 in the compound of Formula (R),(R)-D and in the compound of Formula (R),(S)-D is CH3or CH2CH3; and reacting the compound of Formula (R),(R)-D or the compound of Formula (R),(S)- D with an acid to provide an acid salt of the compound of Formula (R)-l.
[0054] The present application also includes a process for preparing an acid salt of a compound of Formula (S)-l
wherein R1 is selected from CH3 and CH2CH3; the process comprising: reacting a compound of Formula B
B wherein R1 is selected from CH3 and CH2CH3; with (S)-t-butylS(0)NH2 under reductive amination conditions to provide a compound of Formula (S),(S)-C
wherein R1 is selected from CH3 and CH2CH3; or homologating piperonal,
, to provide a compound of Formula B'
reacting the compound of Formula B' with (R)-t-butylS(0)NH2 to provide a compound of Formula (R)-Cim;
reacting the compound of Formula (R)-Cim with a methyl or ethyl organometallic reagent to provide the compound of Formula (S),(R)-C"
wherein R1 is CH3or CH2CH3; methylating the compound of Formula (S),(S)-C or the compound of Formula (S),(R)-C" to provide a compound of Formula (S),(S)-D ora compound of Formula (S),(R)- D', respectively
wherein R1 in the compound of Formula (S),(S)-D and in the compound of Formula (S),(R)-D' is CH3 or CH2CH3; and reacting the compound of Formula (S),(S)-D or the compound of Formula (S),(R)- D' with an acid to provide an acid salt of the compound of Formula (S)-l. [0055] In some embodiments, the present application includes a process for preparing an acid salt of a compound of Formula (R)-l or (S)-l:
wherein R1 is selected from CH3 and CH2CH3; the process comprising: reacting a compound of Formula B:
B wherein R1 is selected from CH3 and CH2CH3; with (R)-t-butyiS(0)NH2 or (S)-t-butyiS(0)NH2 under reductive amination conditions to provide a compound of Formula (R),(R)-C or (S),(S)-C, respectively:
wherein R1 is selected from CH3 and CH2CH3; methylating the compound of Formula (R),(R)-C or (S),(S)-C to provide a compound of Formula (R),(R)-D or (S),(S)-D, respectively:
wherein R1 is CH3or CH2CH3; and reacting the compound of Formula (R),(R)-D or (S),(S)-D -with an acid to provide an acid salt of the compound of Formula (R)-l or (S)-l, respectively.
[0056] In some embodiments, the compound of Formula B is either commercially available or may be prepared using methods known in the art. For example, in some embodiments, the compound of Formula B wherein R1 is CH2CH3,
jS available from Sigma Aldrich (St. Louis, Missouri, USA).
[0057] In some embodiments, R1 is CH3 and the compound of Formula B is
. in some embodiments, the compound of Formula B wherein R1 is CH3 is prepared by a process comprising oxidizing a compound of Formula A or a compound of Formula A':
wherein indicates that the bond is in a cis and/or trans orientation to provide a compound of Formula B:
wherein R1 is CH3. [0058] The compound of Formula (R)-l wherein R1 is CH3 is (R)-3,4- methylenedioxymethamphetamine ((R)-MDMA). The compound of Formula (S)-l wherein R1 is CH3 is (S)-3, 4-methylenedioxymethamphetamine ((S)-MDMA). Accordingly, when R1 is CH3, the present application also includes a process for preparing an acid salt of (R)- 3, 4-methylenedioxymethamphetamine ((R)-MDMA) or an acid salt of (S)-3,4- methylenedioxymethamphetamine ((S)-MDMA):
the process comprising: oxidizing a compound of Formula A or a compound of Formula A':
wherein -« indicates that the bond is in a cis and/or trans orientation to provide a compound of Formula B:
wherein R1 is CH3; reacting the compound of Formula B with (R)-t-butylS(0)NH2 or (S) (R)-t- butyiS(0)NH2 under reductive amination conditions to provide a compound of Formula (R),(R)-C or (S),(S)-C, respectively:
wherein R1 is CH3; methylating the compound of Formula (R),(R)-C or (S),(S)-C to provide a compound of Formula (R),(R)-D or (S),(S)-D, respectively:
wherein R1 is CH3; and reacting the compound of Formula (R),(R)-D or (S),(S)-D with an acid to provide the acid salt of (R)-MDMA or (S)-MDMA, respectively.
[0059] The compound of Formula (R)-l when R1 is CH2CH3 is (R)-N-methyl-1 ,3- benzodioxolylbutanamine ((R)-MBDB). The compound of Formula (S)-l when R1 is CH2CH3 is (S)-N-methyM ,3-benzodioxolylbutanamine ((S)-MBDB). Accordingly, when R1 is CH2CH3, the present application includes a process for preparing an acid salt of (R)-N- methyl-1 ,3-benzodioxolylbutanamine ((R)-MBDB) or (S)-N-methyl-l ,3- benzodioxolylbutanamine ((S)-MBDB):
the process comprising: reacting a compound of Formula B:
B wherein R1 is CH2CH3; with (R)-t-butyiS(0)NH2 or (S) (R)-t-butyiS(0)NH2 under reductive amination conditions to provide a compound of Formula (R),(R)-C or (S),(S)-C. respectively:
wherein R1 is CH2CH3;
methylating the compound of Formula (R),(R)-C or (S),(S)-C to provide a compound of Formula (R),(R)-D or (S),(S)-D, respectively:
wherein R1 is CH2CH3; and reacting the compound of Formula (R),(R)-D or (S),(S)-D with an acid to provide the acid salt of (R)-MBDB or the acid salt of (S)-MBDB, respectively.
[0060] The present application also includes a process for preparing an acid salt of a compound of Formula (R)-l or (S)-l:
wherein R1 is selected from CFh and CFhCFh; the process comprising:
reacting the compound of Formula B' with (S)-t-butyiS(0)NH2 or (R)-t- butyiS(0)NH2 to provide a compound of Formula (S)-Cim or (R)-Cim, respectively:
reacting the compound of Formula (S)-Cim or (R)-Cim with a methyl or ethyl organometallic reagent to provide the compound of Formula (R),(S)-C" or (S)(R)-C", respectively:
wherein R1 is selected from CH3 and CH2CH3; methylating the compound of Formula (R),(S)-C" or (S)(R)-C" to provide a compound of Formula (R),(S)-D' or (S),(R)-D', respectively:
wherein R1 is selected from CH3 and CH2CH3; and reacting the compound of Formula (R),(S)-D', with an acid to provide the acid salt of a compound of Formula (R)-l or reacting the compound of Formula (S),(R)-D', with an acid to provide the acid salt of a compound of Formula (S)-l. [0061] In some embodiments, R1 is CH3, and the compound of Formula I is (R)-
3, 4-methylenedioxymethamphetamine ((R)-MDMA). Accordingly, the present application includes a process for preparing an acid salt of (R)-3,4- methylenedioxymethamphetamine ((R)-MDMA)
the process comprising: homologating piperonal,
, to provide a compound of Formula (B')
reacting the compound of Formula B' with (S)-t-butylS(0)NH2 to provide a compound of Formula S-Cim:
reacting the compound of Formula (S)-Cim with a methyl organometallic reagent to provide the compound of (R),(S)-C":
wherein R1 is CH3; methylating the compound of Formula (R),(S)-C" to provide a compound of
Formula (R),(S)-D':
wherein R1 is CH3; and reacting the compound of Formula (R),(S)-D', with an acid to provide the acid salt of (R)-MDMA.
[0062] In some embodiments, R1 is CH2CH3 and the compound of Formula I is
(R)-N-methyl-1 ,3-benzodioxolylbutanamine ((R)-MBDB). Accordingly, when R1 is CH2CH3, the present application includes a process for preparing an acid salt of (R)-N- methyl-1 ,3-benzodioxolylbutanamine ((R)-MBDB):
the process comprising:
< 1 j 0 homologating piperonal, , to provide a compound of Formula B':
reacting the compound of Formula B' with (S)-t-butylS(0)NH2 to provide a compound of Formula (S)-Cim:
reacting the compound of Formula (S)-Cim with an ethyl organometallic reagent to provide the compound of (R),(S)-C":
wherein R1 is CH2CH3; methylating the compound of Formula (R),(S)-C" to provide a compound of Formula (R),(S)-D'
wherein R1 is CH2CH3; and reacting the compound of Formula (R),(S)-D' with an acid to provide the acid salt of (R)-MBDB.
[0063] In some embodiments, the compound of Formula A is known as safrole.
In some embodiments, the compound of Formula A is either commercially available or may be prepared using methods known in the art. For example, the compound of Formula A (safrole) is available from Sigma Aldrich (St. Louis, Missouri, USA).
[0064] In some embodiments, the compound of Formula A is oxidized to provide a compound of Formula B using any suitable conditions for oxidizing the compound of Formula A to provide the compound of Formula B known in the art, for example, using the synthetic procedures found in Advanced Synthesis & Catalysis 361(11) p2582-2593, 2019 or Forensic Science International, 248, 140-147; 2015.
[0065] In some embodiments, the compound of Formula A is oxidized to provide a compound of Formula B using Wacker oxidation or Wacker-Tsuji oxidation conditions. In some embodiments, the compound of Formula A is oxidized to provide a compound of Formula B in the presence of a palladium (II) catalyst and water or an iron (III) catalyst and water, or a combination thereof at temperatures and at times to provide the
compound of Formula B. In some embodiments, the palladium (II) catalyst is selected from palladium chloride (PdCI2) or palladium (II) trifluoroacetate ((CF3C02)2Pd). In some embodiments, the iron (III) catalyst is iron (III) chloride (FeCI3). In some embodiments, the suitable conditions further comprise a co-oxidant. In some embodiments, the co-oxidant is benzoquinone. In some embodiments, the oxidation conditions further comprise a co solvent. In some embodiments, the co-solvent is selected from dimethylformamide, acetonitrile and methanol, and combinations thereof. As representative, non-limiting examples, the temperature for oxidizing the compound of Formula A to provide the compound of Formula B is about 10 °C, about 20 °C, about 30 °C, about 40 °C, about 50 °C, about 60 °C or about 70 °C.
[0066] In some embodiments, the compound of Formula A is oxidized to provide a compound of Formula B in the presence of an excess amount (for example about 2% to 5% molar equivalents, or a 2.5% molar equivalent) of a palladium (II) catalyst, an excess amount (for example about 1 to 3 molar equivalent, or 1.5 molar equivalent) of an iron (III) catalyst and water at temperatures and at times to provide the compound of Formula B. In some embodiments, the palladium (II) catalyst is palladium (II) trifluoroacetate ((CF3C02)2Pd) and the iron (III) catalyst is iron chloride (FeCI3). In some embodiments, the suitable conditions further comprise using acetonitrile as the co solvent. As representative, non-limiting examples, the temperature for oxidizing the compound of Formula A in the presence of a palladium (II) catalyst, and an iron (III) catalyst to provide the compound of Formula B is about 40 °C, about 50 °C, or about 60 °C and representative, non-limiting example of reaction time, is about 4 hour to about 24 hours, about 8 hours to about 18 hours, about 12 hours to about 18 hours, about 14 hours to about 18 hours or about 16 hours.
[0067] In some embodiments, the compound of Formula A is oxidized to provide a compound of Formula B in the presence of a catalytic amount (for example about 1 to about 15 mole percent) of a palladium (II) catalyst, an excess amount (for example, about 1.1 to about 5 molar equivalents) of a co-oxidant and water at temperatures and at times to provide the compound of Formula B. In some embodiments, the palladium (II) catalyst is palladium (II) chloride (PdCI2) and the co-oxidant is benzoquinone. In some embodiments, the suitable conditions further comprise using methanol as the co-solvent. As representative, non-limiting examples, the temperature for oxidizing the compound of Formula A in the presence of a palladium (II) catalyst and a co-oxidant to provide the compound of Formula B is about 10 °C, about 10 °C, about 20 °C, or about 30 °C, and
representative, non-limiting example of reaction time, is about 1 hour to about 5 hours, about 1 hours to about 4 hours, about 2 hours to about 4 hours, or about 3 hours.
[0068] In some embodiments, the compound of Formula A' is known as isosafrole. In some embodiments, the compound of Formula A' is either commercially available or may be prepared using methods known in the art. For example, the compound of Formula A' (isosafrole) is available from Sigma Aldrich (St. Louis, Missouri, USA).
[0069] In some embodiments, the compound of Formula A' is a mixture of cis and trans isomers. [0070] In some embodiments, the compound of Formula A' is prepared by isomerizing the compound of Formula A. Therefore, alternatively, in some embodiments, the process comprises isomerizing the compound of Formula A:
to provide a compound of Formula A':
wherein indicates that the bond is in a cis and/or trans orientation; and oxidizing the compound of Formula A' to provide a compound of Formula B:
wherein R1 is CH3.
[0071] In some embodiments, the compound of Formula A is isomerized to provide a compound of Formula A' using any suitable conditions for isomerizing the compound of Formula A to provide the compound of Formula A' known in the art, for example, using the synthetic procedures found in Forensic Science International 155 (2005) 141-157.
[0072] In some embodiments, the step of isomerizing a compound of Formula A to provide a compound of Formula A' comprises reacting the compound of Formula A in the presence of a base and an inert solvent at a temperature and for a time to provide the compound of Formula A'. In some embodiments, the base is potassium tert-butoxide, sodium hydroxide or potassium hydroxide. In some embodiments, the base is potassium hydroxide. In some embodiments, the inert solvent is DMSO. In some embodiments, the step of isomerizing a Formula A to provide a compound of Formula A' is in the presence of potassium tert-butoxide in DMSO at a temperature and for a time to provide the compound of Formula A'. As representative, non-limiting example of temperature and reaction times for the step of isomerizing a Formula A to provide a compound of Formula B in the presence of a base in an insert solvent, the temperature is maintained at boiling point of the solvent (reflux) for about 1 hour to about 6 hours, about 2 hours to about 5 hours, about 3 hours to about 5 hours, or about 4 hours to provide the compound of Formula B.
[0073] In some embodiments, the step of isomerizing a compound of Formula A to provide a compound of Formula A' comprises reacting the compound of Formula A in the presence of a base and a phase transfer catalyst at a temperature and for a time to provide the compound of Formula A'. In some embodiments, the phase transfer catalyst is an ionic liquid. In some embodiments, the phase transfer catalyst is aliquot 336 (Stark’s catalyst). In some embodiments, the step of isomerizing a Formula A to provide a compound of Formula A' comprises reacting the compound of Formula A in the presence of a potassium hydroxide and aliquot 336 at a temperature and for a time to provide the compound of Formula A'. In some embodiments, the compound of Formula A, the base and the phase transfer catalyst are combined at room temperature and are agitated for about 15 minutes to about 30 minutes, or about 20 minutes, followed by heating to a temperature of about 50°C to about 90°C, about 60°C to about 90°C, or about 80°C for about 30 minutes to about 2 hours, about 45 minutes to about 90 minutes, about 60 minutes to about 90 minutes or about 75 minutes to provide the compound of Formula A'.
[0074] In some embodiments, the compound of Formula A' is oxidized to provide a compound of Formula B using any suitable conditions for oxidizing the compound of Formula A' to provide the compound of Formula B known in the art, for example, using the synthetic procedures found in Forensic Science International 155 (2005) 141-157.
[0075] In some embodiments, the compound of Formula A' is oxidized to provide a compound of Formula B in the presence of hydrogen peroxide and formic acid in water
at a time and a temperature to provide the compound of Formula B. In some embodiments, the step of oxidizing a compound of Formula A' to provide a compound of Formula B further comprises an inert solvent. In some embodiments, the inert solvent is acetone. In some embodiments, the hydrogen peroxide and formic acid in water is added, for example, dropwise to a solution of the compound of Formula B in an inert solvent to provide a reaction mixture which is maintained with cooling at a temperature of from about 18 °C to about 45 °C, about 25°C to about 40 °C, or about 30 °C to about 40 °C. In some embodiments, after the addition of the hydrogen peroxide and formic acid in water, the reaction mixture is maintained at room temperature (e.g., about 18 °C to about 25 °C) for about 14 to about 20hours, or about 16 hours. In some embodiments, the reaction mixture is concentrated and then dissolved in a solvent and treated with an acid for a time and at a temperature to provide the compound of Formula B. In some embodiments, the solvent is methanol or ethanol. In some embodiments, the solvent is methanol. In some embodiments, the acid is sulfuric acid. As representative, non-limiting example of temperature and reaction times, the reaction is heated to about 30 °C to about 80°C, about 30 °C to about 60 °C, or about 40 °C to about 60 °C for about 1 hour to about 6 hours, about 2 hours to about 4 hours or about 3 hours.
[0076] In some embodiments, the (R)-t-butylS(0)NH2 has an enantiomeric purity of about 97% or greater or of about 98% or greater. In some embodiments, the (R)-t- butyiS(0)NH2 has an enantiomeric purity of about 97% to about 99.9%, about 97% to about 99.8%, about 97% to about 99.5%, about 97% to about 99%, about 97% to about 98%, about 98% to about 99.8%, about 98% to about 99.5%, or about 98% to about 99%. In some embodiments, the (R)-t-butyiS(0)NH2 having an enantiomeric purity of about 97% or greater or of about 98% or greater is either commercially available or may be prepared using methods known in the art. For example, (R)-t-butyiS(0)NH2with a purity of about 98% or greater is available from Sigma Aldrich (St. Louis, Missouri, USA) or Fischer Scientific (Waltham, Massachusetts, USA).
[0077] In some embodiments, the (S)-t-butyiS(0)NH2 has an enantiomeric purity of about 97% or greater. In some embodiments, the (S) -t-butyiS(0)NH2 has an enantiomeric purity of about 97% to about 99.9%, about 97% to about 99.8%, about 97% to about 99.5%, about 97% to about 99%, about 97% to about 98%, or about 98% to about 99%. In some embodiments, the (S)-t-butyiS(0)NH2 having an enantiomeric purity of about 97% or greater is either commercially available or may be prepared using methods known in the art. For example, (S)-t-butyiS(0)NH2with a purity of about 97% or greater is available from Sigma Aldrich (St. Louis, Missouri, USA).
[0078] In some embodiments, the compound of Formula B is reacted with (R)-t- butyiS(0)NH2 or (S)-t-butylS(0)NH2 under any suitable reductive amination conditions to provide a compound of Formula (R),(R)-C or (S),(S)-C, respectively, for example, using the synthetic procedures found in Llabres et al (2014), European Journal of Medicinal Chemistry 81 (2014) 35-46.
[0079] In some embodiments, the suitable reductive amination conditions comprise a first step of reacting a compound of Formula B with (R)-t-butylS(0)NH2 or (S)- t-butyiS(0)NH2 in the presence of a titanium catalyst followed by a second step of adding a suitable reducing agent to provide the compound of Formula (R),(R)-C or (S),(S)-C. In some embodiments, the suitable reductive amination conditions comprise a first step of reacting a compound of Formula B with (R)-t-butylS(0)NH2 or (S)-t-butylS(0)NH2 in the presence of a titanium catalyst to provide a compound of Formula C:
wherein R1 is selected from CH3 and CH2CH3; followed by a second step of adding a suitable reducing agent to provide the compound of Formula (R),(R)-C or (S),(S)-C.
[0080] In some embodiments, the suitable reductive amination conditions comprise a first step of reacting a compound of Formula B with an excess amount (for example, about 1.1 to about 2 molar equivalents) of (R)-t-butylS(0)NH2 or (S)-t- butyiS(0)NH2 in the presence of an excess amount (for example, about 1.1 to about 10 equivalents) of a titanium catalyst in a solvent at a temperature and a time to react the compound of Formula B with (R)-t-butylS(0)NH2 or (S)-t-butylS(0)NH2 to provide a compound of Formula C, followed by a second step of adding a suitable reducing agent to the compound of Formula C to provide the compound of Formula (R),(R)-C or (S),(S)- C. In some embodiments, the compound of Formula C is not isolated. As representative, non-limiting example of temperature and reaction times, the reaction of the compound of Formula B with the titanium catalyst is maintained at boiling point of the solvent (reflux) for about 1 hour to about 8 hours, about 2 hours to about 6 hours, about 3 hours to about 6 hours, or about 5 hours to provide the compound of Formula C, and then cooled to about -25 °C to about 15 °C, or about -20°C before the second step of adding a suitable reducing agent to provide the compounds of Formula (R),(R)-C or (S),(S)-C. In some
embodiments, the reduction reaction to provide the compound of Formula (R),(R)-C or (S),(S)-C is maintained at about -25 °C to about -15 °C, or about -20°C for about 1 hour to about 4 hours or about 2 to about 3 hours or about 3 hours and then at room temperature (e.g., about 18 °C to 25 °C) for about 8 to about 12 hours.
[0081] In some embodiments, the first and second step of the reduction amination of the compound of Formula B to provide the compound of Formula (R),(R)-C or (S),(S)- C occur sequentially in one reaction vessel (one pot). In some embodiments, the compound of Formula C, is isolated before proceeding with the second step.
[0082] Accordingly, in some embodiments, the suitable reductive amination conditions comprise reacting the compound of Formula B with (R)-t-butylS(0)NH2or (S)- t-butylS(0)NH2 to provide a compound of Formula C, and
wherein R1 is selected from CH3 and CH2CH3; reducing the compound of Formula C with a reducing agent to provide a compound of Formula (R),(R)-C or (S),(S)-C.
[0083] In some embodiments, the titanium catalyst is selected from titanium (IV) isopropoxide (Ti(OiPr)4) and titanium (IV) ethoxide (Ti(OEt)4). In some embodiments, the titanium catalyst is titanium (IV) ethoxide (Ti(OEt) In some embodiments, the inert solvent is tetrahydrofuran, toluene or xylene. In some embodiments, the inert solvent is tetrahydrofuran.
[0084] In some embodiments, the suitable reducing agent to provide the compound of Formula (R),(R)-C or (S),(S)-C is any suitable reducing agent that reduces the fe/f-butanesulfinyl imine compound of Formula C to provide a compound of Formula (R),(R)-C or (S),(S)-C. In some embodiments, the suitable reducing agent is sodium borohydride.
[0085] In some embodiments, piperonal is either commercially available or may be prepared using methods known in the art. For example, piperonal is available from Sigma Aldrich (St. Louis, Missouri, USA).
[0086] In some embodiments, piperonal is homologated to provide a compound of Formula B' using any suitable conditions for homologating piperonal to provide a
compound of Formula B' known in the art, for example, using the synthetic procedures found in Tetrahedron: Asymmetry, 27(6), 274-284; 2016.
[0087] In some embodiments, the step of homologating piperonal to provide a compound of Formula (B') is with the Wittig reagent methoxymethylenetriphenylphosphine under Wittig reaction conditions. Accordingly, in some embodiments, the process comprises homologating piperonal with methoxymethylenetriphenylphosphine under Wittig reaction conditions to provide a compound of Formula (B').
[0088] In some embodiments, the methoxymethylenetriphenylphosphine is generated in situ, for example, by the deprotonation of, for example, methoxymethyl(triphenyl)phosphonium chloride with a suitable base. Accordingly, in some embodiments, the Wittig reaction conditions comprise combining methoxymethyl(triphenyl)phosphonium chloride with an excess amount (for example, about 1.1 to about 2 molar equivalents) of suitable base in an inert solvent at a temperature of about 0 °C to about 15°C, about 0 °C to about 10 °C, or about 0 °C to about 5 °C or about 0 °C and then stirring at about room temperature (e.g., about 18 °C to 25 °C) for about 15 minutes to about 1 hour, about 30 minutes to about 1 hour, about 30 minutes to about 45 minutes, or about 30 minutes, to provide the methoxymethylenetriphenylphosphine. In some embodiments, the suitable base is selected from alkyllithiums; alkoxides such as sodium methoxide or potassium tert- butoxide; dimsyl sodium; hydrides such as sodium hydride, amides; and amines such as triethylamine. In some embodiments, the suitable base is an alkoxide such as sodium methoxide or potassium tert-butoxide. In some embodiments, the suitable base potassium tert-butoxide. In some embodiments, the suitable inert solvent is THF or toluene.
[0089] In some embodiments, the Wittig reaction conditions further comprise reacting piperonal with the methoxymethylenetriphenylphosphine for a time and at temperature to provide a vinyl ether intermediate,
reacting the vinyl ether intermediate with a suitable acid for a time and at a temperature to provide the compound of Formula B'.
[0090] As representative, non-limiting examples of temperature and reaction times to provide the vinyl ether intermediate, the piperonal is reacted with the methoxymethylenetriphenylphosphine at about room temperature (e.g., about 18 °C to 25 °C) for about 8 to about 20 hours, about 10 to about 16 hours, about 10 to about 14 hours or about 12 hours (e.g. overnight).
[0091] As representative, non-limiting examples of temperature and reaction times for reacting the vinyl ether intermediate with a suitable acid, the vinyl ether intermediate is reacted with a suitable acid at room temperature (e.g., about 18 °C to 25 °C) for about 24 hours about 72 hours, about 36 to about 60 hours, about 40 hours to about 50 hours, about 36 hours to about 72 hours, about 48 hours to about 72 hours, or about 72 hours. In some embodiments, the suitable acid is selected from hydrochloric acid and formic acid. In some embodiments, the suitable acid is formic acid.
[0092] In some embodiments, the compound of Formula B' is reacted with (S)-t- butyiS(0)NH2 or (R)-t-butylS(0)NH2 under any suitable conditions to provide a compound of Formula (S)-Cim or (R)-Cim, respectively, for example, using the synthetic procedures found in Angewandte Chemie, International Edition, 53(48), 13215-13219; 2014 and Wakefield, Bryan Hall (2008) Synthetic studies on (E)-alkene peptide isosteres and thiophene-containing furanosteroids [Ph.D Thesis, University of Pittsburgh]
[0093] In some embodiments, the compound of Formula B' is reacted with (S)-t- butyiS(0)NH2 or (R)-t-butyiS(0)NH2 in the presence of a catalyst such as pyridinium p- toluenesulfonate (PPTS) or a titanium catalyst to provide the compound of Formula (S)- Cim or (R)-Cim. In some embodiments, the compound of Formula B' is reacted with (S)-t- butyiS(0)NH2 or (R)-t-butyiS(0)NH2 in the presence of a catalyst such as pyridinium p- toluenesulfonate or a titanium catalyst in an inert solvent at a temperature and a time to provide the compound of Formula (S)-Cim or (R)-Cim . In some embodiments, the compound of Formula B' is reacted with (S)-t-butyiS(0)NH2 or (R)-t-butyiS(0)NH2 in the presence of pyridinium p-toluenesulfonate in an inert solvent at a temperature and a time to provide the compound of Formula (S)-Cim or (R)-Cim . In some embodiment, the compound of Formula B' is reacted with (S)-t-butyiS(0)NH2 or (R)-t-butyiS(0)NH2 in the presence of pyridinium p-toluenesulfonate and a dehydrating agent in an inert solvent at a temperature and a time to provide the compound of Formula (S)-Cim or (R)-Cim .
[0094] In some embodiments, the compound of Formula B' is reacted with a slight excess (for example, about 1.1 to about 1.5 molar equivalents) of (S)-t-butyiS(0)NH2 or (R)-t-butyiS(0)NH2 in the presence of catalytic amounts (for example, 0.1 to 1 , or about
0.25 to about 0.75 molar equivalents) of pyridinium p-toluenesulfonate in the present of an excess amount (for example, about 7 to about 12 molar equivalents, or about 9 to about 11 molar equivalents) of a dehydrating agent in an inert solvent at a temperature and a time to provide the compound of Formula (S)-Cim or (R)-Cim . In some embodiments, the dehydrating reagent is magnesium sulfate. As representative, non-limiting example of temperature and reaction times, the reaction of the compound of Formula B' with (S)-t- butyiS(0)NH2 or (R)-t-butylS(0)NH2 in the presence of pyridinium p-toluenesulfonate and a dehydrating agent in an inert solvent at room temperature (e.g., about 18 °C to 25 °C) for about 36 hours to about 60 hours, about 40 to about 56 hours, about 45 to about 50 hours, about 48 hours to about 60 hours, or about 60 hours to provide the compounds of Formula (S)-Cim or (R)- Cim. In some embodiments, the inert solvent is methylene chloride.
[0095] In some embodiments, the compound of Formula B' is reacted with excess amount (for example, about 1.1 to about 2 molar equivalents) of (S)-t-butylS(0)NH2 or (R)-t-butylS(0)NH2 in the of an excess amount (for example, about 1.1 to about 10 molar equivalents) of a titanium catalyst in a solvent at a temperature and a time to react the compound of Formula B with (R)-t-butylS(0)NH2 (R)-t-butylS(0)NH2 to provide a compound of Formula (S)-Cim or (R)-Cim . As representative, non-limiting example of temperature and reaction times, the reaction of the compound of Formula B' with the titanium catalyst is maintained at boiling point of the solvent (reflux) for about 1 hour to about 8 hours, about 2 hours to about 6 hours, about 3 hours to about 6 hours, or about 5 hours to provide the compound of Formula (S)-Cim or (R)-Cim .
[0096] In some embodiments, the titanium catalyst is selected from titanium (IV) isopropoxide (Ti(OiPr)4) and titanium (IV) ethoxide (Ti(OEt)4). In some embodiments, the titanium catalyst is titanium (IV) ethoxide (Ti(OEt) In some embodiments, the inert solvent is tetrahydrofuran, toluene or xylene. In some embodiments, the inert solvent is tetrahydrofuran.
[0097] In some embodiments, the conditions for providing the compound of formula (R),(S)-C" or (S),(R)-C" are any suitable conditions for reacting the compound of Formula (S)-Cim or (R)-Cim, respectively, with a methyl or ethyl organometallic reagent to provide a compound of Formula (R),(S)-C" or (S),(R)-C" known in the art, for example, using the synthetic procedures found Tetrahedron, 55(29), 8883-8904; 1999.
[0098] In some embodiments, the compound of Formula (S)-Cim or (R)-Cim is reacted with an excess amount (for example, about 1.1 to about 3, or about 2 molar
equivalent) of the methyl or ethyl organometallic reagent in a suitable inert solvent for a time and a temperature to provide the compound of Formula (R),(S)-C" or (S),(R)-C" . In some embodiments, the suitable inert solvent is selected from methylene chloride, tetrahydrofuran, and diethyl ether. In some embodiments, the suitable inert solvent is methylene chloride.
[0099] In some embodiments, the methyl or ethyl organometallic reagents is a
Grignard reagent or methyl lithium or ethyllithium, respectively. In some embodiments, the methyl or ethyl organometallic reagents is a Grignard reagent. In some embodiments, the methyl or .ethyl organometallic reagent is methyl lithium or ethyllithium, respectively.
[00100] In some embodiments, the methyl or ethyl organometallic reagent is a Grignard reagent. In some embodiments, the methyl or ethyl Grignard reagent is Ch MgBr or CH3CH2MgBr, respectively. In some embodiments, the methyl or ethyl organometallic reagent is a Grignard reagent and the compound of Formula Cim is reacted with the methyl or ethyl Grignard reagent at a temperature of about -60 °C to about -20 °C, about -50 °C to about -30 °C , -50 °C to about -40 °C or about -50 °C for about 2 to about 6 hours, about 3 to about 5 hours, or about 4 hours and then at about room temperature (e.g., about 18 °C to 25 °C) for about 4 hours to about 18 hours, about 6 hours to about 16 hours, about 8 hours to about 14 hours, or about 12 hours (e.g., overnight) to provide the compound of Formula (R),(S)-C" or (S),(R)-C".
[00101] In some embodiments, the compound of Formula (R),(R)-C or (S),(S)-C or the compound of Formula (R),(S)-C" or (S),(R)-C" is methylated under any suitable methylation conditions to methylate the compound of Formula R),(R)-C or (S),(S)-C or the compound of Formula (R),(S)-C" or (S),(R)-C" provide the compound of Formula
(R),(R)-D or (S),(S)-D or the compound of Formula (R),(S)-D' or (S),(R)-D', respectively, known in the art, for example, using the synthetic procedures found in European Journal of Medicinal Chemistry, 81 , 35-46; 2014.
[00102] In some embodiments, the compound of Formula (R),(R)-C or (S),(S)-C or the compound of Formula (R),(S)-C" or (S),(R)-C" is methylated with a methyl halide in the presence of a base in an inert solvent at a temperature and a time to react the compound of Formula (R),(R)-C or (S),(S)-C or the compound of Formula (R),(S)-C" or
(S),(R)-C" with the methyl halide to provide the compound of Formula R),(R)-D or (S),(S)- D or the compound of Formula (R),(S)-D' or (S),(R)-D'. In some embodiments, the compound of Formula (R),(R)-C or (S),(S)-C or the compound of Formula (R),(S)-C" or (S),(R)-C" is methylated with an excess amount (for example, about 1.1 to about 8, or
about 6 molar equivalents) of a methyl halide such as methyl iodide (Mel) in the presence of an excess amount (for example, about 1.1 to about 2 equivalents) of a base such as sodium hydride in an inert solvent at a temperature and a time to react the compound of Formula (R),(R)-C or (S),(S)-C or the compound of Formula (R),(S)-C" or (S),(R)-C" with the methyl halide to provide the compound of Formula (R),(R)-D or (S),(S)-D or the compound of Formula (R),(S)-D' or (S),(R)-D'. In some embodiments, the inert solvent is dimethylformamide. As representative, non-limiting example of temperatures and reaction times, the compound of Formula (R),(R)-C or (S),(S)-C or the compound of Formula (R),(S)-C" or (S),(R)-C" is reacted with the base at about 0 °C to about 10 °C or 0 °C to about 5 °C and then at room temperature (e.g., about 18 °Cto 25 °C) for about 15 minutes to about 1 hours, about 20 minutes to about 45 minutes, or about 20 minutes to about 30 minutes to form a reaction mixture which is then cooled to at a temperature of about 0 °C to about 10 °C or 0 °C to about 5 °C and reacted with the methyl halide such as methyl iodide and then at about room temperature (e.g., about 18 °C to 25 °C) for about 4 hours to about 18 hours, about 6 hours to about 16 hours, about 8 hours to about 14 hours, or about 12 hours (e.g., overnight) to provide the compound of Formula (R),(R)-D or (S),(S)- D or the compound of Formula (R),(S)-D' or (S),(R)-D'.
[00103] In some embodiments, the compound of Formula (R),(R)-D or (S),(S)-D or the compound of Formula (R),(S)-D' or (S),(R)-D' is reacted with an acid under any suitable conditions to provide the acid salt of the compound of Formula (R)-l (i.e., (R)- MDMA and (R)-MBDB) or (S)-l (i.e., (S)-MDMA and (S)-MBDB), respectively, known in the art, for example, using the synthetic procedures found in European Journal of Medicinal Chemistry, 81 , 35-46; 2014.
[00104] In some embodiments, the compound of Formula (R),(R)-D or (S),(S)-D or the compound of Formula (R),(S)-D' or (S),(R)-D' is reacted with an excess amount (for example, about 1.1 to about 6 equivalents) of acid in a solvent at a temperature and a time to provide the acid salt of the compound of Formula (R)-l (i.e., (R)-MDMA and (R)- MBDB) or (S)-l (i.e., (S)-MDMA and (S)-MBDB)). In some embodiments, the solvent is water, methanol, dioxane, and mixtures thereof. In some embodiments, the solvent is methanol and dioxane. In some embodiments, the solvent is methanol. As representative, non-limiting examples of temperature and reaction times, the compound of Formula (R),(R)-D or (S),(S)-D or the compound of Formula (R),(S)-D' or (S),(R)-D' is combined with the acid at a temperature of about 0 °C to about 10 °C or 0 °C to about 5 °C and then at then (at about room temperature (e.g., about 18 °C to 25 °C) for about for about 1 hours to about 24 hours, about 3 hours to about 16 hours, about 4 hours to about 14 hours,
about 6 hours to about 12 hours, about 8 hours to about 12 hours, or about 10 hours to about 12 hours(e.g overnight).
[00105] In some embodiments, the acid is sulfuric acid (H2S0 ), trifluoroacetic acid (TFA) or hydrochloric acid (HCI). In some embodiments, the acid is HCI. Accordingly, in some embodiments the compound of Formula (R),(R)-D or (S),(S)-D or the compound of Formula (R),(S)-D' or (S),(R)-D' is reacted with HCI to provide an HCI salt of the compound of Formula (R)-l (i.e., (R)-MDMA.HCI and (R)-MBDB.HCI) or (S)-l (i.e., (S)- MDMA.HCI and (S)-MBDB).HCI). In some embodiments the compound of Formula
(R),(R)-D or (S),(S)-D wherein R1 is CH3 is reacted with HCI to provide an HCI salt of (R)- MDMA ((R)-MDMAHCI) or (S)-MDMA ((S)-MDMA.HCI). In some embodiments the compound of Formula (R),(R)-D or (S),(S)-D or compound of Formula (R),(S)-D' or
(S),(R)-D' wherein R1 is CH2CH3 is reacted with HCI to provide an HCI salt of (R)-MBDB ((R)-MBDB HCI) or (S)-MBDB ((S)-MBDB.HCI).
[00106] In an exemplary embodiment, the present application includes a process for preparing an HCI salt of a compound of Formula (R)-l:
wherein R1 is selected from CH3 and CH2CH3; the process comprising: reacting a compound of Formula B:
wherein R1 is selected from CH3 and CH2CH3; with (R)-t-butyiS(0)NH2 under reductive amination conditions in the presence of a titanium catalyst to provide a compound of Formula (R),(R)-C:
wherein R1 is selected from CH3 and CH2CH3;
methylating the compound of Formula (R),(R)-C to provide a compound of Formula (R),(R)-D:
wherein R1 is selected from CH3 and CH2CH3; and reacting the compound of Formula (R),(R)-D with hydrochloric acid to provide the
HCI salt of the compound of Formula (R)-l.
[00107] In an exemplary embodiment of the process of the application, the application includes a process for preparing an HCI salt of (R)-N-methyl-1 ,3- benzodioxolylbutanamine ((R)-MBDB):
the process comprising: oxidizing a compound of Formula A or a compound of Formula A':
wherein /v/v/vr indicates that the bond is in a cis and/or trans orientation, to provide a compound of Formula B:
wherein R1 is CH3; reacting the compound of Formula B with (R)-t-butylS(0)NH2 under reductive amination conditions in the presence of a titanium catalyst to provide a compound of Formula (R),(R)-C:
wherein R1 is CH3; methylating the compound of Formula (R),(R)-C to provide a compound of Formula (R),(R)-D:
wherein R1 is CH3; and reacting the compound of Formula (R),(R)-D with hydrochloric acid to provide (R)- MDMAHCI.
[00108] In an exemplary embodiment, the present application includes a process for preparing an HCI salt of (R)-N-methyl-1,3-benzodioxolylbutanamine ((R)-MBDB):
the process comprising: reacting the compound of Formula B with (R)-t-butyiS(0)NH2 under reductive amination conditions in the presence of a titanium catalyst to provide a compound of Formula (R),(R)-C:
wherein R1 is CH2CH3; methylating the compound of Formula (R),(R)-C to provide a compound of Formula (R),(R)-D:
wherein R1 is CH2CH3; and reacting the compound of Formula (R),(R)-D with hydrochloric acid to provide the (R)- MBDB.HCI.
[00109] In an exemplary embodiment of the process of the application, the present application also includes a process for preparing an HCI salt of a compound of Formula (R)-l:
wherein R1 is selected from CH3 and CH2CH3; the process comprising: homologating piperonal,
, with methoxymethylenetriphenylphosphine under Wittig reaction conditions to provide a compound of Formula B':
reacting the compound of Formula B' with (S)-t-butylS(0)NH2 to provide a compound of Formula (S)-Cim:
reacting the compound of Formula (S)-Cim with a methyl or ethyl organometallic reagent to provide the compound of Formula (R),(S)-C":
wherein R1 is selected from CH3 and CH2CH3; methylating the compound of Formula (R),(S)-C" to provide a compound of Formula (R),(S)-D':
wherein R1 is selected from CH3 and CH2CH3; and reacting the compound of Formula (R),(S)-D' with hydrochloric acid to provide the HCI salt of a compound of Formula (R)-l.
[00110] In some embodiments, the Wittig reaction conditions further comprise reacting piperonal with the methoxymethylenetriphenylphosphine to provide a vinyl ether intermediate,
reacting the vinyl ether intermediate with a suitable acid the compound of Formula B'.
[00111] In some embodiments, the compound of Formula B' is reacted with (S)-t- butylS(0)NH2 or (R)-t-butylS(0)NH2 in the presence of a catalyst such as pyridinium p- toluenesulfonate to provide the compound of Formula (S)-Cim or (R)-Cim, respectively.
[00112] In some embodiments, the compound of Formula (R),(S)-D' or (S),(R)-D' is reacted hydrochloric acid to provide the hydrochloric acid salt of the compound of Formula (R)-l or (S)-l, respectively.
[00113] In an exemplary embodiment of the process of the application, the present application includes a process for preparing an HCI salt of (R)- 3,4- methylenedioxymethamphetamine ((R)-MDMA):
the process comprising: homologating piperonal,
, with methoxymethylenetriphenylphosphine under Wittig reaction condition to provide a compound of Formula B':
reacting the compound of Formula B' with (S)-t-butyiS(0)NH2 to provide a compound of Formula (S)-Cim:
reacting the compound of Formula (S)-Cim with a methyl organometallic reagent to provide the compound of (R),(S)-C":
wherein R1 is CH3; methylating the compound of Formula (R),(S)-C" to provide a compound of Formula (R),(S)-D':
wherein R1 is CH3; and reacting the compound of Formula (R),(S)-D', with hydrochloric acid to provide the HCI salt of (R)-MDMA ((R)-MDMA.HCI).
[00114] In some embodiments, the compound of Formula B' is reacted with (S)-t- butyiS(0)NH2 in the presence of a catalyst such as pyridinium p-toluenesulfonate to provide the compound of Formula (S)-Cim. [00115] In an exemplary embodiment of the process of the application, when R1 is
CFhCFh, the present application includes a process for preparing an HCI salt of (R)-N- methyl-1 ,3-benzodioxolylbutanamine ((R)-MBDB):
the process comprising: homologating piperonal,
with methoxymethylenetriphenylphosphine under Wittig reaction conditions to provide a compound of Formula B':
reacting the compound of Formula B' with (S)-t-butyiS(0)NH2 to provide a compound of Formula (S)-Cim:
reacting the compound of Formula (S)-Cim with an ethyl organometallic reagent to provide the compound of (R),(S)-C":
wherein R1 is CH2CH3; methylating the compound of Formula (R),(S)-C" to provide a compound of Formula (R),(S)-D':
wherein R1 is CH2CH3; and reacting the compound of Formula (R),(S)-D', with hydrochloric acid to provide the HCI salt of (R)-MBDB ((R)-MBDB.HCI). [00116] In an exemplary embodiment, the present application includes a process for preparing an acid salt of a compound of Formula (S)-l:
wherein R1 is selected from CH3 and CH2CH3; the process comprising: reacting a compound of Formula B:
B wherein R1 is selected from CH3 and CH2CH3; with (S)-t-butyiS(0)NH2 under reductive amination conditions to provide a compound of Formula (S),(S)-C:
wherein R1 is selected from CH3 and CH2CH3; methylating the compound of Formula (S),(S)-C to provide a compound of Formula (S),(S)-D:
wherein R1 is CH3or CH2CH3; and reacting the compound of Formula (S),(S)-D with an acid to provide an acid salt of the compound of Formula (S)-l.
[00117] When R1 is CH3, the present application also includes an exemplary process for preparing (S)-3, 4-methylenedioxymethamphetamine (S-MDMA):
the process comprising: oxidizing a compound of Formula A or a compound of Formula A':
wherein indicates that the bond is in a cis and/or trans orientation to provide a compound of Formula B:
wherein R1 is CH3; reacting the compound of Formula B with (S)-t-butyiS(0)NH2 under reductive amination conditions to provide a compound of Formula (S),(S)-C:
wherein R1 is CH3; methylating the compound of Formula (S),(S)-C to provide a compound of Formula (S),(S)-D:
wherein R1 is CH3; and reacting the compound of Formula (S),(S)-D with an acid to provide an acid salt of (S)-MDMA.
[00118] When R1 is CH2CH3, the present application also includes an exemplary process for preparing an acid salt of (S)-N-methyl-1 ,3-benzodioxolylbutanamine (S- MBDB):
the process comprising: reacting a compound of Formula B:
wherein R1 is CH2CH3;
with (S)-t-butylS(0)NH2 under reductive amination conditions to provide a compound of Formula (S),(S)-C:
wherein R1 is CH2CH3; methylating the compound of Formula (S),(S)-C to provide a compound of
Formula (S),(S)-D:
wherein R1 is CH2CH3; and reacting the compound of Formula (S),(S)-D with an acid to provide an acid salt of (S)-MBDB.
[00119] The present application also includes an exemplary process for preparing an acid salt of a compound of Formula (S)-l:
wherein R1 is selected from CH3 and CH2CH3; the process comprising:
reacting the compound of Formula B' with (R)-t-butyiS(0)NH2 to provide a compound of Formula (R)-Cim:
reacting the compound of Formula (R)-Cim with a methyl or ethyl organometallic reagent to provide the compound of Formula (S),(R)-C":
wherein R1 is selected from CH3 and CH2CH3; methylating the compound of Formula (S),(R)-C" to provide a compound of Formula (S),(R)-D':
wherein R1 is selected from CH3 and CH2CH3; and reacting the compound of Formula (S),(R)-D', with an acid to provide an acid salt of the compound of Formula (S)-l.
[00120] In some embodiments, the process further comprises converting the acid salt of S-MDMA to S-MDMA.
[00121] In some embodiments, the acid salt of the compound of Formula (R)-l or (S)-l prepared by a process of the application is further converted to a solvate and/or prodrug thereof, for example, a pharmaceutically acceptable salt, solvate and/or prodrug thereof. In some embodiments, the acid salt of (R)-MDMA or (S)-MDMA prepared by a process of the application is further converted to a solvate and/or prodrug thereof, for example, a pharmaceutically acceptable salt, solvate and/or prodrug thereof. In some embodiments, the acid salt of (R)-MBDB or (S)-MBDB prepared by a process of the application is further converted to a solvate and/or prodrug thereof, for example, a pharmaceutically acceptable salt, solvate and/or prodrug thereof.
[00122] In some embodiments, the process of the application further comprises converting the acid salt of the compound of Formula (R)-l or (S)-l to the free base of the compound of Formula (R)-l or (S)-l, respectively. In some embodiments, the process of
the application further comprises converting the acid salt of (R)- or (S)-MDMA to the free base of (R)- or (S)-MDMA. In some embodiments, the process of the application further comprises converting the acid salt of (R)- or (S)-MBDB to the free base of (R)- or (S)- MBDB.
[00123] In some embodiments, the acid salt of the compound of Formula (R)-l or (S)-l is converted to the free base, for example, using any suitable base under any suitable conditions known in the art, for example, using a suitable base and conditions known in the art as described below.
[00124] In some embodiments, the free base of the compound of Formula (R)-l or (S)-l, (i.e. (R)- or (S)-MDMA and (R)- or (S)-MBDB), prepared by a process of the application is further converted to a salt, solvate and/or prodrug thereof, for example, a pharmaceutically acceptable salt, solvate and/or prodrug thereof.
[00125] In some embodiments, the process provides the R or S enantiomer as the major isomer. In some embodiments, the process provides the R or S enantiomer in greater than 60% ee, 65% ee, 70% ee, 75% ee, 80% ee, 85% ee, 90% ee, 95% ee, 98% ee or 99% ee. In some embodiments, the process provides the R or S enantiomer of the MDMA ((R)-MDMA or (S)-MDMA) or the acid salt of (R)-MDMA or (S)-MDMA such as (R)-MDMAHCI or (S)-MDMA.HCI as the major isomer. In some embodiments, the process provides (R)-MDMA or (S)-MDMA or acid salt of (R)-MDMA or (S)-MDMA in greater than 60% ee, 65% ee, 70% ee, 75% ee, 80% ee, 85% ee, 90% ee, 95% ee, 98% ee or 99% ee. In some embodiments, the process provides the R or S enantiomer of the MBDB ((R)- MBDB or (S)-MBDB) or the acid salt of (R)-MBDB or (S)-MBDB such as (R)- MBDB.HCI or (S)-MBDB.HCI as the major isomer. In some embodiments, the process provides (R)-MBDB or (S)-MBDB or acid salt of (R)-MBDB or (S)-MBDB in greater than 60% ee, 65% ee, 70% ee, 75% ee, 80% ee, 85% ee, 90% ee, 95% ee, 98% ee or 99% ee.
[00126] In some embodiments the pharmaceutically acceptable salt is an acid addition salt and the selection of a suitable salt may be made by a person skilled in the art (see, for example, S. M. Berge, et al., "Pharmaceutical Salts," J. Pharm. Sci. 1977, 66, 1-19).
[00127] An acid addition salt that is pharmaceutically acceptable, that is suitable for, or compatible with, the treatment of subjects, is any non-toxic organic or inorganic acid addition salt of any basic compound. Basic compounds that form an acid addition salt include, for example, compounds comprising an amine group. Illustrative inorganic
acids which form suitable salts include hydrochloric, hydrobromic, sulfuric, nitric and phosphoric acids, as well as acidic metal salts such as sodium monohydrogen orthophosphate and potassium hydrogen sulfate. Illustrative organic acids which form suitable salts include mono-, di- and tricarboxylic acids. Illustrative of such organic acids are, for example, acetic, trifluoroacetic, propionic, glycolic, lactic, pyruvic, malonic, succinic, glutaric, fumaric, malic, tartaric, citric, ascorbic, maleic, hydroxymaleic, benzoic, hydroxybenzoic, phenylacetic, cinnamic, mandelic, salicylic, 2-phenoxybenzoic, p- toluenesulfonic acid and other sulfonic acids such as methanesulfonic acid, ethanesulfonic acid and 2-hydroxyethanesulfonic acid. In some embodiments, the mono- or di-acid salts are formed, and such salts exist in either a hydrated, solvated or substantially anhydrous form. In general, acid addition salts are more soluble in water and various hydrophilic organic solvents, and generally demonstrate higher melting points in comparison to their free base forms. The selection criteria for the appropriate salt will be known to one skilled in the art. Other non-pharmaceutically acceptable salts such as but not limited to oxalates may be used, for example in the isolation of compounds of the application for laboratory use, or for subsequent conversion to a pharmaceutically acceptable acid addition salt.
[00128] Solvates include, for example, those made with solvents that are pharmaceutically acceptable. Examples of such solvents include water (resulting solvate is called a hydrate) and ethanol and the like. Suitable solvents are physiologically tolerable at the dosage administered.
[00129] The formation of a desired compound salt is achieved using standard techniques. For example, the neutral compound is treated with an acid in a suitable solvent and the formed salt is isolated by filtration, extraction or any other suitable method.
[00130] The formation of solvates will vary depending on the compound and the solvate. In general, solvates are formed by dissolving the compound in the appropriate solvent and isolating the solvate by cooling or using an antisolvent. The solvate is typically dried or azeotroped under ambient conditions. The selection of suitable conditions to form a particular solvate can be made by a person skilled in the art.
[00131] Prodrugs may be, for example, conventional esters formed with the available amino group. Some common esters which have been utilized as prodrugs are phenyl esters, aliphatic (C1-C24) esters, acyloxymethyl esters, carbamates and amino acid esters.
[00132] Examples of inert solvents include, but are not limited to, benzene, toluene, tetrahydrofuran, ethyl ether, ethyl acetate, dimethyl formamide (DMF), acetonitrile, Ci_ 6alkylOH (e.g. methanol, ethanol, n-propanol, 2-propanol, n-butanol, butan-2-ol and 2- methyl-1 -propanol), diethylcarbonate, hexane and dimethylsulfoxide (DMSO). Further examples can include aqueous solutions, such as water and dilute acids and bases, and ionic liquids, provided that such solvents do not interfere with the reaction.
III. Compounds of the Application
[00133] The present application also includes compound of Formula (R)-C', (S)-C', (R),(R)-C, (S),(S)-C and (R),(R)-D and (S),(S)-D, useful forthe preparation of compounds of Formula (R)-l or (S)-l.
[00134] Accordingly, the present application also includes a compound of Formula (R)-C':
wherein R1 is CH3 orCH2CH3. [00135] The present application also includes a compound of Formula (S)-C':
wherein R1 is CH3 orCH2CH3.
[00136] In some embodiments, R1 in the compound of Formula (R)-C' or (S)C' is CH3 In some embodiments, R1 in the compound of Formula (R)-C' or (S)-C' is CH2CH3 [00137] The present application also includes a compound of Formula (R),(R)-C:
wherein R1 is selected from CH3 and CH2CH3.
[00138] The present application also includes a compound of Formula (S),(S)-C:
wherein R1 is selected from CH3 and CH2CH3
[00139] In some embodiments, R1 in the compound of Formula (R),(R)-C or (S),(S)-C is CH3 In some embodiments, R1 in the compound of Formula (R),(R)-C or (S),(S)-C is CH2CH3
[00141] The present application also includes a compound of Formula (R)-Cim:
[00142] The present application includes a compound of Formula (R),(S)-C":
wherein R1 is CH3or CH2CH3.
[00143] The present application also includes a compound of Formula (S),(R)-C":
wherein R1 is selected from CH3 and CH2CH3.
[00144] In some embodiments, R1 in the compound of Formula (R),(S)-C" or (S),(R)-C" is CH3 In some embodiments, R1 in the compound of Formula (R),(S)-C" or (S),(R)-C" is CH2CH3
[00145] The present application also includes a compound of Formula (R),(R)-D:
wherein R1 is CH3or CH2CH3.
[00146] The present application also includes a compound of Formula (S),(S)-D:
wherein R1 is CH3or CH2CH3.
[00147] In some embodiments, R1 in the compound of Formula (R),(R)-D or (S),(S)-D is CH3 In some embodiments, R1 in the compound of Formula (R),(R)-D or (S),(S)-D is CH2CH3
[00148] The present application also includes a compound of Formula (R),(S)-D':
wherein R1 is CH3or CH2CH3.
[00150] wherein R1 is CH3or CH2CH3.ln some embodiments, R1 in the compound of Formula (R),(S)-D' or (S),(R)-D' is CH3 In some embodiments, R1 in the compound of Formula (R),(S)-D' or (S),(R)-D' is CH2CH3
[00151] As the process of the application provides a compound of Formula (R)-l or (S)-! or an acid salt of compound of Formula (R)-l or (S)-l, the application also includes compound of Formula (R)-l or (S)-l or an acid salt of compound of Formula (R)-l or (S)-l prepared by process of the application as described above. As the process of the application provides (R)-MDMA, (S)-MDMA or an acid salt of (R)-MDMA or (S)-MDMA,
the application also includes (R)-MDMA, (S)-MDMA or an acid salt of (R)-MDMA or (S)- MDMA prepared by process of the application as described above. As the process of the application provides (R)-MBDB or (S)-MBDB or an acid salt of (R)-MBDB or (S)-MBDB, the application also includes (R)-MBDB, (S)-MBDB or an acid salt of (R)-MBDB, (S)- MBDB or an acid salt of (R)-MBDB or (S)-MBDB prepared by process of the application as described above.
[00152] In some embodiments, the acid salt is the HCI salt.
EXAMPLES
[00153] The following non-limiting examples are illustrative of the present application.
Example 1. Exemplary process for preparing (R)-MDMA
Step 1
[00155] A solution of 5-(prop-2-en-1-yl)-2h-1,3-benzodioxole (4.055 g, 25 mmol) in acetonitrile (50 ml) is added under nitrogen atmosphere to a Schlenk flask containing a mixture of palladium(ll) trifluoroacetate (208 mg, 0.625 mmol, 2.5 mol% eq.), sodium trifluoroacetate (680 mg, 5 mmol, 0.2 eq.) and iron(lll) chloride (6.1 g, 37.6 mmol, 1.5 eq.) in water (400 mL). The reaction is stirred at 60 °C for 16 h in the absence of light and with the closed flask using crystal cap. After this time, the mixture is extracted with EtOAc (2 x 100 mL) and the organic phases are combined, dried over sodium sulfate and filtered off. The solvent is removed under reduced pressure and the resulting reaction crude is
purified by column chromatography on silica gel (10% EtOAc/hexane) to give the desired compound.
Steps 2 and 3
[00156] In a 2 necked 250 mL round bottomed flask was dissolved (R)-tert- butylsulfinamide (485 mg, 4.0 mmol, 2 equiv) in anhydrous THF (11 mL). To this solution is added Ti(OEt) ( 4.607 g, 20.2 mmol, 10 equiv) and the product of step 1 (356.4 mg, 2.0 mmol) in anhydrous THF (13 mL). The solution is heated to reflux and monitored by TLC. After 5 h the reaction is allowed to cool to room temperature. The reaction is then cooled down to -20 C, NaBH4 (75.7 mg, 2.0 mmol, 1 equiv) is added and the reaction is stirred 3 h at 20 °C and overnight at room temperature. The solution is then filtered through celite and the solvent evaporated under reduced pressure to provide the desired compound.
Step 4
[00157] In a 100mL round bottomed flask, NaH (60 % dispersion in mineral oil) (68 mg, 1.7 mmol) is suspended in anhydrous DMF (15 mL). A solution of the product of Step 3 (211 mg, 0.75 mmol) in anhydrous DMF (3.5 mL) is added and the reaction is stirred 20 min under ice bath. Mel (280 mL, 4.5 mmol) is added via syringe and the reaction is monitored by TLC. When the starting material is consumed, water (50 mL) and EtOAc (50 mL) are added. The organic phase is dried (MgS04) and evaporated and purified to give the desired compound.
Step 5
[00158] A solution of the product of Step 4 (1.136 g, 3.82 mmol) in MeOH (15 mL) is added to a 250 mL round bottomed flask. 4 M HCI in dioxane (10 mL, 40 mmol) is added to the flask at room temperature. The reaction is stirred overnight. The reaction mixture is concentrated, and the residue is triturated with ether to give (R)-MDMA as the HCI salt.
Example 2. Exemplary process for preparing (S)-MDMA
Step 1
[00160] A solution of 5-(prop-2-en-1-yl)-2h-1,3-benzodioxole (4.055 g, 25 mmol) in acetonitrile (50 ml) is added under nitrogen atmosphere to a Schlenk flask containing a mixture of palladium(ll) trifluoroacetate (208 mg, 0.625 mmol, 2.5 mol% eq.), sodium trifluoroacetate (680 mg, 5 mmol, 0.2 eq.) and iron(lll) chloride (6.1 g, 37.6 mmol, 1.5 eq.) in water (400 mL). The reaction is stirred at 60 °C for 16 h in the absence of light and with the closed flask using crystal cap. After this time, the mixture is extracted with EtOAc (2 x 100 mL) and the organic phases are combined, dried over sodium sulfate and filtered off. The solvent is removed under reduced pressure and the resulting reaction crude is purified by column chromatography on silica gel (10% EtOAc/hexane) to give the desired compound.
Steps 2 and 3
[00161] In a 2 necked 250 mL round bottomed flask was dissolved (S)-tert- butylsulfinamide (485 mg, 4.0 mmol, 2 equiv) in anhydrous THF (11 mL). To this solution is added Ti(OEt) ( 4.607 g, 20.2 mmol, 10 equiv) and the product of step 1 (356.4 mg, 2.0 mmol) in anhydrous THF (13 mL). The solution is heated to reflux and monitored by TLC. After 5 h the reaction is allowed to cool to room temperature. The reaction is then cooled down to -20 C, NaBH4 (75.7 mg, 2.0 mmol, 1 equiv) is added and the reaction is stirred 3 h at 20 °C and overnight at room temperature. The solution is then filtered through celite and the solvent evaporated under reduced pressure to provide the desired compound.
Step 4
[00162] In a 100mL round bottomed flask, NaH (60 % dispersion in mineral oil) (68 mg, 1.7 mmol) is suspended in anhydrous DMF (15 mL). A solution of the product of Step
3 (211 mg, 0.75 mmol) in anhydrous DMF (3.5 mL) is added and the reaction is stirred 20
min under ice bath. Mel (280 mL, 4.5 mmol) is added via syringe and the reaction is monitored by TLC. When the starting material is consumed, water (50 mL) and EtOAc (50 mL) are added. The organic phase is dried (MgS0 ) and evaporated and purified to give the desired compound. Step 5
A solution of the product of Step 4 (1.136 g, 3.82 mmol) in MeOH (15 mL) is added to a 250 mL round bottomed flask. 4 M HCI in dioxane (10 mL, 40 mmol) is added to the flask at room temperature. The reaction is stirred overnight. The reaction mixture is concentrated, and the residue is triturated with ether to give (S)-MDMA as the HCI salt. Example 3: Exemplary synthesis of a compound of Formula B
Step 1
[00163] To 20 g of safrole are added 8.3 g of solid KOH and 3 g of aliquot 336 (phase transfer catalyst). After a vigorous shaking (20 min) at room temperature, the mixture is left at 80°C within 1 h 15min. After cooling to room temperature, the mixture is diluted with 500 ml of methylene chloride and filtered through celite. The filtrate is then dried (MgS04) and concentrated by a rotary evaporation. The crude product is then purified in vacuum to yield 14.9 g (75%) of isosafrole as colorless oil.
Step 2 [00164] To a well stirred solution of 29 g of 35% hydrogen peroxide in 136 g of formic acid (88%) and 20.5 g of water, is added dropwise to a solution of 32.4 g isosafrole in 120 ml acetone, with cooling to keep the mixture from exceeding 40 °C. After stirring for 16 h at room temperature, the mixture is concentrated under vacuum without heating. The crude product is dissolved in 55 ml of methyl alcohol, treated with 240 g of 15% sulfuric acid and heated for 3 h. After cooling, the reaction mixture is extracted with diethyl ether. Organic layers are washed with water and then with dilute sodium hydroxide. Solvent is removed by rotary evaporation. The residue is distilled under vacuum to provide 17.4 g (50%) of the title compound as pale yellow oil.
Example 4: Exemplary process for preparing (R)-MBDB
[00165] (R)-MBDB.HCI can be prepared starting from 1-(benzo[d][1 ,3]dioxol-5- yl)butan-2-one following steps 2 to 5 of Example 1 .
[00166] (S)-MBDB.HCI can be prepared starting from 1-(benzo[d][1 ,3]dioxol-5- yl)butan-2-one following steps 2 to 5 of Example 2.
Example 6: Exemplary process for preparing compounds of Formula (R)-l
*R1 is CH3or CH2CH3
Step 1: Homopiperonal
[00167] Homopiperonal can be prepared using the synthetic procedures found in Tetrahedron: Asymmetry, 27(6), 274-284; 2016.
[00168] KOtBu (6.48 g, 66.6 mmol) was added portionwise to a stirred suspension of [MeOCH2PPh3]+ [Cl] (12.6 g, 36.6 mmol) in THF (50 mL) at 0°C. The resultant mixture was stirred for 30 min at rt and then a solution of piperonal (5.00 g, 33.3 mmol) in THF (50 mL) was added dropwise. The resultant mixture was stirred at rt for 12 h and then quenched by the addition of satd aq NH4CI (50 mL). The aqueous layer was extracted with Et20 (375 mL) and the combined organics were washed with brine (2 100 mL), then dried and concentrated in vacuo. Pentane (50 mL) was added to the residue and the resultant suspension was stirred at rt for 30 min. The resultant solution was filtered and the filtrate was concentrated in vacuo. This trituration process was repeated three times to give a vinyl ether intermediate {65:35 dr [(E):(Z) ratio]} as a pale yellow oil (5.93 g).
[00169] Formic acid (12.5 mL) was added to a stirred solution of the vinyl ether intermediate (5.93 g) in CH2CI2 (50 mL) at rt. The resultant solution was stirred in the dark for 48 h. H20 (25 mL) was added and the aqueous layer was extracted with CH2CI2 (335 mL). The combined organics were washed with brine (2 100 mL), then dried and concentrated in vacuo. Purification by vacuum distillation gave the homopiperonal as a pale yellow oil (4.37 g, 80% from piperonal).
Step 2
[00170] A 300-mL round-bottomed flask equipped with a magnetic stirring bar was charged with the aldehyde (the product of Step 1) (4.11 g , 25 mmol), (Ss)-2-
methylpropane-2-sulfinamide (3.95 g, 32.6 mmol), anhydrous MgS0 (30.2 g, 251 mmol), and CH2CI2 (25 mL). To the suspension was added PPTS (Pyridinium p-toluenesulfonate) (315 mg, 1.25 mmol) at room temperature. The reaction mixture was stirred for 36 h. The brown suspension was filtered through celite pad. The filtrate was concentrated under reduced pressure to give a crude oil, which was purified by silica gel column chromatography to provide (Ss)-A/-[(1£)-2-(2/-/-1 ,3-benzodioxol-5-yl)ethylidene]-2- methylpropane-2-sulfinamide
Step 3
[00171] To a solution of the product of Step 2 (300 mg , 1.12 mmol) in dichloromethane (7 ml) at -48 °C was added EtMgBr (2.9 M in Et20, 0.46 mL, 1.33 mmol, 1.2 eq.) dropwise. The reaction mixture was stirred at -48 °C for 4-6 h and then warmed to r.t.When complete, the mixture was quenched by addition of sat’d aq. NH4CI and with extrated EtOAc. The organic layer was dried over Na2S04, filtered. The filtrate was concentrated and purified to give A/-[(Ss,2R)-1-(2/-/-1,3-benzodioxol-5-yl)butan-2-yl]-2- methylpropane-2-sulfinamide.
Step 4
[00172] In a 100mL round bottomed flask, NaH (60 % dispersion in mineral oil) (68 mg, 1 .7 mmol) is suspended in anhydrous DMF (15 mL). A solution of the product of Step 3 (211 mg, 0.75 mmol) in anhydrous DMF (3.5 mL) is added and the reaction is stirred 20 min under ice bath. Mel (280 mL, 4.5 mmol) is added via syringe and the reaction is monitored by TLC. When the starting material is consumed, water (50 mL) and EtOAc (50 mL) are added. The organic phase is dried (MgS04) and evaporated and purified to give the desired compound.
Step 5
[00173] A solution of the product of Step 4 (1.136 g, 3.82 mmol) in MeOH (15 mL) is added to a 250 mL round bottomed flask. 4 M HCI in dioxane (10 mL, 40 mmol) is added to the flask at room temperature. The reaction is stirred overnight. The reaction mixture is concentrated, and the residue is triturated with ether to give the compound of Formula (R)-l as the HCI salt ((R)-MDMA.HCI or (R)-MBDB.HCI).
*R1 is CH3or CH2CH3
Step 1: Homopiperonal
[00174] Homopiperonal can be prepared using the synthetic procedures found in Tetrahedron: Asymmetry, 27(6), 274-284; 2016.
[00175] KOt Bu (6.48 g, 66.6 mmol) was added portionwise to a stirred suspension of [MeOCH2PPh3]+ [Cl] (12.6 g, 36.6 mmol) in THF (50 mL) at 0°C. The resultant mixture was stirred for 30 min at rt and then a solution of piperonal (5.00 g, 33.3 mmol) in THF (50 mL) was added dropwise. The resultant mixture was stirred at rt for 12 h and then quenched by the addition of satd aq NH4CI (50 mL). The aqueous layer was extracted with Et20 (375 mL) and the combined organics were washed with brine (2 100 mL), then dried and concentrated in vacuo. Pentane (50 mL) was added to the residue and the resultant suspension was stirred at rt for 30 min. The resultant solution was filtered and the filtrate was concentrated in vacuo. This trituration process was repeated three times to give a vinyl ether intermediate {65:35 dr [(E):(Z) ratio]} as a pale yellow oil (5.93 g).
[00176] Formic acid (12.5 mL) was added to a stirred solution of the vinyl ether intermediate (5.93 g) in CH2CI2 (50 mL) at rt. The resultant solution was stirred in the dark for 48 h. H20 (25 mL) was added and the aqueous layer was extracted with CH2CI2 (335 mL). The combined organics were washed with brine (2 100 mL), then dried and concentrated in vacuo. Purification by vacuum distillation gave the homopiperonal as a pale yellow oil (4.37 g, 80% from piperonal).
Step 2
[00177] A 300-mL round-bottomed flask equipped with a magnetic stirring bar was charged with the aldehyde (the product of Step 1) (4.11 g , 25 mmol), (Ss)-2-
methylpropane-2-sulfinamide (3.95 g, 32.6 mmol), anhydrous MgS0 (30.2 g, 251 mmol), and CH2CI2 (25 mL). To the suspension was added PPTS (Pyridinium p-toluenesulfonate) (315 mg, 1.25 mmol) at room temperature. The reaction mixture was stirred for 36 h. The brown suspension was filtered through celite pad. The filtrate was concentrated under reduced pressure to give a crude oil, which was purified by silica gel column chromatography to provide (Rs)-A/-[(1£)-2-(2/-/-1 ,3-benzodioxol-5-yl)ethylidene]-2- methylpropane-2-sulfinamide
Step 3
[00178] To a solution of the product of Step 2 (300 mg , 1.12 mmol) in dichloromethane (7 ml) at -48 °C was added EtMgBr (2.9 M in Et20, 0.46 mL, 1.33 mmol, 1.2 eq.) dropwise. The reaction mixture was stirred at -48 °C for 4-6 h and then warmed to r.t.When complete, the mixture was quenched by addition of sat’d aq. NH4CI and with extrated EtOAc. The organic layer was dried over Na2S04, filtered. The filtrate was concentrated and purified to give A/-[(Rs,2S)-1-(2/-/-1,3-benzodioxol-5-yl)butan-2-yl]-2- methylpropane-2-sulfinamide.
Step 4
[00179] In a 100mL round bottomed flask, NaH (60 % dispersion in mineral oil) (68 mg, 1 .7 mmol) is suspended in anhydrous DMF (15 mL). A solution of the product of Step 3 (211 mg, 0.75 mmol) in anhydrous DMF (3.5 mL) is added and the reaction is stirred 20 min under ice bath. Mel (280 mL, 4.5 mmol) is added via syringe and the reaction is monitored by TLC. When the starting material is consumed, water (50 mL) and EtOAc (50 mL) are added. The organic phase is dried (MgS04) and evaporated and purified to give the desired compound.
Step 5
[00180] A solution of the product of Step 4 (1.136 g, 3.82 mmol) in MeOH (15 mL) is added to a 250 mL round bottomed flask. 4 M HCI in dioxane (10 mL, 40 mmol) is added to the flask at room temperature. The reaction is stirred overnight. The reaction mixture is concentrated, and the residue is triturated with ether to give the compound of Formula (S)-l as the HCI salt ((S)-MDMA.HCI or (S)-MBDB.HCI).
Step 5 Step 6
Step 1: Preparation of 5-(2-methoxyvinyl)benzo[d][1 ,3]dioxole
[00181] A white suspension of methoxymethyltriphenylphosphonium chloride (25.22 g, 73.6 mmol) in tetrahydrofuran (100 mL) was cooled to 0 °C (ice bath) then treated with potassium fe/f-butoxide (13.06 g, 116.4 mmol) in portions. The suspension slowly darkened to a brown suspension then became a clear brown solution. The resulting mixture was stirred at 0 °C for 30 minutes then piperonal 1 (10.01 g, 66.7 mmol) in tetrahydrofuran (100 mL) was added dropwise to give a yellow suspension. The mixture was stirred at room temperature overnight, then quenched with saturated ammonium chloride solution. The aqueous solution was extracted with diethyl ether and the organic layer was washed with brine, dried (sodium sulphate), filtered and the filtrate was concentrated to a yellow oil. The oil was triturated with hexanes to precipitate out triphenylphosphine oxide, which was removed by filtration. The filtrate was concentrated to give 5-(2-methoxyvinyl)benzo[d][1 ,3]dioxole (11.98 g, crude, quantitative) as a yellow oil .
[00182] Ή NMR (CDCI3, 400 MHz): 87.27 (d, 0.55H, J= 1.6 Hz), 6.89-6.96 (m, 1 H), 6.67-6.78 (m, 1 9H), 6.04 (d, 0.55H, J= 7.0 Hz), 5.92 (d, 2H), 5.76 (d, 0.45H, J= 12.9 Hz), 5.15 (d, 0.55H, J= 7.0 Hz), 3.76 (s, 1.65H), 3.65 (s, 1.35H).
Step 2: Preparation of 2-(benzo[d][1 ,3]dioxol-5-yl)acetaldehyde [00183] Crude 5-(2-methoxyvinyl)benzo[d][1 ,3]dioxole was diluted with dichloromethane (100 mL) and treated with formic acid (30 mL, 660 mmol). The mixture was stirred at room temperature for 3 days, then quenched with water, extracted with
dichloromethane, dried (sodium sulphate), filtered and concentrated to a brown oil. Purification by column chromatography (10-20 % ethyl acetate in hexanes) gave 2- (benzo[d][1 ,3]dioxol-5-yl)acetaldehyde (1.6 g, 15 %) as a yellow oil.
[00184] Ή NMR (CDCI3, 400 MHz): d 9.72 (app td, 1H, J= 2.3, 0.6 Hz), 6.81 (d, 1 H, J= 7.8 Hz), 6.66-6.70 (m, 2H), 5.97 (s, 2H), 3.61 (d, 2H, J= 2.3 Hz).
Step 3: Preparation of(S)-N-(2-(benzo[d][1,3]dioxol-5-yl)ethylidene)-2-methylpropane-2- sulfinamide
[00185] A suspension of 2-(benzo[d][1 ,3]dioxol-5-yl)acetaldehyde (0.18 g, 1.1 mmol), (S)-(-)2-methylpropane-2-sulfinamide (0.173 g, 1.4 mmol), and magnesium sulphate (1.32 g, 10.9 mmol) in dichloromethane (5 mL) was treated with pyridinium p- toluenesulfonate (PPTS) (0.019 g, 0.076 mmol). The mixture was stirred at room temperature for 2.5 days. The solids were filtered away through a Celite pad and the filtrate was concentrated in vacuo. Purification by column chromatography (10-15 % ethyl acetate in hexanes) afforded (S)-N-(2-(benzo[d][1 ,3]dioxol-5-yl)ethylidene)-2- methylpropane-2-sulfinamide 4 (0.17 g, 58 %) as a yellow oil.
[00186] Ή NMR (CDCI3, 400 MHz): d 8.06 (t, 1H, J= 5.2 Hz), 6.75 (d, 1H, J= 7.8 Hz), 6.70 (s, 1 H), 6.66 (d, 1H, J= 7.8 Hz), 5.93 (s, 2H), 3.74 (m, 2H), 1.18 (s, 9H).
Step 4: Preparation of (S)-N-((R)-1-(benzo[d][1,3]dioxol-5-yl)butan-2-yl)-2- methylpropane-2-sulfinamide
[00187] A solution of (S)-N-(2-(benzo[d][1,3]dioxol-5-yl)ethylidene)-2- methylpropane-2-sulfinamide (0.28 g, 1.05 mmol) in anhydrous dichloromethane (5 mL) was treated at -50 °C with ethyl magnesium bromide (2 M solution in diethyl ether; 0.70 mL, 2.1 mmol) dropwise. The mixture was stirred at -50 °C for 4 hours, then at room temperature overnight. The mixture was carefully quenched with saturated ammonium chloride dropwise, extracted with ethyl acetate, dried (sodium sulphate), filtered and concentrated in vacuo to a brown oil. Purification by column chromatography (10-100% ethyl acetate/hexanes) afforded (S)-N-((R)-1-(benzo[d][1 ,3]dioxol-5-yl)butan-2-yl)-2- methylpropane-2-sulfinamide 5 (0.149 g, 48 %) as a colourless oil.
[00188] 1H NMR (CDCI3, 400 MHz): d 6.73 (d, 1H, J= 7.9 Hz), 6.66 (d, 1H, J= 1.6 Hz), 6.63 (dd, 1H, J= 7.8. 1.6 Hz), 5.92 (s, 2H), 3.33 (m, 1H), 3.07 (d, 1H, J= 6.1 Hz), 2.71 (d, 2H, J= 6.7 Hz), 1.56-1.69 (m, 2H), 1.12 (s, 9H), 1.00 (t, 3H, J= 7.4 Hz).
Step 5: Preparation of (S)-N-((R)-1-(benzo[d][1,3]dioxol-5-yl)butan-2-yl)-N,2- dimethylpropane-2-sulfinamide
[00189] An ice-cold solution of (S)-N-((R)-1-(benzo[d][1,3]dioxol-5-yl)butan-2-yl)-2- methylpropane-2-sulfinamide (0.14 g, 0.47 mmol) in A/-A/-dimethylformamide (5 mL) was treated with sodium hydride (60% suspension in mineral oil, 0.037 g, 0.92 mmol) in portions. The mixture was stirred at room temperature for 30 minutes, then cooled to 0 °C. Methyl iodide (0.20 mL, 3.21 mmol) was added dropwise and the resulting mixture was stirred at room temperature overnight. The mixture was carefully quenched with saturated ammonium chloride solution, then concentrated in vacuo to a brown oil. Purification by column chromatography eluting with 25-50 % ethyl acetate/hexanes afforded the (S)-N-((R)-1-(benzo[d][1 ,3]dioxol-5-yl)butan-2-yl)-N,2-dimethylpropane-2- sulfinamide 6 (0.112 g, 76 %) as a colourless oil.
[00190] 1H NMR (CDCI3, 400 MHz): 86.72 (d, 1H, J= 7.8 Hz), 6.66 (d, 1H, J= 1.6 Hz), 6.62 (dd, 1H, J= 7.8, 1.6 Hz), 5.91 (s, 2H), 3.20-3.35 (m, 1H), 2.80-64 (m, 2H), 2.50 (s, 3H), 1.42-1.66 (m, 2H), 1.01 (s, 9H), 0.97 (t, 3H, J= 7.4 Hz).
Step 6: Preparation of (R)-1-(benzo[d][1,3]dioxol-5-yl)-N-methylbutan-2-amine hydrochloride
[00191] An ice-cold solution of (S)-N-((R)-1-(benzo[d][1 ,3]dioxol-5-yl)butan-2-yl)-
N,2-dimethylpropane-2-sulfinamide 6 (0.10 g, 0.32 mmol)in methanol was treated with hydrogen chloride (2 M solution in diethyl ether, 1 mL, 2.0 mmol). The mixture was stirred at 0 °C to room temperature overnight, then concentrated with vacuo to a brown oil. The oil was triturated with methanol and diethyl ether. The off-white solid (R)-1- (benzo[d][1 ,3]dioxol-5-yl)-N-methylbutan-2-amine hydrochloride 7 (0.066 g, 85 %) was collected by vacuum filtration.
[00192] 1H NMR (DMSO-cfe, 400 MHz): 88.80 (br s, 2H), 6.88 (d, 1H, J= 1.6 Hz), 6.85 (d, 1 H, J= 7.8 Hz), 6.72 (dd, 1H, J= 7.8, 1.6 Hz), 5.97 (s, 2H), 3.19-3.25 (m 1H), 2.96 (dd, 1 H, J= 13.8, 5.1 Hz), 2.69 (dd, 1H, J= 13.8, 8.9 Hz), 2.51 (s, 3H), 1.44-1.60 (m, 2H),
O.87 (t, 3H, J= 7.4 Hz).
[00193] MS (ESI) m/z: [M + H]+ Calcd for CI2HI8N02208.13; Found 208.0.
[00194] HPLC: >99 %
[00195] Melting point 182.5-183.6 °C
[00196] Specific rotation [a]D 20 -26.64 (c 1 , H20)
[00197] Anal. Calcd forCi2Hi7N02 HCI: C, 59.14; H, 7.44; N, 5.75; Found: C, 59.16; H, 7.38; N, 5.78.
Example 9: Exemplary process for preparing (S)-MBDB.HCI ((S)-1-
(Benzo[d][1 ,3]dioxol-5-yl)-N-Methylbutan-2-amine Hydrochloride)
[00198] A suspension of 2-(benzo[d][l,3]dioxol-5-)acetaldehyde (10.1 g, 61.5 mmol), (R)-(+)2- methylpropane-2-sulfinamide (9.5 g, 78.4 mmol) in dichloromethane (280 ml) was treated with pyridinium p-toluenesulfonate (1.5 g, 6.0 mmol) and magnesium sulfate (73.4 g, 609.8 mmol). The mixture was stirred at room temperature for 2 days. The solid was filtered away through a Celite pad and the filtrate was concentrated in vacuo. Purification by column chromatography (10-35 % ethyl acetate/hexanes) afforded (R)-N-(2-(benzo[d][1 ,3]dioxol-5-yl)ethylidene)-2- methylpropane-2-sulfinamide (9.3 g, 57 %) as a yellow oil. [00199] 1 H NMR (CDCb, 400 MHz): d= 8.08 (t, 1H, J = 5.2 Hz), 6.78 (d, 1H, J =
7.8 Hz), 6.71 (d, 1H, J = 1.6Hz), 6.68 (dd, 1H, J = 7.8, 1.8 Hz), 5.96 (s, 2H), 3.81 - 3.67 (m, 2H), 1.20 (s, 9H).
[00200] A solution of (R)-N-(2-(benzo[d][1 ,3]dioxol-5-yl)ethylidene)-2- methylpropane-2-sulfinamide (15.7 g, 58.7 mmol) in anhydrous dichloromethane (282 ml) was treated at -50 °C with ethyl magnesium bromide (3M solution in diethyl ether; 59 ml, 177 mmol) dropwise. The mixture was stirred at -50 °c for 4 hours, then at room temperature overnight. The mixture was carefully quenched with saturated ammonium chloride dropwise in an ice bath, extracted with ethyl acetate, dried (sodium sulphate), filtered and concentrated in vacuo to a brown oil. Purification by column chromatography (10-50 % ethyl acetate/hexanes) afforded (R)-N-((S)-1-
(benzo[d][1 ,3]dioxol-5-yl)butan-2-yl)-2-methylpropane-2-sulfinamide (10 .7 g, 61 %) as a pale-yellow oil.
[00201] 1 H NMR (CDCI3, 400 MHz): =6.74 (d, 1H, J = 7.8 Hz), 6.69 (d, 1H, J =
1.6 Hz), 6.64 (dd, 1 H, J = 7.8, 1.8 Hz), 5.93 (s, 2H), 3.39 - 3.30 (m, 1H), 3.10 (d, 1H, J = 6.5 Hz), 2.72 (d, 2H, J =6.8 Hz), 1.71 -1.59 (m, 2H), 1.14 (s, 9H), 1.01 (t, 3H, J = 7.4 Hz).
[00202] An ice-cold solution of (R)-N-((S)-1-(benzo[d][1 , 3]dioxol-5-yl)butan-2-yl)- 2-methylpropane-2- sulfinamide (24.4 g, 82.0 mmol) in N-N-dimethylformamide (150 ml) was treated with sodium hydride (60 % suspension in mineral oil, 6.6 g, 165.0 mmol) in portions. The mixture was stirred at room temperature for 30 minutes, then cooled to 0 oC. Methyl iodide (15.3 ml, 245.8 mmol) was added dropwise and the resulting mixture was stirred at room temperature overnight. The mixture was carefully quenched with saturated ammonium chloride solution in an ice bath, then concentrated in vacuo to a brown oil. Purification by column chromatography eluting with 10-50 % ethyl acetate/hexanes afforded (R)-N-((S)-1-(benzo[d][1 ,3]dioxol-5-yl)butan-2-yl)-N, 2- dimethylpropane-2-sulfinamide (16.0 g, 62 %) as a pale-yellow oil.
[00203] 1H NMR (CDC , 400 MHz): d= 6.74 (d, 1H, J = 7.8 Hz), 6.68 (d, 1H, J = 1.8 Hz), 6.64 (dd, 1H, J = 7.8, 1.8 Hz), 5.93 (s, 2H), 3.36 - 3.24 (m, 1H), 2.83 - 2.65 (m, 2H), 2.52 (s, 3H), 1.70 - 1.42 (m, 2H), 1.03 (s, 9H), 0.99 (t, 3H, J = 7.4 Hz).
[00204] An ice-cold solution of (R) -N-((S)-1 -(benzo[d ][ 1 ,3]dioxol-5-yl)but an-2- yl)-N, 2-dimethylpropane-2-sulfinamide (1 6.0 g, 51.4 mmol) in methanol (121 ml) was
treated with hydrogen chloride (aqueous 3 M solution, 103 ml, 309 mmol) dropwise at 0 °C. The reaction mixture was raised to room temperature and stirred for 2 hours. The mixture was concentrated in vacuo to a brown semi-solid. The slurry was triturated with methanol and diethyl et her. The off-white solid (5)-1- (benzo[d][l, 3]dioxol-5-yl) -N-met hylbutan-2-amine hydrochloride (9.7 g, 77 %) was collected by vacuum filtration.
[00205] 1H NMR (DMSO-d6, 400 MHz): d= 8.67 (s, 2H), 6.89 (d, 1H, J = 1.8 Hz), 6.85 (d, 1 H, J = 7.9 Hz), 6.72 (dd, 1H, J = 7.9, 1.8 Hz), 5.98 (s, 2H), 3.27 - 3.18 (m, 1H), 2.94 (dd, 1 H, J = 13.9, 4.1 Hz), 2.69 (dd, 1 H, J = 13.9, 8.8 Hz), 2.52 (s, 3H), 1.58 - 1.45 (m, 2H), 0.87 (t , 3H, J = 7.5 Hz).
[00206] MS (ESI) m/z: [M + H]+ Calcd for C12H18SN02 208.13; Found 208.0. HPLC: 98.65 %
[00207] Melting point: 181.4 - 182.4 °C
[0100] Specific rotation [a]D 20 26.06 (c 1 , H20) [00208] While the present application has been described with reference to examples, it is to be understood that the scope of the claims should not be limited by the embodiments set forth in the examples, but should be given the broadest interpretation consistent with the description as a whole.
[00209] All publications, patents and patent applications are herein incorporated by reference in their entirety to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated by reference in its entirety. Where a term in the present application is found to be defined differently in a document incorporated herein by reference, the definition provided herein is to serve as the definition for the term.
Claims
1. A process for preparing an acid salt of a compound of Formula (R)-l or (S)-l:
wherein R1 is selected from CH3 and CH2CH3; the process comprising: reacting a compound of Formula B:
B wherein R1 is selected from CH3 and CH2CH3; with (R)-t-butyiS(0)NH2 or (S)-t-butyiS(0)NH2 under reductive amination conditions to provide a compound of Formula (R),(R)-C or (S),(S)-C, respectively:
wherein R1 is selected from CH3 and CH2CH3; or homologating piperonal,
, to provide a compound of Formula B':
reacting the compound of Formula B' with (S)-t-butylS(0)NH2 or (R)-t- butyiS(0)NH2 to provide a compound of Formula (S)-Cim or(R)-Cim respectively:
reacting the compound of Formula (S)-Cim or (R)-Cim with a methyl or ethyl organometallic reagent to provide the compound of Formula (R),(S)-C" or (S),(R)-C", respectively:
wherein R1 is CH3or CH2CH3; methylating the compound of Formula (R),(R)-C or (S),(S)-C to provide a compound of Formula (R),(R)-D or a compound of Formula (S),(S)-D, respectively:
methylating the compound of Formula (R),(S)-C" or (S),(R)-C" to provide a compound of Formula (R),(S)-D' or a compound of Formula (S),(R)-D', respectively:
wherein R1 is CH3or CH2CH3; and reacting the compound of Formula (R),(R)-D or the compound of Formula (S),(S)-
D with an acid to provide the acid salt of the compound of Formula (R)-l, or reacting the compound of Formula (R),(S)-D' or the compound of Formula (S),(R)-D' with an acid to provide the acid salt of the compound of Formula (S)-l.
2. The process of claim 1 , wherein the process comprises: reacting a compound of Formula B:
B wherein R1 is selected from CH3 and CH2CH3; with (R)-t-butyiS(0)NH2 or (R)-t-butyiS(0)NH2 under reductive amination conditions to provide a compound of Formula (R),(R)-C or (S),(S)-C, respectively:
wherein R1 is selected from CH3 and CH2CH3; methylating the compound of Formula (R),(R)-C or (S),(S)-C to provide a compound of Formula (R),(R)-D or (S),(S)-D, respectively:
wherein R1 is CH3or CH2CH3; and reacting the compound of Formula (R),(R)-D or (S),(S)-D with an acid to provide an acid salt of the compound of Formula (R)-l or (S)-l, respectively.
3. The process of claim 1 or claim 2, wherein the (R)-t-butylS(0)NH2 or (S)-t- butyiS(0)NH2 has an enantiomeric purity of about 97% or greater or of about 98% or greater.
4. The process of any one of claims 1 to 3, wherein the reductive amination conditions comprise a first step of reacting a compound of Formula B with (R)-t- butyiS(0)NH2 or (R)-t-butyiS(0)NH2 in the presence of a titanium catalyst to provide a compound of Formula C:
wherein R1 is selected from CH3 and CH2CH3; followed by a second step of adding a suitable reducing agent to provide the compound of Formula (R),(R)-C or (S),(S)-C, respectively.
5. The process of claim 4, wherein the compound of Formula C is not isolated.
6. The process of claim 4 or claim 5, wherein the titanium catalyst is selected from titanium (IV) isopropoxide (Ti(OiPr)4) and titanium (IV) ethoxide (Ti(OEt)4).
7. The process of any one of claims 1 to 6, wherein the reducing agent is sodium borohydride.
9. The process of claim 8, wherein R1 is CH3 and the process is a process for preparing an acid salt of (R)-methylenedioxymethamphetamine ((R)-MDMA) or (S)- methylenedioxymethamphetamine ((S)-MDMA) comprising: oxidizing a compound of Formula A or a compound of Formula A':
wherein LLLR indicates that the bond is in a cis and/or trans orientation to provide a compound of Formula B:
wherein R1 is CH3; reacting the compound of Formula B with (R)-t-butyiS(0)NH2 or (S)-t- butylS(0)NH2 under reductive amination conditions to provide a compound of Formula (R),(R)-C or (S),(S)-C, respectively:
wherein R1 is CH3; methylating the compound of Formula (R),(R)-C or (S),(S)-C to provide a compound of Formula (R),(R)-D or (S),(S)-D, respectively:
wherein R1 is CH3; and reacting the compound of Formula (R),(R)-D or (S),(S)-D with an acid to provide an acid salt of (R)-MDMA or an acid salt of (S)-MDMA, respectively.
10. The process of claim 8 or claim 9, wherein the compound of Formula A is oxidized in the presence of a palladium (II) catalyst and water or an iron (III) catalyst and water, or a combination thereof at temperatures and at times to provide the compound of Formula B.
11. The process of claim 10, wherein the palladium (II) catalyst is selected from palladium chloride (PdCI2) or palladium (II) trifluoroacetate ((CF3C02)2Pd), and/or the iron (III) catalyst is iron (III) chloride (FeCI3).
12. The process of any one of claims 1 to 7, wherein R1 is CH2CH3 and the process is for preparing an acid salt of (R)-N-methyl-1 ,3-benzodioxolylbutanamine ((R)-MBDB) or (S)-N-methyl-1,3-benzodioxolylbutanamine ((S)-MBDB) comprising: reacting a compound of Formula B:
wherein R1 is CH2CH3; with (R)-t-butyiS(0)NH2 or (S)-t-butyiS(0)NH2 under reductive amination conditions to provide a compound of Formula (R),(R)-C or (S),(S)-C, respectively:
wherein R1 is CH2CH3; methylating the compound of Formula (R),(R)-C or (S),(S)-C to provide a compound of Formula (R),(R)-D or (S),(S)-D, respectively:
wherein R1 is CFhCFh; and reacting the compound of Formula (R),(R)-D or (S),(S)-D with an acid to provide an acid salt of (R)-MBDB or an acid salt of (S)-MBDB, respectively.
13. The process of claim 1 , wherein the process comprises: homologating piperonal,
, to provide a compound of Formula B':
reacting the compound of Formula B' with (S)-t-butyiS(0)NH2 or (R)-t- butyiS(0)NH2 to provide a compound of Formula (S)-Cim or (R)-Cim, respectively:
reacting the compound of Formula (S)-Cim or (R)-Cim with a methyl or ethyl organometallic reagent to provide the compound of Formula (R),(S)-C" or (S),(R)-C", respectively:
wherein R1 is selected from CH3 and CH2CH3; methylating the compound of Formula (R),(S)-C" or (S),(R)-C" to provide a compound of Formula (R),(S)-D or (S),(R)-D, respectively:
wherein R1 is selected from CH3 and CH2CH3; and reacting the compound of Formula (R),(S)-D' or (S),(R)-D', with an acid to provide an acid salt of the compound the acid salt of a compound of Formula (R)-l or the acid salt of a compound of Formula (S)-l, respectively.
14. The process of claim 13, wherein the process comprises homologating piperonal with methoxymethylenetriphenylphosphine under Wittig reaction conditions to provide a compound of Formula B'.
15. The process of claim 13 or claim 14, wherein the (S)-t-butyiS(0)NH2 or (R)-t- butylS(0)NH2 has an enantiomeric purity of about 97% or greater.
16. The process of any one of claims 13 to 15, wherein the compound of Formula B' is reacted with (S)-t-butyiS(0)NH2 or (R)-t-butyiS(0)NH2 in the presence of a catalyst selected from pyridinium p-toluenesulfonate or a titanium catalyst to provide the compound of Formula (S)-Cim or (R)-Cim.
17. The process of claim 16, wherein the catalyst is pyridinium p-toluenesulfonate.
18. The process of any one of claims 1, and 13 to 17, wherein the methyl or ethyl organometallic reagent is a Grignard reagent, or methyl lithium or ethyllithium, respectively.
19. The process of claim 18, wherein the methyl or ethyl organometallic reagent is a Grignard reagent.
20. The process of any one of claims 1 to 19, wherein the compound of Formula (R),(R)-C or (S),(S)-C or the compound of Formula (R),(S)-C" or (S),(R)-C" is methylated with a methyl halide in the presence of a base in an inert solvent at a temperature and a time to react the compound of Formula (R),(R)-C or (S),(S)-C with the methyl halide to provide the compound of Formula (R),(R)-D or (S),(S)-D or to react the compound of
Formula R),(S)-C" or (S),(R)-C" with the methyl halide to provide the compound of Formula R),(S)-D' or (S),(R)-D\
21. The process of any one of claims 1 to 20, wherein the acid is sulfuric acid (H2S0 ), trifluoroacetic acid (TFA) or hydrochloric acid (HCI).
22. The process of any one of claims 1 to 21 , wherein the process further comprises converting the acid salt of the compound of Formula (R)-l or (S)-l to the free base of the compound of Formula (R)-l or (S)-l, respectively.
23. A process for preparing an HCI salt of a compound of Formula (R)-l:
wherein R1 is selected from CH3 and CH2CH3; the process comprising: reacting a compound of Formula B
wherein R1 is selected from CH3 and CH2CH3; with (R)-t-butylS(0)NH2 under reductive amination conditions in the presence of a titanium catalyst to provide a compound of Formula (R),(R)-C:
wherein R1 is selected from CH3 and CH2CH3; methylating the compound of Formula (R),(R)-C to provide a compound of Formula (R),(R)-D:
wherein R1 is selected from CH3 and CH2CH3; and
reacting the compound of Formula (R),(R)-D with hydrochloric acid to provide the HCI salt of the compound of Formula (R)-l.
25. The process of claim 23 or claim 24, wherein R1 is CH3 and the process is for preparing an HCI salt of (R)-3, 4-methylenedioxymethamphetamine ((R)-MDMAHCI):
the process comprising: oxidizing a compound of Formula A or a compound of Formula A':
wherein indicates that the bond is in a cis and/or trans orientation to provide a compound of Formula B:
wherein R1 is CH3; reacting the compound of Formula B with (R)-t-butyiS(0)NH2 under reductive amination conditions in the presence of a titanium catalyst to provide a compound of Formula (R),(R)-C:
wherein R1 is CH3; methylating the compound of Formula (R),(R)-C to provide a compound of Formula (R),(R)-D:
wherein R1 is CH3; and reacting the compound of Formula (R),(R)-D with hydrochloric acid to provide (R)- MDMAHCI.
26. The process of claim 23, wherein R1 is CH2CH3 and the process is for preparing the HCI salt of (R)-N-methyM ,3-benzodioxolylbutanamine ((R)-MBDB):
the process comprising: reacting the compound of Formula B with (R)-t-butyiS(0)NH2 under reductive amination conditions in the presence of a titanium catalyst to provide a compound of Formula (R),(R)-C:
wherein R1 is CH2CH3; methylating the compound of Formula (R),(R)-C to provide a compound of Formula (R),(R)-D:
wherein R1 is CH2CH3; and reacting the compound of Formula (R),(R)-D with hydrochloric acid to provide the (R)- MBDB.HCI.
27. A process for preparing an HCI salt of a compound of Formula (R)-l:
wherein R1 is selected from CH3 and CH2CH3; the process comprising: homologating piperonal,
, with methoxymethylenetriphenylphosphine under Wittig reaction conditions to provide a compound of Formula B';
reacting the compound of Formula B' with (S)-t-butylS(0)NH2 to provide a compound of Formula (S)-Cim:
reacting the compound of Formula (S)-Cim with a methyl or ethyl organometallic reagent to provide the compound of Formula (R),S)-C":
wherein R1 is selected from CH3 and CH2CH3; methylating the compound of Formula (R),(S)-C" to provide a compound of Formula (R),(S)-D':
wherein R1 is selected from CH3 and CH2CH3; and reacting the compound of Formula (R),(S)-D', with hydrochloric acid to provide the HCI salt of a compound of Formula (R)-l.
28. The process of claim 27 wherein R1 is CH3 and the process if or preparing an HCI salt of (R)-3, 4-methylenedioxymethamphetamine ((R)-MDMAHCI).
29. The process of claim 27, wherein R1 is CH2CH3 and the process is for preparing the HCI salt of (R)-N-methyM ,3-benzodioxolylbutanamine ((R)-MBDB.HCI).
30. The process of any one of claims 1 to 22, wherein the process provides the compound of Formula (R)-l or (S)-l or the acid salt of the compound of Formula (R)-l or
(S)-l in greater than 60% ee, 65% ee, 70% ee, 75% ee, 80% ee, 85% ee, 90% ee, 95% ee, 98% ee or 99% ee.
31. The process of any one of claims 22 to 29, wherein the process provides the compound of Formula (R)-l or the acid salt of the compound of Formula (R)-l in greater than 60% ee, 65% ee, 70% ee, 75% ee, 80% ee, 85% ee, 90% ee, 95% ee, 98% ee or 99% ee.
34. A compound of Formula (S)-Cim or (R)-Cim:
36. The compound of claim 35, wherein wherein R1 is CH2CH3.
39. The compound of claim 38, wherein wherein R1 is CH2CH3.
40. A compound of Formula (R)-l or (S)-l or an acid salt of compound of Formula (R)- I or (S)-l prepared by process of any one of claims 1 to 22.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163201610P | 2021-05-06 | 2021-05-06 | |
US63/201,610 | 2021-05-06 | ||
US202163203101P | 2021-07-08 | 2021-07-08 | |
US63/203,101 | 2021-07-08 | ||
US202263298799P | 2022-01-12 | 2022-01-12 | |
US63/298,799 | 2022-01-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022232949A1 true WO2022232949A1 (en) | 2022-11-10 |
Family
ID=83932587
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CA2022/050720 WO2022232949A1 (en) | 2021-05-06 | 2022-05-06 | Processes for the preparation of the enantiomers of 3,4-methylenedioxymethamphetamine (mdma) and n-methyl-1,3-benzodioxolylbutanamine (mbdb) |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2022232949A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023019369A1 (en) * | 2021-08-20 | 2023-02-23 | Pharmala Biotech Inc. | Compositions comprising non-racemic mixtures of (r)- and (s)-3,4-methylenedioxymethamphetamine or (r) and (s) n-methyl-1,3-benzodioxolylbutanamine and uses thereof |
WO2023092044A3 (en) * | 2021-11-17 | 2023-06-22 | Terran Biosciences, Inc. | Phenethylamine compounds salts, polymorphic forms and methods of use thereof |
US11939312B2 (en) | 2021-06-03 | 2024-03-26 | Arcadia Medicine, Inc. | Enantiomeric entactogen compositions and their use |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2021106190A4 (en) * | 2021-08-20 | 2021-10-28 | Mind Medicine Australia Limited | Improved method of synthesis of 1-(3’,4’-methylene dioxyphenyl)-2-(methylamino) propane (mdma) |
-
2022
- 2022-05-06 WO PCT/CA2022/050720 patent/WO2022232949A1/en active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2021106190A4 (en) * | 2021-08-20 | 2021-10-28 | Mind Medicine Australia Limited | Improved method of synthesis of 1-(3’,4’-methylene dioxyphenyl)-2-(methylamino) propane (mdma) |
Non-Patent Citations (7)
Title |
---|
BRAUN, U. ET AL.: "Centrally Active N-substituted analogs of 3,4- Methylenedioxyphenylisopropylamine (3,4-Methylenedioxyamphetamine", J. PHARM. SCI., vol. 69, no. 2, 1 February 1980 (1980-02-01), pages 192 - 195, XP000653590, ISSN: 1520-6017, DOI: https://doi.org/10.1002/jps.2600690220 * |
BUCHANAN HILARY A. S., DAÉID NIAMH NIC, KERR WILLIAM J., CARTER JAMES F., HILL JENNY C.: "Role of Five Synthetic Reaction Conditions on the Stable Isotopic Composition of 3,4-Methylenedioxymethamphetamine", ANALYTICAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 82, no. 13, 1 July 2010 (2010-07-01), US , pages 5484 - 5489, XP093004749, ISSN: 0003-2700, DOI: 10.1021/ac1002432 * |
GIMENO, P. ET AL.: "A Study of Impurities in Intermediates and 3,4- Methylenedioxymethamphetamine (MDMA) samples produced via Reductive Amination Route s", FORENSIC SCIENCE INTERNATIONAL, vol. 155, no. 2-3, 30 January 2005 (2005-01-30), pages 141 - 157, XP025270330, ISSN: 0379-0738, DOI: https://doi.org/10.1016/j.forsciint. 2004.11.01 3 * |
LLABRES, SALOME ET AL.: "Molecular Basis of the Selective Binding of MDMA Enantiomers to the alpha4beta2 Nicotinic Receptor Subtype: Synthesis, Pharmacological Evaluation and Mechanistic Studies", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 81, 2 May 2014 (2014-05-02), pages 35 - 46, XP028851806, ISSN: 0223-5234, DOI: https://doi.org/10.1 0 16/j.ejmech.20 14.04.044 * |
NICHOLS, D.E. ET AL.: "Derivatives of 1-(l,3-Benzodioxol-5-yl)-2-butanamine: Representatives of a Novel Therapeutic Class", J. MED. CHEM., vol. 29, no. 10, 1 October 1986 (1986-10-01), pages 2009 - 2015, XP001109751, ISSN: 0022-2623, DOI: https://doi.org/10.1021/jm00160a035 * |
RENTON, R.J. ET AL.: "A Study of the Precursors, Intermediates and Reaction by-products in the synthesis of3,4-Methylenedioxymethylamphetamine and its application to Forensic Drug Analysis", FORENSIC SCIENCE INTERNATIONAL, vol. 60, no. 3, 1 August 1993 (1993-08-01), pages 189 - 202, XP026243316, ISSN: 0379-0738, DOI: https://doi.org/10.1 0 16/0379-0738(93)90238 -6 * |
WANG RUNPING, LUO JINGFAN, ZHENG CHUNMEI, ZHANG HONGYUN, GAO LU, SONG ZHENLEI: "O 2 ‐Assisted Four‐Component Reaction of Vinyl Magnesium Bromide with Chiral N ‐ tert ‐Butanesulfinyl Imines To Form syn ‐1,3‐Amino Alcohols", ANGEWANDTE CHEMIE INTERNATIONAL EDITION, VERLAG CHEMIE, vol. 60, no. 46, 8 November 2021 (2021-11-08), pages 24644 - 24649, XP093004747, ISSN: 1433-7851, DOI: 10.1002/anie.202109566 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11939312B2 (en) | 2021-06-03 | 2024-03-26 | Arcadia Medicine, Inc. | Enantiomeric entactogen compositions and their use |
WO2023019369A1 (en) * | 2021-08-20 | 2023-02-23 | Pharmala Biotech Inc. | Compositions comprising non-racemic mixtures of (r)- and (s)-3,4-methylenedioxymethamphetamine or (r) and (s) n-methyl-1,3-benzodioxolylbutanamine and uses thereof |
WO2023092044A3 (en) * | 2021-11-17 | 2023-06-22 | Terran Biosciences, Inc. | Phenethylamine compounds salts, polymorphic forms and methods of use thereof |
US11958821B2 (en) | 2021-11-17 | 2024-04-16 | Terran Biosciences Inc. | Phenethylamine compounds salts, polymorphic forms and methods of use thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2022232949A1 (en) | Processes for the preparation of the enantiomers of 3,4-methylenedioxymethamphetamine (mdma) and n-methyl-1,3-benzodioxolylbutanamine (mbdb) | |
US6028224A (en) | Fluoxetine process from benzoylpropionic acid | |
JP6013326B2 (en) | Process for the preparation of chiral triazolones | |
SK133198A3 (en) | Piperazine and piperidine compounds, process for their preparation and pharmaceutical compositions containing them | |
FR2945531A1 (en) | 7-AZA-SPIRO® 3,5-NONANE-7-CARBOXYLATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | |
EP0428437A1 (en) | 1,2-Benzisoxazole derivatives, process for their preparation and pharmaceutical compositions containing them | |
US8288569B2 (en) | Carbonyl asymmetric alkylation | |
KR19990036165A (en) | Single Port Synthesis of 2-oxazolidinone Derivatives | |
WO2022232948A1 (en) | Processes for the preparation of the enantiomers of 3,4-methylenedioxymethamphetamine (mdma) and n-methyl-1,3-benzodioxolylbutanamine (mbdb) | |
CA2627724A1 (en) | Process for the preparation of betamimetic benzoxazinone derivatives | |
EP2958893B1 (en) | Asymmetric synthesis of a substituted pyrrolidine-2-carboxamide | |
ITMI951073A1 (en) | PROCEDURE FOR THE PREPARATION OF [R- (R *)] - 5- (3-CHLOROPHENYL) -3- [2- (3,4-DIMETOXYPHENYL) -1-METHYL] -OSSAZOLIDIN-2-ONE " | |
EP1008590B1 (en) | Process for preparing optically active oxazolidinone derivatives | |
EP0511031B1 (en) | 3-Aryl-oxazolidinon derivatives, process for their preparation and their use in therapeutics | |
EP3794001B1 (en) | Intermediates and processes for the preparation of linagliptin and its salts | |
Takemoto et al. | A versatile method for the preparation of 2, 2-disubstituted morpholine analogues | |
JP2009073739A (en) | Method for producing highly pure optically active 1-aryl-1,3-propanediol acceptable as medicine intermediate | |
EP1926709A1 (en) | Process for the preparation of chiral 3-hydroxy pyrrolidine compound and derivatives thereof having high optical purity | |
FR2772378A1 (en) | DERIVATIVES OF IMIDAZOLE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | |
KR100850558B1 (en) | Process for preparing useful in synthesis of atorvastatin | |
WO2004039785A1 (en) | Process for the preparation of pyrrolidinyl ethylamine compounds via a copper-mediated aryl amination | |
KR101299720B1 (en) | A novel process for preparing 3-amino-5-fluoro-4-dialkoxypetanoic acid ester | |
JP2011520876A (en) | Process for the production of chiral intermediates for the production of HMG-CoA reduction inhibitors | |
JP2005531545A (en) | Method for preparing benazepril hydrochloride | |
JP3002978B2 (en) | Method for producing propoxynitrobenzenes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22798488 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 22798488 Country of ref document: EP Kind code of ref document: A1 |